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 | A B B R E V I AT I O N S  &  G E N E  N O M E N C L AT U R E
2’-F 2’-Fluoro 
2’-MOE 2’-O-methoxyethyl 
2’-OMe 2’-O-methyl 
A Adenine 
a.u. Arbitrary units 
AAV Adeno-associated virus 
ACTA1* Actin, alpha 1, skeletal muscle 
ACTB* Actin, beta 
AGO2* Argonaute 2, RISC catalytic component 
AIDS Acquired immune deficiency syndrome 
aka Also known as 
AON Antisense oligonucleotide 
Ara-C Cytosine β-D-arabinofuranoside 
ATP Adenosine triphosphate 
BNA Bridged nucleic acid 
bp Base pairs 
C Cytosine 
CDM Congenital myotonic dystrophy type 1 
cDNA Copy/complementary deoxyribonucleic acid 
CELF1* CUGBP, elav-like family member 1 (aka CUGBP1) 
cET Constrained-ethyl 
CHQ Chloroquine 
CK* Creatine kinase 
CLCN1* Chloride voltage-gated channel 1 
CNBP* CCHC-type zinc finger nucleic acid binding protein (aka ZNF9) 
CNS Central nervous system 
Cy3 Cyanine dye family member 3 
DDX5* DEAD (Asp-Glu-Ala-Asp) box helicase 5 
DGC Dystrophin-glycoprotein complex 
DM Dystrophia myotonica 
DM1 Myotonic dystrophy type 1 
DM2 Myotonic dystrophy type 2 
DM500 Mouse model derived from the DM300-328 line with a (CTG)500 repeat 
DMD Duchenne muscular dystrophy 
DMD* Dystrophin 
DMEM Dulbecco’s modified eagles medium 
DMPK* Dystrophia myotonica protein kinase 
DMSO Dimethylsulfoxide 
DMSXL Mouse model derived from the DM300-328 line with a (CTG)>1200 repeat 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
DTT Dithiothreitol 
(E)GFP (Enhanced) green fluorescence protein 
A B B R E V I AT I O N S  &  G E N E  N O M E N C L AT U R E
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EBD Evans blue dye 
EDTA Ethylenediaminetetraacetic acid 
eIF2A* Eukaryotic translation initiation factor 2A 
ELISA Enzyme-linked immunosorbent assay 
ENA 2’-O,4’-C-ethylene-bridged nucleic acid 
ER Endoplasmic reticulum 
ESE Exonic splicing enhancer 
FAM Carboxyfluorescein 
FANA Fluoro-arabino nucleic acid 
FEN1* Flap structure-specific endonuclease 1 
FISH Fluorescence in situ hybridization 
G Guanine 
GAPDH* Glyceraldehyde-3-phosphate dehydrogenase 
GEP Gene expression profiling 
GTP Guanosine triphosphate 
HD Huntington’s disease 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hnRNP Heterogeneus nuclear ribonucleoprotein 
HSALR Human skeletal actin large repeat (DM1 mouse model) 
HTT* Huntingtin 
I Inosine 
i.c.v Intracerebroventricular 
IFN-γ* Interferon-gamma 
Lamp1* Lysosome associated membrane protein 1 
LNA Locked nucleic acid 
MBNL* Muscleblind like splicing regulator 1 
mdx Mouse model of Duchenne muscular dystrophy 
MOPS 3-(N-morpholino)propanesulfonic acid 
MRI Magnetic resonance imaging 
mRNA messenger RNA 
NMD Nonsense mediated decay 
NTC No template control 
ORF Open reading frame 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PEI Polyethylenimine 
PFA Paraformaldehyde 
PK Pharmacokinetics 
PKC* Protein kinase C 
PKR* Protein kinase R 
PMO phosphorodiamidate morpholino oligomer 
PMSF Phenylmethylsulfonyl fluoride 
PNA Peptide nucleic acid 
PO Phosphate 
Poly-Q Polyglutamine 
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PROMM Proximal myotonic myopathy (DM2) 
PS  Phosphorothioate 
PVDF Polyvinylidene difluoride 
qPCR Quantitative real-time PCR 
RISC RNA-induced silencing complex 
RNA Ribonucleic acid 
RNAi RNA interference 
RNase H* Ribonuclease H 
RNP Ribonucleoprotein 
ROS Reactive oxygen species 
rpm Revolutions per minute 
RT Reverse transcription 
SDS Sodium dodecyl sulphate 
PAGE Polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SERCA* ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting (ATP2A1) 
shRNA Small hairpin RNA 
siRNA Small interfering RNA 
SIX5* SIX homeobox 5 
SNP Single nucleotide polymorphism 
STAU1* Staufen double-stranded RNA binding protein 1 
T Thymine 
TBE Tris-borate-EDTA 
tc-DNA Tricyclo-DNA 
Tm Melting temperature 
TRED Trinucleotide repeat expansion disorder 
tRNA Transfer RNA 
U Uracil 
UTR Untranslated region 
UV Ultraviolet 
vs Versus 
WT Wildtype 
*According to the HUGO Gene Nomenclature Committee guidelines (Wain, Bruford et al. 2002), gene 
names and symbols are written in italics. Same names are used to refer to mRNA, cDNA and proteins 
from the corresponding gene, but the protein name is not italicised. Human genes are written with 
all letters in uppercase, whereas mouse genes are written in lowercase but capitalized. In some 
cases (chapter 2), we additionally included the letter “h” or “m” preceding the gene name to further 
distinguish between human or mouse, respectively (e.g. hDMPK and mDmpk). The list of abbreviations 
only includes a selection of the genes, transcripts and proteins most relevant for this PhD thesis. For 
other names mentioned, a full description is given in the corresponding chapter when required.
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 | I N T R O D U C T I O N  TO  M YOTO N I C  DY S T R O P H Y
Myotonic dystrophy (abbreviated DM for its Latin name: dystrophia myotonica) is a genetic, 
multisystem disorder described by a German physician (Hans Steinert) in a study published 
in 1909 [1], followed by another publication the same year by Batten and Gibb [2]. DM 
is the most common form of muscular dystrophy in adults, but disease symptoms are 
not limited to skeletal muscle, and include also neurological, cardiac, gastrointestinal, 
ocular, dermatological and endocrinal features [3,4]. There are two different forms of DM: 
type 1 and 2.
DM type 1 (DM1), also known as Steinert’s disease, is the most prevalent of the two 
[3]. The genetic cause was identified in 1992 as an expansion of a (CTG)n trinucleotide 
repeat sequence in the last exon of the dystrophia myotonica protein kinase (DMPK) gene 
on chromosome 19 [5-7]. However, soon after the discovery of the mutation, patients 
with DM1-like symptoms were identified that did not carry this triplet-repeat expansion. 
Immediately it became evident that these individuals belonged to families with myotonic 
dystrophy type 2 (DM2), a disorder characterized by slightly different, difficult to identify, 
myopathic problems. The genetic cause of this form of DM, also known as proximal myotonic 
myopathy (PROMM), was described in 2001 [8]. DM2 mutation was identified as an expanded 
(CCTG)n repeat in intron 1 of the gene for zinc finger protein 9 (CNBP) on chromosome 3 
[9]. Interestingly, both the DM1 and the DM2 mutation are located in non-coding areas of 
the harboring gene: the 3’ UTR of DMPK mRNA and an intron of CNBP pre-mRNA, respectively.
Both disorders have very similar phenotypes, and differences in clinical manifestation 
are hard to distinguish: DM2 is generally milder and there is no congenital form of it like in 
DM1. Neurologic involvement is also milder in DM2 compared to DM1 [3,10,11] and different 
muscles and fiber types are preferentially affected in each DM type. DM1 patients mainly 
develop alterations in type 1 fibers of distal muscles, whereas DM2 patients experience most 
problems with type 2 fibers of proximal muscles [12,13].
The focus of my thesis will be on DM1, since most of the findings described here are based 
on models and specific treatments for this type of DM. Nevertheless, similar approaches may 
be potentially developed for DM2 [14].
Epidemiology
DM1 is most common in Europe or populations of European descent (3-15 patients per 
100,000) [15], but is also present at lower prevalence in Japan (1 per 100,000), and even 
rarer in India [16-18]. Although several members of a family from the sub-Saharan region in 
Africa have been diagnosed with DM1 [19], the disease is practically absent in this continent 
[20]. In regions with special immigration and migration history, such as the Saguenay 
area in Quebec, the prevalence can be as high as 1 per 500 due to a  founder effect [21]. 
Higher prevalence has also been reported in northern Sweden, the Basque region of 
Spain and Iceland (1 per 10,000) [3]. Prevalence numbers in different populations may 
even be slightly underestimated as older patients suffering mild DM1 symptoms remain 
frequently undiagnosed.
I N T R O D U C T I O N  TO  M YOTO N I C  DY S T R O P H Y
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Symptoms
DM1 patients can present a highly variable clinical picture. So far, no consensus on DM1 
clinical classification has been adopted but, depending on the severity and age of onset, 
different categories of disease manifestation can be distinguished [22,23].
Late-onset myotonic dystrophy type 1
In this form of the disease, onset typically occurs after 40 years of age. It generally presents 
with mild weakness, possible myotonia (delayed relaxation of skeletal muscle after voluntary 
contraction or electrical stimulation) and cataracts at an early age (under 60). As mentioned 
in the previous section, not all patients in this category are properly diagnosed. Usually this 
happens only when a family member is diagnosed with DM1.
Adult-onset/classical myotonic dystrophy type 1
This is the most common manifestation of DM1 [23]. Patients develop the first symptoms 
in the age interval between 20 and 40 years, which include skeletal muscle weakness 
(eventually leading to immobility), respiratory insufficiency, dysarthria and dysphagia 
[4]. Heart problems due to conduction defects and tachycardia are frequent and usually 
caused by fibrosis in the conduction system and sinoatrial node [24]. Together with cardiac 
complications, problems related to skeletal muscle weakness, frequently leading to 
respiratory failure [25], are the main cause of death in DM1.
Muscle weakness develops in facial, neck and distal limb muscles in parallel with 
muscle wasting. Atrophy of the temporal muscles and ptosis contribute to a characteristic 
myopathic facial appearance. Muscle fiber alterations in DM1 biopsies are found more 
frequently in distal muscles and include presence of central nuclei, sarcoplasmic masses, 
ring fibers and moderate atrophy of type 1 fibers in clinically weak muscles [3]. The most 
characteristic symptom of DM1 is myotonia, which is invariably present in the adult-onset 
form on both clinical examination and electromyography [3], but can occasionally be difficult 
to detect clinically.
DM1 patients may also develop neuropsychiatric problems. The most characteristic 
features are daytime sleepiness and apathy, involving a reduced perception and awareness 
of own disease symptoms and signs. Mild cognitive impairment is also frequently present 
[26,27]. Together, these changes may have an impact on cognition, learning, professional 
activity and sociologic aspects of the life of affected persons [28]. These neurological changes 
are normally accompanied by structural brain alterations, including abnormal white-matter 
changes, which can be detected by magnetic resonance imaging (MRI) [29].
A very frequent symptom is the development of cataracts, which are usually present 
much earlier than the average age in non-affected population. Although the specific type 
of cataract in DM1 (iridescent posterior subcapsular opacities) is almost pathognomonic 
of the disease [30], it is very often overlooked and surgically removed before proper 
identification. Retinal degenerative changes have also been reported [3,31].
19
1
Introdcution to myotonic dystrophy
The most frequent complaints from DM1 patients relates to gastrointestinal problems 
like constipation, diarrhea or incontinence [32]. In a disease advanced stage, dysphagia can 
become a challenge and lead to problems like aspirations and pneumonia [3,31]. 
DM1 patients suffer different endocrine alterations [3]. They are prone to develop insulin 
resistance and diabetes. Hypothyroidism is also common and can worsen the symptoms. 
Male patients frequently present hypogonadism and infertility. Miscarriages are a common 
feature in female patients.
Juvenile/infantile myotonic dystrophy type 1
In this form of DM1, cognitive and behavioral alterations start much earlier than muscle 
symptoms (before 10 years of age), causing intellectual disability early in the life of the patient 
[33]. Several psychiatric problems can be observed, including attention deficit disorder, 
anxiety, and mood disorder [34]. Approximately 50% of these children show intellectual 
impairment. Children do not suffer muscle weakness, wasting, or myotonia until an older 
age, which eventually causes physical symptoms similar to severe adult-onset DM1 [35,36]. 
Congenital myotonic dystrophy (CDM)
This is the most severe form of the disease, which is already present prenatally [37]. CDM 
can be detected in approximately 4% of all patients [23] and causes neonatal mortality in 
18% of the infants [38]. However, these numbers could be higher in reality, because CDM 
may be incorrectly dismissed when the mother has not been diagnosed with DM1 and 
there is no prior history in the family [39]. It is characterized by reduced fetal movements, 
polyhydramnios, and various deformities [3,31]. At birth, babies have severe hypotonia 
caused by developmental defects (not by muscular degenerative changes), that can lead to 
respiratory failure and feeding difficulties [3,31]. 
Comparable to juvenile/infantile DM1, neurological alterations can be detected early 
(between birth and 10 years of age). Mental retardation and autism spectrum disorder 
are commonly seen in these patients [33]. During childhood, individuals with CDM exhibit 
delayed motor milestones that include oropharyngeal weakness, facial diplegia, marked 
dysarthria, and impairment of expressive communication [37]. Later on, between the age 
of 20 and 40, patients with CDM start to develop myotonia and other muscle symptoms 
characteristic of the classical form.
Genetics 
DM1 is caused by expansion of an unstable (CTG)n trinucleotide repeat in the 3’ untranslated 
region (UTR) of the DMPK gene, located on chromosome 19q13.3 [6,7]. In the non-affected 
population, the (CTG)n repeat length ranges between 5 and 37 triplets [31]. A repeat length 
between 37 and 50 is generally considered a “pre-mutation” [40], because individuals with 
a number of (CTG)n triplets in this range are asymptomatic but at risk of having children with 
larger, pathologically expanded repeats (due to an anticipation phenomenon, explained 
below). Full penetrance alleles occur with repeats greater than 50 CTGs and are, in most 
20
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cases, associated with disease [41]. However, many patients with a repeat size of 50-100 
triplets are frequently underdiagnosed due to the fact that no or few mild symptoms (such 
as cataracts) appear at an older age. Individuals with a repeat size between 100 and 1000 
triplets will inevitably develop either juvenile/infantile or adult onset DM1. Patients with 
more than ~1000 triplets (up to ~4000) normally suffer CDM, with severe symptoms present 
at birth, as detailed in the previous section. There is a certain correlation between (CTG)n 
length and age of onset and clinical severity [23], which is more reliable for repeat sizes 
in the range of 50 to ~500 [42]. Generally, patients with repeat sizes up to ~60 triplets 
develop first symptoms after the age of 60 and patients with less than 200-500 triplets are 
asymptomatic until adulthood or middle age [15].
As mentioned earlier, the DM1 mutation is unstable, with the length of the (CTG)n 
repeat changing size over time in different cells and tissues. Both expansion and contraction 
events may occur, but there is a strong tendency towards expansion of the newly generated 
alleles [43]. The instable behavior of the DMPK expansion is determined by interference 
of the DNA repair machinery with the topologically anomalous (CTG)n repeat track [44]. 
Failure to structurally repair the DNA across the mutation, possibly in combination with 
transcription-coupled events in DNA repair activity [45], determine the extent of instability. 
DNA replication itself seems to have no direct role, the DM1 repeat is actually more unstable 
in non-dividing cells [46,47].
Instability occurs at variable rates in different cells and tissues of the body, resulting in 
tissue heterogeneity and mosaicism of the repeat length. The level of repeat instability differs 
for example between cells in skeletal muscle, heart, brain and blood [48]. This phenomenon 
explains in part the broad spectrum of clinical manifestations seen in patients and the age-
dependent and progressively worsening nature of the symptoms. It also has important 
implications for diagnosis and clinical management since the (CTG)n repeat in cells of 
the hematopoietic system is more stable [47]. Therefore, quantification of DM1 repeat length 
in blood is not a good predictor of the genotypic load in other tissues like muscle, where 
repeat length can increase at a higher rate as the patient ages [49]. Repeats of >37 CTG 
triplets are also unstable in the germline, causing the anticipation phenomenon by which 
the repeat expands between one generation and the next [50]. There are marked differences 
in repeat instability between spermatogenesis and oogenesis, being this phenomenon 
more active in the latter. Therefore, large genotypic jumps in DM1 most frequently happen 
when the disease allele is transmitted from the mother [51]. In fact, children with congenital 
DM1 are born almost exclusively from carrier mothers. 
Interruptions of the (CTG)n repeat tract with other triplets, like CCG and CGG, usually 
at its 3’ end,  have been reported in some patients [52]. Repeat imperfections are generally 
associated with modified phenotypic manifestations and reduced anticipation [53].
Pathology
DM1 is the first disease for which RNA was proposed as the initiator of pathology 
(RNA-mediated toxicity). As functions of protein products of the gene remain unaffected 
by the repeat mutation, being located outside the open reading frame, disease etiology 
21
1
Introdcution to myotonic dystrophy
in DM is thus thought to be based on dominant negative effects of RNA-gain-of-function 
(Fig. 1). Until now this model is the most widely accepted as it accounts for the majority 
of symptoms present in DM1 and can also explain similarities with DM2 [54,55]. In fact, 
the mutations in both diseases are located in non-coding areas and there is no known 
functional relationship between the products of DMPK and CNBP. Model studies have 
demonstrated that transcription of expanded (C/CTG)n repeats into RNA are both 
necessary and sufficient to reproduce many aspects of the disease [4,56]. Expression of 
toxic RNA produces a variety of downstream alterations that can be broadly classified in 
two categories: (I) RNA splicing and processing alterations and (II) effects that compromise 
protein homeostasis and maintenance of cellular physiology. Below, I give a more extensive 
description of mechanisms associated with these two types of problems, but already here it 
is important to emphasize that it is almost impossible to distinguish between their primary 
and secondary causative effects on cell integrity and cellular function.
Figure 1. DM1 molecular pathogenesis. DM1 pathogenesis is complex and affects RNA and protein 
homeostasis. First, the long (CTG)n repeat in the mutant allele causes chromatin remodeling of the locus 
leading to reduced expression of the neighbouring gene SIX5 (A). Transcripts from the expanded DMPK 
gene form long (CUG)n hairpins that bind multiple proteins (e.g. MBNL, DDX5 and different types of 
hnRNPs) forming large ribonuclear inclusions (foci) that are retained in the nucleus. As a consequence, 
only wildtype DMPK transcripts will be translated, presumably causing DMPK haploinsufficiency 
(B). MBNL proteins are sequestered in foci reducing their steady-state levels (C). Toxicity exerted by 
the mRNA repeat expansion activates stress responses in the cell (D) leading to kinase activation and 
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DM1 splicing and RNA processing alterations
DMPK transcripts with a long (CUG)n repeat are retained in the cell nucleus, where they 
form long hairpin loops with C-G base pairs interrupted by U-U mismatches [57]. This type 
of structures tend to bind transcription factors and ribonucleoproteins (RNPs), forming 
aggregates in insoluble or diffuse/soluble state (named foci, after their detection by RNA FISH) 
[58]. DMPK foci abnormally bind RNPs, including members of the muscleblind-like family of 
proteins (MBNL1-3), hnRNP-H and DDX5 [59-61]. In turn, DMPK RNP foci cause stabilization 
of expression and activation of other proteins that are also involved in RNA metabolism, 
like CUG-binding protein 1 (CUGBP1, aka CELF1) [62] and Staufen1 (STAU1) [63,64]. These 
proteins function in various RNA processing and trafficking steps. Therefore, their alteration 
has serious consequences in trans for proper alternative splicing, polyadenylation, mRNA 
cellular distribution and miRNA expression [4].
Several of the mRNA processing alterations can be explained by diminished availability 
of MBNL proteins for normal cellular functions due to their sequestration and immobilization 
in ribonuclear foci [65-68]. Conversely, the steady-state concentration of CELF1 increases 
due to hyperphosphorylation and stabilization of the protein [69]. This posttranslational 
modification is most likely a secondary effect of repeat-mediated stress responses executed 
by different signaling kinases including protein kinase C (PKC). CELF1 and MBNL have 
antagonistic effects in pre-mRNA splicing, whereby the former factor normally acts as 
a splicing regulator that promotes production of isoforms that are typical for the embryonic 
developmental stage [70] and the latter factor promotes splice production of adult RNA 
isoforms [71]. The resulting effect of combined imbalance in these protein factors is 
aberrant splicing of pre-mRNAs from several genes [72], characterized by overexpression of 
embryonic splice isoforms in adult tissues [73-75]. 
RNA splicing alterations of multiple gene products have been studied, mostly in attempts 
where the authors tried to find direct associations with DM1 pathology. For example, 
aberrant splicing of chloride channel 1 (CLCN1) mRNA results in abnormal inclusion of 
exon 7a (normally only during embryogenesis), that abrogates expression of the protein 
by generation of a premature stop codon. Loss of CLCN1 function has been identified as 
the cause of myotonia [76], the most characteristic symptom in DM1. Likewise, aberrant 
exclusion of exon 11 of the amphiphysin gene (BIN1), mediated by MBNL1 reduction, has been 
associated with central nuclei, developmental weakness and hypotonia in congenital DM1. 
Missplicing of calcium channels like CaV1.1 and SERCA has been linked to muscle weakness 
and altered Ca2+ reuptake [77,78]. In addition, aberrant splicing of mRNAs for sarcomeric 
stabilization of CELF1 proteins (E). Imbalance of MBNL and CELF1 factors (with antagonistic functions) 
leads to anomalous RNA processing (F), including abnormal splicing, mRNA transport, polyadenylation 
and miRNA expression. PKR is another kinase activated by the stress responses that in turn inactivates 
the translation initiation factor eIF2A, leading to overall reduced protein synthesis in the cell (G). 
Finally, antisense transcripts from the mutant DM1 locus, which carry an expanded (CAG)n repeat, are 
susceptible to repeat-associated non-ATG (RAN) translation,  giving rise to homopolymeric peptides 
(e.g. poly-Q) potentially toxic to the cell (H).
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muscle proteins, such as the LIM domain binding 3 (encoded by LDB3), myomesin (MYOM1), 
myosin heavy chain 14 non-muscle (MYH14) and dystrophin (DMD) has also been noted in 
patients with DM1 [66,79-81]. Aberrant inclusion of exon 5 of cardiac troponin T (cTNT) may 
explain cardiac conduction defects [72]. Finally, alternative splicing of the insulin receptor 
(IR) can lead to expression of the insulin-insensitive form of this protein (due to exclusion of 
exon 11 in the mRNA), explaining insulin resistance in DM1 patients [82]. Taken combined, 
this evidence provides strong support for a model in which single events of missplicing 
are directly causal for distinct disease features of DM1. However, correlations between 
splicing abnormalities and pathobiological problems are not always that clear-cut, and 
evidence for a role of missplicing in DM pathology remains therefore circumstantial for most 
gene transcripts.
Perhaps not surprising, Mbnl1 knockout mice [83,84] and transgenic mice overexpressing 
CELF1 [85,86] (both lacking expanded toxic RNA expression) show widespread aberrant 
splicing. However, detailed phenotyping of these animal models revealed that consequences 
of abnormal splicing cannot always be directly translated to disease features as observed 
in DM1 patients [83,85,87]. For instance, although Mbnl1 knockout mice and transgenic 
mice expressing (CUG)n repeats from a transgene unrelated to DMPK (so-called HSALR mice, 
see below) show similar patterns of missplicing observed in patients [66,75], both failed to 
recapitulate several features associated with DM1, like muscle wasting and weakness [56,83]. 
In addition, MBNL1 complementation in HSALR mice prevented myotonia and restored 
adult-splicing patterns [88], but failed to rescue histological abnormalities, suggesting 
that muscle degeneration might not be due to MBNL1 loss alone. Therefore, other 
pathomechanisms than spliceopathy must be involved in the development of the disease.
Loss of cellular homeostasis
Nuclear retention of expanded DMPK transcripts is expected to lead to haploinsufficiency and 
reduction of DMPK protein levels, so the role of reduced DMPK expression in DM1 pathology 
should be also considered a possible contributing factor [89,90]. In fact, it should be noted 
that, although Dmpk -/- mice do not initially develop a characteristic DM1 phenotype, aged 
mice eventually did develop abnormalities [91-93]. Based on this, one would predict that 
a therapy that selectively silences the expanded allele would be safer for patients than total 
silencing of all DMPK gene products.
The (CTG)n expansion in the DMPK gene has been reported to suppress expression 
of the neighboring gene SIX5 (formerly known as DMAHP) by chromatin remodeling [94], 
a process that has been associated with cataract formation [95]. Methylation of CTCF sites 
flanking the (CTG)n repeat prevents binding of the CCCTC-binding factor and is related to 
antisense transcription of the DMPK, locus [96,97]. The transcription starts from the area 
of the SIX5 gene and reads through the DMPK sequence, including the repeat track. This 
phenomenon happens in all individuals, but the antisense transcript generated by DM1 
patients contains an abnormally large (CAG)n repeat, which also forms stable hairpins. 
Antisense transcripts from the mutant DM1 locus may contribute to the imbalance in 
proteostasis by a process called repeat-associated non-ATG (RAN) translation [98]. This 
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phenomenon consists of the synthesis of peptides from the (CAG)n repeat, which is 
independent of the canonical AUG translation start codon in humans [99]. RAN translation 
of DMPK antisense transcripts gives rise to homopolymeric peptides (e.g. poly-Q) in patient 
cells, including skeletal muscle cells, and in mouse models of the disease. Poly-Q peptides 
are central in the pathology of several neurodegenerative disorders [100]. However, what 
the contribution of RAN-translation products is to the overall DM1 pathology is currently 
still elusive [101].
Also global effects could be involved in creating imbalance in the DM1 proteome. A clear 
reduction in overall protein synthesis in muscles of DM1 patients has been reported [102]. 
This phenomenon is attributed to PKR activation upon its binding to the (CUG)n repeat (Fig. 
1). PKR inactivates the eukaryotic translation initiation factor 2A (eIF2A) by phosphorylation 
at serine 51, which in turn reduces initiation of translation in the cell [103]. Importantly, 
PKR forms stress granules in cells expressing expanded (CUG)n transcripts and activates 
several cellular stress pathways [104], including the innate immune response and interferon 
signaling, which also may have a role in the development of cataracts. Prolonged activation 
of PKR and subsequent eIF2A inactivation also leads to stress in the endoplasmic reticulum 
(ER) in DM1 [105]. ER stress further blocks protein translation and eventually leads to 
apoptosis. Collectively, these ribostasis and proteostasis problems may be the principal 
pathophysiological contributors to the multisystemic phenotype in DM1 patients.
Animal models for RNA-based toxicology in DM1
The first animal model providing clear evidence for the toxic RNA gain-of-function 
hypothesis was the HSALR mouse [56]. These mice carry a human transgenic insert composed 
of the actin alpha skeletal muscle (ACTA1) gene with its own promoter and a (CTG)n repeat 
of ~250 triplets in the 3’ UTR (Table 1). Onset of transcription of this gene occurs relatively 
late in myogenesis and accumulation of transgenic (CUG)n-repeat RNA to high levels in 
this model is therefore not seen until late myofiber formation in vivo [106]. Then, abundant 
presence of (CUG)n-containing RNA leads to MBNL1 sequestration in ribonuclear foci and 
myotonic discharges. However, as also discussed in the last paragraph of section 1.4.1., 
the HSALR model fails to recapitulate muscle wasting or weakness. Another disadvantage is 
that transgene expression is limited to skeletal muscle only.
Another mouse model developed for DM1 carries a cosmid-sized human transgenic insert 
spanning the entire expanded DMPK gene from a DM patient, including neigbouring genes 
DMWD and SIX5 plus all genomic cis elements that control temporal and spatial expression of 
DMPK [107]. The first generation of these mice, named DM300-328, contained an expansion 
of 300 CTG triplets (Table 1). Homozygous animals show mild multisystem features that 
include muscle histopathology, progressive muscle weakness, growth retardation and mild 
brain abnormalities [108]. Interestingly, this model also recapitulates the intergenerational 
instability of the mutation seen in patients [109]. Careful monitoring of repeat lengths over 
several generations of mice allowed the French researchers who developed this model to 
identify descendants with longer repeats, e.g. DM500 mice carrying 500 triplets, and DMSXL 
mice carrying 1000–1800 CTG triplets. Homozygous offspring of DMSXL mice present a more 
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severe phenotype, including splicing abnormalities in skeletal muscle, heart and CNS that 
are already present at one month of age [110].
Other mouse models that contributed to the elucidation of DM1 molecular pathogenesis 
(but are not used in this thesis) include DMPK and SIX5 knockout models [91,95], the Tg26 
model overexpressing a (CTG)11 repeat in the DMPK gene [111], models for inducible 
expression of expanded CUG repeats [87,112], and models for MBNL inactivation [83,84] or 
CELF1 upregulation [85,86]. In addition, DM1 models that have been developed in other 
species like Drosophila [113], zebrafish [114] and Caenorhabditis elegans [115] can be useful 
for high-throughput screening of therapeutic compounds that alter repeat expansion 
behavior or RNA toxicity in vivo.
Biomarkers
In therapeutic screening studies, DM1 biomarkers are important as indicators of disease 
progression and possibly reversal, i.e. for monitoring the benefit of a therapeutic intervention. 
Not all biomarkers can be universally used, however. The choice of the right biomarker will 
depend strongly on the type of model that is under study, since, as described in the previous 
section, each model recapitulates different aspects of the disease. On the other hand, 
Table 1. Information about the most relevant mouse models in DM1. DM300-328 mice contain the entire 
human DMPK locus with a repeat of 300-500 CTG triplets. DMSXL mice derived from the previous model by 
intergenerational repeat instability, leading to generation of mice with more than thousand triplets. HSALR 
mice contain a repeat of ~250 CTG triples in the 3’-UTR of the ACTA gene, under control of the promotor of 
this gene. The phenotype, symptoms and original references of these models are summarized in the table.
Mouse 
model Transgene/Mutation Promoter/Expression Phenotype/Symptoms
Original 
references
DM300-328 Human DM1  
locus with ~300-500 
CTG triplets
Human DMPK 
promoter/all DM1 
related tissues  
(e.g., skeletal muscle, 
heart, CNS)
Homozygous mice: 
myopathy, reduced 
muscle strength, myotonia 
(generally very mild 
phenotype)
[107,108]
DMSXL Human DM1  
locus with ~1000-
1800 CTG triplets 
(descendant of 
the DM300-328 line)
Human DMPK 
promoter/all DM1 
related tissues  
(e.g., skeletal muscle, 
heart, CNS)
Homozygous mice: 
myopathy, reduced muscle 
strength, myotonia, 
reduced body size (more 
severe phenotype than 
DM500 mice)
[110]
HSALR Human ACTA1 gene 
with ~250 CTG 
triplets
Human ACTA1 
promoter/ skeletal 
muscle only
Homozygous mice: strong 
myotonia, myopathy, no 
muscle weakness
[56]
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when analyzing patient material, the source of the tissue (e.g. type of muscle biopsy) will 
also determine the analysis to follow. Moreover, for studies in vitro (with either cells derived 
from patients or from DM1 models, e.g. fibroblasts, myoblasts) one should also consider 
the limitations, as not all cell types or differentiation stages thereof will recapitulate every 
aspect of the corresponding adult tissue.
A broadly applicable and obvious method to assay the development of treatments aimed 
to reduce the load of toxic RNA in DM1 cells relies on the quantification of expanded DMPK 
transcripts, either present in the entire cell or in the fraction that is retained in the nucleus. 
Different techniques can be implemented to distinguish between products from normal and 
expanded alleles, like Northern blotting or allele-specific PCR assays. 
Formation of ribonuclear inclusions (or foci) represent another biomarker that is frequently 
used. These foci can be detected in different amounts and shapes (diffuse/condensed) using 
FISH or MBNL immunostaining in cell nuclei of DM1 patients and models, both in vivo and 
in vitro [65]. This biomarker is useful not only to monitor treatments targeting the toxic RNA 
by silencing, but also treatments that aim to relieve toxicity by opening the hairpin structure 
and preventing abnormal MBNL binding [116].
A physiological readout for monitoring disease progression and severity in vivo is skeletal 
muscle myotonia. This symptom can be easily measured in patients by electromyography 
(EMG) and offers a good estimate of disease burden. For studies in DM1 animal models, it is 
important to consider that myotonia is only evident in HSALR mice [56].
Finally, there are several characteristic spicing biomarkers in DM1 that can be measured 
[117]. Splice abnormalities that are most commonly used include CLCN1, SERCA, BIN1, DMD 
and MBNL1. Variation in alternative RNA splicing of these and other candidates can be tested 
in vivo and in vitro, and it is important to consider that different models and cells show 
distinct patterns of splicing abnormalities. Ideally, the characteristic DM1 splicing pattern 
in the model/cell type used should be determined in advance, as it has been done in some 
studies [118]. For instance, alternative splicing of exon 7a in CLCN1 is frequently used to 
monitor disease progression in muscle, but its application in vitro is more challenging because 
this gene is expressed late during myogenic differentiation, in stages that cannot be easily 
attained in cell culture. Furthermore, in addition to measuring an isoform change by RT-PCR, 
it is possible to monitor the correct location and functionality of the transcript isoform 
products. For instance, following the CLCN1 example, it is common to study the expression 
and location of CLCN1 proteins in the membrane of muscle fibers by immunohistochemistry.
Treatment prospects
Symptomatic treatment and care
Currently, there is no approved treatment to eliminate the root cause of DM1 or its direct 
downstream effects. Clinical efforts can only be taken to manage symptoms and minimize 
disability by palliative care. For instance, mobility problems are counteracted using canes, 
braces, walkers or scooters. Cardiac and respiratory functions should be always monitored 
longitudinally to apply the corresponding treatment if necessary (e.g. using a pacemaker 
or defibrillator). As discussed above, cataracts are frequently removed surgically. Excessive 
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daytime sleepiness can be improved using methylphenidate or modafinil. Gastrointestinal 
complications can also be treated with medication. All these measures can contribute to 
alleviate symptomatology but, given the progressively worsening nature of DM1 pathology, 
they are inefficient to provide a sustained relieve of disease burden and complications for 
patients and relatives. Therapies to treat myotonia are currently undergoing clinical trials 
(ClinicalTrials.gov Identifier: NCT01406873), involving the use of Na+ channel blockers like 
mexiletine [119].
Development of molecular therapies
Multiple approaches aiming to neutralize toxic DMPK RNA to stop progression of disease 
are under development [120]. There are two possible ways to achieve this: by silencing/
degradation of (expanded) DMPK transcripts or by blocking the associated toxic effects (i.e. 
by interfering with protein binding and foci formation).
The first ever developed strategy for RNA targeting in DM1 made use of ribozymes, 
RNA molecules with catalytic activity, to reduce the amount of (CUG)n triplets in the cell by 
modulation of splicing events [121,122] or induction of an endonucleolytic cleavage [123].
RNA interference (RNAi) [124,125] with transient inhibition by short RNAs or permanent 
expression of shRNA (small hairpin RNA), has been also applied to silence DMPK transcripts. 
For example, DMPK mRNA was silenced by lentiviral vectors that delivered shRNAs targeting 
the 5’ end of the mRNA, resulting in reduction of both normal and expanded transcripts 
[126]. Others used siRNAs targeting the (CUG)n repeat itself, leading to reduced levels of 
toxic RNA in HSALR mice [127]. More recently, another study used adeno-associated virus 
to deliver RNAi hairpins systemically to target the (CUG)n repeat in HSALR mice, leading to 
a reduction of toxic RNA, myotonia inhibition and splicing correction [128].
Other therapeutic strategies make use of small organic molecules or peptides that bind 
the expanded (CUG)n repeat and displace sequestered MBNL proteins, thus disrupting 
nuclear foci. Pentamidine was the first molecule identified with this role [129], although 
the exact mechanism of action is not clear. Other studies focused on the specific design of 
chemically synthesized aminoglycosides based on compounds that bind RNA loops [130], 
resulting in the discovery of modularly assembled ligands that bind (CUG)n repeats with 
high affinity. Finally, from large screenings in Drosophila, other promising (CUG)n-binding 
compounds have been identified, like the peptide ABP1 as a recent example, which also 
showed beneficial effects in a mouse model [116].  
Antisense oligonucleotide strategies are currently the most extensively studied 
and promising approaches to treat DM1 [131]. Since this was the strategy investigated 
during my Ph.D. research, it will receive special attention and will be discussed in detail in 
the next section.
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 | I N T R O D U C T I O N  TO  A N T I S E N S E  O L I G O N U C L E OT I D E S
AONs are single-stranded, short nucleotide sequences complementary to RNA or DNA 
targets in the cell. They were applied for the first time in cell culture by Zamecnik and 
Stephenson in 1978 to inhibit viral replication [132]. Since then, many other applications 
have been developed, because AONs can be potentially used to modulate expression of 
virtually any gene or transcript in the cell.
Mechanisms of action
There are several mechanisms of RNA modulation in antisense technology [133]. Most AONs 
interact or block certain cellular pathways involved in RNA biology (Fig. 2). They can recruit 
endogenous enzymes and factors to modulate expression of the intended RNA target. 
The most relevant mechanisms that are currently being employed include:
Modulation of pre-mRNA processing
AONs can alter pre-mRNA splicing by either blocking donor or acceptor splice sites or splicing 
enhancer or silencer sequences [134]. Upon binding, AONs sterically block access to protein 
factors or ribonucleoprotein complexes involved in pre-mRNA splicing. Therefore, this 
approach can be used to induce exon skipping or promote exon inclusion of an alternatively 
spliced exon. In addition, AONs can be designed to interfere with poly(A) site selection in 
a transcript [135].
Translation inhibition
AONs can be directed towards the translation initiation site of a given mRNA to specifically 
block ribosomal assembly and protein synthesis [136]. The application of this strategy is 
challenging due to the limited sequence stretch of mRNA available to design AONs that can 
bind in this region and efficiently block the process.
RNase-H recruitment
RNase H is involved in DNA repair and the removal of Okazaki fragments during DNA 
replication. This enzyme binds to RNA-DNA heteroduplexes and cleaves the RNA strand, 
leaving an unprotected 5’-phosphate end and releasing the DNA strand intact [137]. RNase 
H is represented by a family of enzymes present in all mammalian cells. When using an AON 
of five or more consecutive DNA nucleotides, this enzyme mediates cleavage of the RNA 
in the RNA-AON heteroduplex [138]. Since RNase H is more abundant in the cell nucleus, 
silencing of RNAs in this compartment by this mechanism has been shown to be more 
effective [139].
RNA interference
Careful design of AONs to mimic the activity of miRNAs is possible, but certain requirements 
in nucleotide chemistry have to be met in order to obtain successful recognition of 
the AON by the RNAi machinery [140-143]. AONs with this property have also been termed 
I N T R O D U C T I O N  TO  A N T I S E N S E 
O L I G O N U C L E OT I D E S
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single-stranded siRNAs (ss-siRNAs). They successfully enter the RNAi pathway, being 
directly recruited by RISC downstream of Dicer processing [144]. On the other hand, AONs 
can also be used to interfere with the activity of miRNAs. These AONs, usually termed 
antimiRs or antagomirs, function as competitive inhibitors of miRNAs, blocking their ability 
to bind target mRNAs [145,146].
Ribozymes and other RNA-silencing strategies
Other approaches developed to induce selective RNA degradation include ribozymes and 
DNAzymes, well-structured oligonucleotide-based molecules that possess inherent catalytic 
activity as nucleases [147-149]. In addition, other nucleases and natural RNA-degrading 
pathways present in the cell can be potentially used to promote specific RNA knock-down 
[150]. For instance, nonsense-mediated decay can be triggered with AONs that generate 
premature stop codons by aberrant exon skipping [151]. Finally, the fast growing collection 
of CRISPR/Cas type of nucleases may be used in the future to target RNA for degradation in 
living cells [152].
Figure 2. Molecular mechanisms of RNA modulation by antisense oligonucleotides. An antisense 
oligonucleotide (AON) can modulate the fate of (pre-)mRNA by multiple mechanisms. They can 
influence pre-mRNA processing, like polyadenylation or splicing. Exon skipping can be achieved by 
blocking exonic splicing enhancers or donor/acceptor splice sites. Skipping of an in-frame exon can be 
used to remove mutations, but results in a shorter mRNA and protein. In contrast, when the skipped 
exon is out-of-frame, a premature stop codon is generated, which generally leads to transcript 
degradation by nonsense mediated decay (NMD). AONs can also be designed to block translation or to 
silence gene expression by several other mechanisms, for instance, gapmer-type of AONs can recruit 
RNase H, an enzyme that is mainly expressed in the nucleus. As such, gapmers can also be directed 
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AON chemistry 
Chemical modification of an AON is necessary to modulate its fate in vitro and in vivo. 
Unmodified oligonucleotides undergo fast degradation by endogenous nucleases present 
in the cell or biological fluids. Moreover, when administered in vivo, circulating DNA and RNA 
are rapidly removed by liver and kidney [153]. Together, plasma nucleases and excretion 
produce an estimated half-life of ~15 minutes in serum [154], a time that can be significantly 
extended by changing the nucleotide chemical composition (see below). In addition to 
increase stability and improve pharmacokinetics, AON modifications can be used to enhance 
RNA binding affinity. These aspects are of importance for successful application of AONs as 
therapeutic agents in medical applications [133,155].  
to intronic regions in pre-mRNA. AONs that meet certain chemical characteristics can be recruited by 
the RNA-induced silencing complex (RISC) and activate the RNA interference pathway (RNAi). 
Alternatively, other endogenous ribonucleases in the nucleus or cytosol can also mediate in transcript 
degradation (e.g. RNase P).  In addition, oligonucleotide sequence can be designed to have catalytic 
activity by itself (ribozymes).
Figure 3. Some chemical modifications applied in antisense technology. The first generation of 
AONs consisted of the introduction of phosphorothioate (PS) internucleoside linkages by replacing 
an oxygen atom by a sulfur in the phosphate backbone. In a second generation of modifications, 
alkylation of the 2’ position of the ribose was implemented to further improve nuclease resistance 
while increasing binding affinity. A vast amount of chemical modifications in the sugar pentose or 
overall nucleotide structure have been implemented in a third generation of AONs (only the most 
relevant examples are depicted in this figure). PS internucleoside linkages are usually combined with 
those chemical modifications that maintain the phosphate backbone, but is not possible in PMO and 
PNA. Arrows point to specific chemical modifications in the nucleotide structure. B: Nitrogenous base. 
*Relative order of some types of nucleotide modifications according to their approximate change in Tm 
compared to unmodified DNA. BNA: bridged nucleic acid (ENA, LNA and cEt).
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The nucleotide structure can be divided in three parts (Fig. 3), all amenable to manipulation: 
internucleoside linkage (phosphate backbone), pentose sugar and nitrogenous base. 
To date, a vast collection of chemical modifications has been implemented in successive 
generations of antisense technology [156]. According to the part of the nucleotide that is 
modified, they can be broadly classified in four groups:
Modifications in the internucleoside linkage
Eckstein and colleagues generated in 1969 the first generation of AON modifications [157], 
which consisted of the introduction of a phosphorothioate (PS) modification of the nucleotide 
backbone. In this class of AONs, one of the non-bridging oxygen atoms in the phosphodiester 
backbone is replaced with a sulfur (Fig. 3) [158]. This modification notably improved nuclease 
resistance and pharmacokinetic properties, increasing the half-life in serum to approximately 
9 hours [159] and resulting in improved biodistribution and pharmacokinetics [160]. PS 
AONs are characterized by non-specific binding to proteins, especially those that interact 
with polyanions [161]. Binding to plasma proteins and cells allow these AONs to be retained 
in the body for longer periods [162]. However, PS oligodeoxynucleotides have a somewhat 
reduced binding affinity to RNA compared to unmodified DNA, with an approximate melting 
temperature (Tm) reduction of 0.5 °C per linkage [163,164].
Pentose sugar modifications
After the introduction of the PS linkage, research focused on improving binding affinity to 
RNA. As RNA/RNA duplexes are more stable (i.e. have a higher Tm) than DNA/RNA duplexes, 
introduction of RNA-type nucleotides into DNA type AONs was found to increase affinity 
towards complementary RNA targets [155]. The most commonly used modification involves 
changes at the 2’ position of the pentose sugar (Fig. 3), very frequently combined with 
a PS backbone.
AONs consisting of full-length 2’-modified RNA are not able to recruit RNase H because 
this enzyme only recognizes DNA-RNA hybrids (see above). To induce RNase H-mediated 
degradation of target RNA, it is possible though to design a gapmer type of AON, which 
possesses a central gap of PS DNA to enable formation of a RNase H-recruiting DNA/RNA 
duplex, flanked by 2’-modified RNA ‘wings’ which enhance affinity and confer nuclease 
resistance for the entire AON.
The most relevant examples of pentose-modified AONs include:
2’-O-alkyl modifications
2’-O-alkyl modifications were developed after the introduction of the PS backbone and, as 
such, they are very frequently classified as the second generation of AON modifications [155]. 
They include an O-alkyl group at the 2’ position of the ribose sugar. The two most important 
modifications that are frequently applied in antisense technology involve the introduction 
of 2’-O-methyl (2’-OMe) and 2’-O-methoxyethyl (2’-MOE) groups [165]. These modifications 
confer increased binding to RNA by reducing the flexibility of the furanose ring, resulting in 
a more stable hybridization.
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Bridged nucleic acids (BNAs)
BNAs consist of ribonucleotides in which the 2’-oxygen of the ribose is linked to the 4’-carbon 
(Fig. 3). The most relevant BNAs are: ethylene-bridged nucleic acid (ENA) [166], locked nucleic 
acid (LNA) [167] and constrained-ethyl nucleic acid (cEt) [168,169]. ENAs contain an ethylene 
bridge, whereas LNA and cEt contain a methylene bridge. BNAs confer enhanced stability 
against nucleolytic degradation [170], and an even further increased  binding affinity to 
RNA, due to a more reduced flexibility of the furanose ring over 2’-substituted nucleotides. 
They provide an increase in Tm of 5-10°C per nucleotide when introduced into unmodified 
DNA [171,172]. This feature makes BNAs ideally suited when strong binding to the target 
RNA is desired. Caution should be taken however, when trying to introduce many BNAs 
in an AON: inducing a too-high Tm may well lead to loss of mismatch discrimination and 
thus cause synthesis issues (aggregation) and/or off-target effects (binding to unintended 
sequences). Thus, combining a few BNA residues with other type of chemical modifications is 
normally the approach of choice to generate gapmers or mixmers. On the other hand, BNAs 
can be very helpful when short AON sequences are required, like those designed to block 
miRNAs [145].
2’-Fluoro-2’-deoxy nucleic acid (2’-F) and 2’-F arabinosyl nucleic acid (FANA)
2’-F and FANA are characterized by a fluorine substituent on the 2’ position of the pentose 
ring (Fig. 3). In 2’-F RNA, this confers increased binding affinity, to between that of 2’-O-alkyl 
RNA and LNA/ENA. In FANA, an arabinose sugar (the 2’ epimer of ribose) is used instead to 
generate the oligonucleotide. AONs with FANA chemistry are recognized by RNase H and are 
therefore able to induce cleavage of target RNA by this mechanism [173].
Tricyclo-DNA (tc-DNA)
This chemical modification is derived from DNA by addition of three carbon atoms between 
the 5’ and 3’ position of the ribose (Fig. 3). This type of conformationally constrained DNA 
analog shows enhanced binding affinity to RNA and nuclease resistance, but it is not able to 
recruit RNase H [174]. Tc-DNA has been shown to possess interesting pharmacokinetic and 
tissue uptake properties [175].
Alternative scaffolds 
This group is formed by AONs in which both the phosphate backbone and pentose sugar 
have been completely replaced by other structures. As such, the introduction of a PS 
modification is not possible, since phosphate linkages are not present in this type of AONs. 
Two relevant examples of these modifications are described below.
Phosphorodiamidate morpholino oligomer (PMO)
These AONs are nonionic nucleotide analogs with a backbone of phosphorodiamidate 
linkages instead of phosphodiester/phosphorothioate bonds, and morpholine-derived 
scaffolds instead of ribose-derived ones (Fig. 3) [176]. These AONs (often called morpholinos) 
are frequently used in developmental and functional gene studies in zebrafish [177]. Because 
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their backbone is uncharged, PMOs do not interact with proteins and have reduced cellular 
uptake properties compared to other chemistries. Their binding affinity to RNA is higher 
than unmodified DNA but lower than second generation modifications.
Peptide nucleic acids (PNAs)
PNAs are composed of repeating N-(2-aminoethyl)-glycine units connected by amide 
(peptide) bonds with bases linked by a carboxymethylene moiety (Fig. 3) [178]. As such, PNAs 
are depicted as peptides, with the N- and C-termini corresponding to the conventional 5’/3’ 
denomination, respectively. PNAs can bind complementary sequences in both antiparallel 
and parallel orientation [179] and are able to invade duplex DNA with high affinity and 
specificity [180,181].
Nitrogenous base modifications
Nitrogenous bases are responsible for nucleic acid hybridization by conventional Watson-
Crick hydrogen bonds. The nitrogenous bases are adenine (A), guanine (G), cytosine (C), 
thymine (T, only present in DNA), and uracil (U, only present in RNA). Several modifications 
can be applied that are sometimes also present in nature, like the introduction of 
a 5-methyl group in a cytosine (as present in natural DNA via epigenetic modifications), or 
the replacement by non-conventional bases. For instance, the introduction of inosine (I, 
naturally present in RNA by post-transcriptional modifications) [182], can be used to expand 
the hybridization possibilities since it can bind to adenine, uracil and cytosine.
AON delivery
Pharmacokinetics (PK)
Oral administration is generally ineffective because the physicochemical properties of AONs 
impede their gastrointestinal absorption. These properties include their relatively large size/
molecular weight (~5-10 kDa) and their hydrophilic nature [183]. Therefore, AONs are most 
frequently administered by subcutaneous or intravenous routes in vivo. As discussed above, 
AONs with PS backbone have improved PK characteristics compared to their PO analogs or 
uncharged AONs, like PNAs and PMOs, which are rapidly excreted with the urine [184,185]. 
This advantage is due to PS binding to serum proteins, something that delays the process 
of glomerular filtration, resulting in improved tissue distribution and bioavailability [133]. 
Levels of PS-modified AONs in circulation decline during the first hours post-administration 
because they are rapidly transferred from blood into tissues. Accumulation occurs mainly in 
the liver parenchyma and proximal epithelium of renal cortex, but there is some functional 
uptake in most other tissues, except the central nervous system (CNS). In addition, after 
reaching peripheral organs, they can reside for long periods of time (weeks to months) [186].
Specific delivery into the CNS is very challenging because AONs do not cross 
the blood-brain barrier easily [187]. Therefore, the potential application of antisense 
technology to treat neurological disorders has to overcome this limitation using alternative 
administration routes, like intracerebroventricular (i.c.v.) infusion. AONs inoculated into 
the cerebrospinal fluid show remarkable broad distribution through the CNS [188,189]. 
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This has important implications for the clinic, since diseases affecting brain can be 
potentially treated with AONs using less invasive administration methods than i.c.v., like 
intrathecal injections.
Cellular uptake
A challenge for successful application of an AON treatment is the delivery of these molecules 
to their targets in the relevant compartment inside the cell. Several studies have focused 
on understanding the mechanisms behind free-AON uptake and intracellular trafficking 
[190]. Currently, it is commonly accepted that endocytosis and fluid phase pinocytosis are 
the major mechanisms of oligonucleotide internalization [191]. Most of the AONs accumulate 
in the lysosomal compartment over time, where they can reside for long periods of time due 
to their intrinsic resistance to cellular nucleases [192]. However, in the course of vesicular 
trafficking, a small fraction of AON is believed to escape to reach the functional target in 
the cytosol or the nucleus [193].
Antisense strategies for DM1
AONs currently developed for DM1 can be broadly divided in two groups: those that target 
the expanded (CUG)n repeat tract in DMPK mRNA and those that are specifically designed 
for binding to unique target sequences elsewhere in the transcript.
AONs that target the (CUG)n repeat in DMPK mRNA
This category of AONs can be used to displace MBNL proteins sequestered by the hairpin 
and/or to induce preferential degradation of expanded DMPK RNAs. Interestingly, two 
independent studies using AONs with blocking chemistries (non RNase H-recruiting) found 
that this type of strategy also leads to degradation of expanded (CUG)n mRNA. In both cases, 
transcripts from the expanded allele were silenced to a large extent, possibly since more 
AONs were able to bind to these transcripts than to RNAs from the healthy allele. In the first 
study that was published on this topic, Wheeler et al. [194] described the use of a 25 nt AON 
with PMO chemistry and (AGC)8A sequence named CAG25. In test tube experiments, CAG25 
was able to invade (CUG)n hairpins to release MNBL1 protein and prevent it from binding. 
Treatment of HSALR mice by intramuscular injections resulted in reduction of nuclear foci, 
redistribution of Mbnl1 protein and normalization of aberrant splicing, restoring Clcn1 
protein expression and minimizing myotonia. Contrary to expectation, CAG25 administration 
also resulted in ~50% reduction of expression from the transgene, while other transcripts 
with short (CUG)n repeat remained unaffected [194].
In the second study on (CUG)n-specific AONs, our own laboratory identified a 2’-OMe 
AON of (CAG)7 sequence, called PS58, as a promising therapeutic agent for DM1 [195]. PS58 
reduced expanded DMPK transcript levels in a DM1 mouse cell model and in patient myoblast 
cultures. DMPK mRNA bearing a repeat of normal size and other transcripts with short 
(CUG)n repeats were left essentially intact. Findings were corroborated in DM300-328 
and HSALR mice by intramuscular administration, which resulted in ~50% reduction of 
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(CUG)n RNA in both models. In the HSALR model, nuclear foci were reduced and DM1 splicing 
abnormalities were moderately improved [195].
More recently, an approach by which an engineered hU7-snRNA containing a poly-CAG 
antisense sequence was delivered by an adeno-associated virus (AAV) also resulted in 
specific degradation of expanded DMPK transcripts via an unknown mechanism [196].
The RNA silencing mechanism of the blocking antisense strategies directed to 
the (CUG)n repeat is currently unknown. This topic will be discussed further in this thesis, 
since much experimental effort was put in elucidating this pathway.
Other researchers in the DM1 field subsequently used LNA and MOE gapmers targeting 
(CUG)n repeats [197]. They found that these AONs are able to silence expanded DMPK 
transcripts in vivo, after local administration in muscle of a DM1 mouse model. In addition, 
combined administration of gapmers with CAG25 AON (described above), further enhanced 
silencing activity. Interestingly, small fully-modified LNA AONs complementary to the repeat 
displaced MBNL proteins from the hairpin and corrected foci and alterative splicing defects 
without inducing degradation of expanded DMPK transcripts [118].
AONs that target DMPK transcripts outside the repeat
The disadvantage of strategies aimed to silence DMPK mRNA via binding to unique 
sequences outside the expanded repeat is that both normal and expanded DMPK 
transcripts might be blocked or degraded, so detrimental effects of total DMPK knock-
down could become a concern. Normal roles of the DMPK gene that have been described 
include remodeling of the actomyosin cytoskeleton [198], maintaining nuclear envelop 
integrity [199] and preventing ROS-induced damage [199]. As discussed above, complete 
lack of DMPK protein function, as achieved in Dmpk knockout mice, has no direct overt 
phenotypic consequences, but eventually abnormalities do develop [91-93]. Thus loss of 
DMPK function could be a point of future concern, but possible problems from expression of 
repeat-carrying RNA may outweigh the problems associated with total DMPK RNA loss. We 
think that arguments of this kind must have pushed developments further, and currently 
complete DMPK mRNA breakdown strategies have already entered the stage of clinical trials, 
testing safety, tolerability and efficacy of IONIS-DMPKRx in DM1 patients (ClinicalTrials.gov 
Identifier: NCT02312011). 
One of the first preclinical studies of this kind employed 2’-MOE gapmers to target 
transgenic ACTA1 RNA in HSALR mice outside the repeat region [139]. These AONs showed 
long-lasting silencing capabilities after systemic administration, especially for gapmers 
binding downstream to the repeat. Transgenic RNA reduction and correction of Serca splicing, 
myotonia and central nuclei were still apparent one year after the treatment. Furthermore, 
gapmers targeting the 3’ UTR of DMPK RNA at unique sequences could also silence these 
transcripts after systemic administration in another DM1 model [139]. The authors of this 
study claim that RNase H can induce an efficient and continuous cleavage of the mRNA 
target with only small amounts of gapmers present in the nucleus.
Finally, a recent study characterized the effect of systemic administration of a gapmer 
that targets mouse, monkey and human DMPK mRNA outside the repeat [200]. This AON, 
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containing 2’-4’ constrained ethyl (cEt) modifications, showed silencing activity against 
DMPK RNA in muscles of wildtype mice, DM1 mouse models and cynomolgus monkeys.
Other AONs in the clinic
The first antisense drug approved for commercialization was fomivirsen, a fully-modified 
PS AON that was registered in 1998 as a treatment for cytomegalovirus-induced retinitis 
in immunocompromised patients with AIDS [201]. This AON was delivered via intraocular 
injection and reached efficiently the target site (retina), something that contributed to 
the success of the drug. Since then, many other antisense strategies have been tested in 
the clinic with only limited success [202]. Recently, mipomersen (Kynamro®), a 2’-MOE gapmer 
with 5-methyl cytosines targeting the mRNA of apolipoprotein B in the liver [203,204], was 
approved for treatment of familial hypercholesterolemia.
Despite their slow entry on the market, AONs still represent a drug platform with high 
therapeutic potential if ways to overcome the biological barriers towards improved delivery 
are developed. Given the central role of RNA in molecular biology [205], this technology 
could be used to interfere with molecular pathomechanisms in many disorders [133]. It 
is therefore not surprising that there is a broad spectrum of diseases for which AONs are 
currently in development, including β-thalassemia [206], hypertriglyceridemia [207], 
Duchenne muscular dystrophy (DMD), Huntington’s disease (HD), spinal muscular atrophy 
[208], amyotrophic lateral sclerosis [209], infectious diseases [210], inflammatory conditions 
[211] and cancer [212]. Since it would be impossible to cover them all here, only two examples 
with clear relevance for the DM1 field will be given. First, I will describe developments 
in DMD, a neuromuscular disorder currently undergoing clinical trials in which AONs are 
tested. Secondly, I will focus on HD as an example of a disease caused by a trinucleotide 
repeat expansion.
Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is the most common lethal X-linked disease in 
man, affecting 1 in 3500 male births [213]. DMD is associated with severe, progressive 
muscle weakness and typically leads to death between the ages of 20 to 35 years. Other 
symptoms include poor motor skills, progressive difficulty moving, fatigue and higher risk 
of neurobehavioral disorders. Patients are frequently wheelchair-bound before the age 
of 12 and need respiratory support by the second decade of their life. DMD is caused by 
lack of dystrophin expression. This protein forms a multi-subunit complex, the dystrophin-
glycoprotein complex (DGC), responsible for connecting the cytoskeleton of muscle fibers to 
the extracellular basal lamina [214]. In absence of dystrophin, the DGC structure is disrupted, 
affecting the membrane stability of muscle fibers [215], eventually leading to cell death and 
replacement by connective tissue. Despite extensive efforts, there is no treatment available 
for DMD patients yet.
Dystrophin loss in DMD patients is caused by mutations in the DMD gene at locus 
Xp21 [216]. Deletions, duplications or point mutations in this gene result in a frame shift 
in the open reading frame (ORF) in the transcript [217], often creating a premature stop 
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codon that abrogates functional dystrophin protein synthesis. In an approach to restore 
the ORF of DMD transcripts, AONs targeting exon splicing enhancer (ESE) sequences in 
exons containing DMD mutations have been tested with promising results [218]. These AONs 
recover dystrophin expression by generating a shorter but functional transcript by exon 
skipping. Two types of AON chemistries using this strategy have been evaluated clinically: 
2’-OMe PS [219] and PMO [220].
Huntington’s disease
Huntington’s disease (HD) is a devastating inherited neurodegenerative disease caused 
by an expansion of a (CAG)n repeat in exon 1 of the huntingin (HTT) gene, located in 
chromosome 4p16. The (CAG)n repeat is present in the ORF of the gene and it codes for 
a polyglutamine (poly-Q) tract located at the N-terminus of the HTT protein, ubiquitously 
expressed throughout the body and brain [221]. HD is characterized by progressive motor 
and cognitive decline, leading to dementia and other psychiatric manifestations like 
depression and psychosis. Generally, first symptoms occur in midlife, eventually leading 
to premature death within 15-20 years after disease onset [222]. Together with DM1, it is 
one of the most well-known trinucleotide repeat disorders and today still remains incurable 
and insufficiently understood. HD has a prevalence of 5-10 per 100,000 in populations of 
European descent [223]. Similarly to DM1, repeat length is correlated to age of onset and 
disease symptoms, starting with 36 or more CAG triplets [224]. Above this threshold, it 
confers a neurotoxic gain-of-function to the mutant protein [225], producing intracellular 
aggregates and leading to progressive neuronal loss in several brain regions, predominantly 
in the striatum [226].
As in DM1, the most promising antisense therapies in development for HD aim to reduce 
the amount of mutant HTT RNA (and protein) [227]. Also in this case, two possible strategies 
using AONs are in (pre)clinical development: (a) targeting the expanded trinucleotide 
repeat, resulting in preferential silencing of RNA products from the expanded allele [228], or 
(b) targeting the HTT transcript outside the repeat, which can also be designed to be allele-
specific in certain subpopulations of patients by using SNPs [229]. There is overall consensus 
that achieving silencing selectivity for products of the mutant allele would be preferable, 
given the important and diverse cellular functions of the wildtype HTT protein, including 
normal development, function and maintenance of neurons [230,231]. Nevertheless, the first 
clinical study testing an antisense strategy for HD uses an AON (IONIS-HTTRx) to reduce levels 
of both wildtype and mutant HTT transcripts. The trial has recently started and will evaluate 
the safety, tolerability, pharmacokinetics and pharmacodynamics of AONs administered in 
HD patients by intrathecal injections (ClinicalTrials.gov Identifier: NCT02519036).
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 | T H E S I S  O U T L I N E
The collection of experiments described in this thesis aim to elucidate aspects of antisense 
oligonucleotide (AON) treatment for neuromuscular diseases, focusing especially on their 
application to myotonic dystrophy type 1 (DM1). Chapter 1 serves as a general introduction 
of this book. This chapter is divided in two sections: the first part describes several aspects 
of DM1, such as epidemiology, symptoms, genetics, pathogenesis and care. The second 
section introduces AONs, giving a description of their development and applications, and 
a discussion on why they represent a promising therapeutic approach for DM1. Other 
aspects, such as in vivo distribution and cellular uptake are also considered.
During my research, I mainly focused on the development of AONs that make use of 
the most important polymorphism in DM1: the (CTG)n repeat in the DMPK gene. RNA 
products of this gene, when expanded above a certain threshold, represent the root cause 
of the disease. We tested a battery of (CAG)n AONs of different lengths and chemistries and 
studied their silencing effect on expanded DMPK transcripts, comparing our data to other 
approaches being currently developed. These experiments are presented and discussed 
in Chapter 2. Important parameters for preclinical development, such as allele selectivity, 
immunogenicity, stability, intracellular localization and potential effects on unrelated 
transcripts bearing (CUG)n or (CAG)n repeats were also studied. Additionally, based on 
some experimental evidence of this chapter and previous knowledge, a discussion about 
the silencing mechanism of AONs targeting mRNA trinucleotide repeats is started in this 
chapter. This topic is further extended in Chapter 3, where AON-RNA interactions with 
cytoplasmic and nuclear proteins of a DM1 model were studied in vitro. We implemented 
a pull-down method to isolate AONs hybridizing to a (CUG)n-containing RNA and studied 
proteins that interact with this duplex. Some of the identified proteins have molecular roles 
potentially related to the mechanism, such as nuclease and RNA helicase activity.
In Chapter 4, I present the analysis of transcriptome changes after treatment with 
(CAG)n and control AONs in cells from unaffected individuals and patients suffering from 
DM1. These experiments were performed to monitor changes in expression pattern 
upon AON treatment. Some of these changes might respond to the normalization of 
the genetic disease signature upon silencing of the corresponding mutation (pathologic 
reversal) and could give very valuable information on how fast altered molecular features 
could be corrected. On the other hand, other changes may be due to unspecific response 
of the cells to triplet repeat AONs, and their study might help to predict side effects of 
the treatment. In order to discriminate changes responding to pathologic reversal or side 
effects, an extensive and careful analysis of the data (based on RNA-Seq and SAGE) was 
performed using several bioinformatics tools.
The main challenge for a therapeutic approach with AONs is improving intracellular 
localization within cells of targeted tissues after systemic treatment in vivo. In some disease 
conditions, such as DMD, affected cells suffer from loss of membrane integrity, which in 
turn facilitates uptake of large compounds like AONs. Essentially nothing was known on 
membrane integrity in DM1, as this had never been addressed in detail. Information on 
this topic in DM1 will be useful to anticipate the scope of the treatment and design of 
T H E S I S  O U T L I N E
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adequate delivery strategies. I deal with this subject in Chapter 5, where we performed 
an exhaustive analysis of membrane integrity in muscles and other tissues of DM1 mouse 
models and patients and related our findings to several in vivo studies with AONs that 
were performed by our group and others. Since results of Chapter 5 clearly show that cell 
membranes in DM1 do not have affected integrity (being indistinguishable from healthy 
controls in terms of permeability) new studies investigating mechanisms of AON uptake 
and intracellular distribution in DM1 are important. Therefore, we next investigated how 
AONs of different chemistries, including AONs conjugated to a muscle-homing peptide, 
are internalized by DM1 myoblasts and myotubes. These experiments are presented and 
discussed in Chapter 6. Free uptake incubation of AONs (so-called gymnosis), intracellular 
vesicular trafficking and nuclear delivery and activity were studied by microscopy combined 
with molecular biological analysis of the fate of the RNA targets. Effects of interference with 
cellular import and trafficking mechanisms were also investigated in this chapter. Finally, 
the results presented in this thesis are summarized, discussed and put into perspective 
in Chapter 7.
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 | A B S T R A C T
Myotonic dystrophy type 1 (DM1) is caused by DM protein kinase (DMPK) transcripts 
containing an expanded (CUG)n repeat. Antisense-oligonucleotide-(AON)-mediated 
suppression of these mutant RNAs is considered a promising therapeutic strategy for this 
severe disorder. Earlier, we identified a 2’-O-methyl phosphorothioate-modified (CAG)7 
oligo (PS58), which selectively silences mutant DMPK transcripts through recognition 
of the abnormally long (CUG)n tract. We present here a comprehensive collection of 
triplet repeat AONs and found that oligo length and nucleotide chemistry are important 
determinants for activity. For significant reduction of expanded DMPK mRNAs a minimal 
length of five triplets was required. 2’-O,4’-C-ethylene-bridged nucleic-acid-(ENA)-modified 
AONs appeared not effective, probably due to lack of nuclear internalization. Selectivity for 
products from the expanded DMPK allele in patient myoblasts, an important requirement to 
minimize unwanted side effects, appeared also dependent on AON chemistry. In particular, 
RNase-H dependent (CAG)n AONs did not show (CUG)n-length specificity. We provide 
evidence that degradation of long DMPK transcripts induced by PS58-type AONs is an 
RNase-H independent process, does not involve oligo-intrinsic RNase activity nor does it 
interfere with splicing of DMPK transcripts. Our collection of triplet-repeat AONs forms an 
important resource for further development of a safe therapy for DM1 and other unstable 
microsatellite diseases.
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 | I N T R O D U C T I O N
Myotonic dystrophy type 1 (DM1) is an autosomal dominant, trinucleotide repeat 
expansion disease and the most common form of adult-onset muscular dystrophy [1-3]. 
The multisystemic symptoms are highly variable and involve different tissues and organs, 
including skeletal muscle, heart, brain, eyes, reproductive systems and the gastrointestinal 
tract. No cure to slow or stop the disease process is currently available.
The genetic basis of DM1 is an unstable (CTG)n expansion in the 3’ untranslated region of 
the DM protein kinase (DMPK) gene. Length of the (CTG)n segment is correlated with age of 
onset and severity of disease [1]. In the healthy population, the CTG repeat is polymorphic in 
length, with a triplet number that ranges from 5 to 37 (mostly below 15 [4]), whereas disease 
alleles may contain between 50 and >2000 triplets [1].
The DM1 pathogenic mechanism involves an RNA gain-of-function. Repeat-containing 
transcripts from the expanded allele accumulate in cell nuclei and alter the function of 
RNA-binding proteins, whose association with disease has been most intensively studied 
for muscleblind (MBNL) and CUG Binding Protein 1 (CUGBP1) [2]. In adult DM1 tissue, 
the resulting imbalance in availability of these antagonistic splicing regulators causes 
misregulation of events in which embryonic patterns of splicing occur. For example, 
myotonia and insulin resistance, two key features of DM1, may be caused by altered splicing 
of muscle chloride channel and insulin receptor transcripts, respectively [2]. Also effects on 
miRNA processing and function have been reported [5].
Results obtained with DM1 mouse models that inducibly express (CUG)n RNA show 
that features of RNA toxicity are reversible [6], strongly suggesting that reducing the level 
of expanded DMPK transcripts will be beneficial to patients. In the past decade, different 
antisense strategies have been developed with the intention to eliminate expanded DMPK 
transcripts via either antisense RNA expression, ribozyme activity, oligo-mediated RNase-H 
activity or RNA interference (RNAi) technology [7]. Reduction of DMPK transcript levels 
was achieved by several of these methods, but selectivity between toxic and normal-sized 
transcripts was generally low.
To be functional and safe for therapeutic use in DM1 patients, an antisense approach 
should ideally silence transcripts from the expanded allele only and leave normal-sized 
DMPK transcripts or unrelated transcripts containing (CUG)n segments intact. Since length 
of the (CUG)n repeat is the only consistent polymorphic difference between mutant and 
normal DMPK (pre)mRNAs, the repeat tract itself forms an attractive therapeutic target. 
Besides, despite the fact that normal and mutant DMPK transcripts are both made in 
the nucleus, (CUG)n-length selectivity may be enhanced by directing active compounds to 
this compartment where mutant transcripts accumulate after synthesis.
Earlier, we published on the identification and characterization of PS58, an antisense 
oligonucleotide (AON) complementary to the (CUG)n repeat [8]. PS58 is a (CAG)7 fully 
2’-O-methyl (2’-OMe) phosphorothioate (PS) modified AON, which silences expanded 
(CUG)n transcripts in DM1 cell and animal models. Other in vivo AON studies directed at 
the expansion mutation made use of a (CAG)n morpholino to interfere with the (CUG)n 
repeat-MBNL interaction [9] or LNA (locked nucleic acid)/MOE (2’-O-methoxyethyl)-PS-type 
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(CAG)n gapmers to recruit RNase H activity for degradation of (CUG)n-containing transcripts 
[10]. François et al. engineered a hU7-(CAG)15-snRNA which preferentially reduced 
pathogenic DMPK mRNA in DM1 cells, via a yet unknown mechanism [11].
Here, we report on specific properties that (CUG)n-directed AONs require for effective 
knockdown of expanded DMPK RNA. Triplet repeat AONs with different chemistries and 
lengths were tested in an unbiased screen for silencing capacity in a transgenic DM1 cell 
culture model expressing human DMPK (CUG)500 transcripts. AON length and nucleotide 
chemistry appeared to be major parameters for therapeutic efficacy. A selection of effective 
AONs was tested in DM1 patient myoblasts. Findings of this study are important for 
transition towards in vivo studies with AONs and ultimately for development of a specific 
AON-mediated therapy for DM1. As a first step in support of this transition we report on 
effects on in vitro complement activation by some of these AONs.
 | R E S U LT S
AONs complementary to DMPK’s (CUG)n repeat
A series of triplet repeat AONs that differed in length, chemistry and nucleotide composition 
was designed and analyzed for their ability to silence expanded DMPK transcripts in cultured 
cells (see AON description in Figure 1A). AONs were tested via transfection in the DM500 
myoblast-myotube cell model [8]. The human DMPK (hDMPK) transgene in this model is under 
near-normal myogenic transcriptional control and produces hDMPK transcripts bearing 
a (CUG)500 repeat at levels comparable to that of endogenous mouse Dmpk (mDmpk) 
transcripts. It should be noted that mDmpk transcripts contain a CCG(CUG)2(CAG)2CUG 
sequence instead of the generally believed to be uninterrupted (CUG)n segment found 
in hDMPK transcripts. Monitoring AON silencing effects was done by Northern blotting to 
follow steady-state levels of full-length transgenic hDMPK transcripts and possible stable 
breakdown products. Analysis of endogenous mDmpk transcripts was used as a control. 
Real-time reverse-transcriptase PCR (RT-qPCR) was included for quantitative assessment of 
expression of defined transcript segments.
DNA-based (CAG)n AONs
DNA-type oligonucleotides are known to allow specific RNase-H mediated cleavage of 
RNA in a DNA-RNA heteroduplex [12]. For these AONs several chemical modifications have 
been developed that improve their metabolic stability, while maintaining hybridization 
affinity to target RNA and ability to recruit RNase H [13]. We tested three DNA-type (CAG)7 
AONs in DM500 myotubes: PS56, a pure DNA AON; PS142, a PS-modified DNA AON; and 
PS260, a PS-modified chimeric AON, so-called gapmer, comprised of 2’-O-methyl (2’-OMe) 
wings on the 5’ and 3’ sides of a DNA gap. DNA AON PS56 did not show silencing activity 
(Figure 1A), probably because it was quickly degraded inside cells 
(Supplementary Figure S1). In contrast, PS142 and PS260 - both stabilized against nuclease 
breakdown - were able to silence expanded hDMPK mRNA for ~50% and ~80%, respectively 
(Figure 1A,B). Endogenous mDmpk mRNA was left intact. A concentration-response 
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A
B C D
Figure 1. Collection of triplet repeat AONs tested for their ability to silence expanded hDMPK mRNA 
in DM500 myotubes. (A) Summary of silencing efficiency. Endogenous mDmpk RNA was included 
as a negative control, since it lacks a pure (CUG)n repeat. AONs are grouped according to their main 
chemical modification: a, DNA (capital); RNA (capital, underlined); PS, phosphorothioate linkage (*); 
2’-OMe, 2’-O-methyl sugar modification (capital, underlined, bold); ENA, 2’-O,4’-C-ethylene-bridged 
nucleic acid (capital, italics); PMO, morpholino phosphorodiamidate (lower case); b, Cy3-labeled; 
c, coupled to octaguanidine dendrimer. The means of at least three independent experiments for each 
AON are shown. Dashed line indicates 100% levels (mock samples). (B) Representative Northern blots 
with RNA isolated from AON-treated DM500 myotubes probed with a hDMPK and a Gapdh probe. Results 
of treatment with three AONs (200 nM) or mock treatment is shown. (C) Concentration-response curves 
of PS58 and PS142. DM500 myotubes were treated with a concentration series of 0.01-500 nM AON 
(see also Supplementary Figure S2). (D) RT-qPCR analysis of hDMPK RNA levels in DM500 myotubes 
after treatment with a selection of 2’-OMe AONs (200 nM, n ≥ 3). PCR amplicons were located in exon 
15, either 5’ or 3’ to the (CUG)n tract.
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analysis yielded an IC50 of 0.3 ± 0.4 mM for DNA/PS oligo PS142, which is about 1000-fold 
lower than that of 2’-OMe/PS lead compound PS58 (Figure 1C, Supplementary Figure S2 
and [8]).
Oligo-length and base variations of 2’-O-methyl AONs
To investigate length as a potential parameter in the performance of PS58-type oligos, we 
tested a series of fully 2’-OMe-modified (CAG)n AONs consisting of four to thirteen triplets 
in the DM500 myotube culture system. All, except PS251 (CAG)4, effectively and selectively 
silenced (CUG)500 transcripts (>80% efficiency) (Figure 1A,B). A (CUG)7 2’-OMe sense oligo or 
2’-OMe oligos directed against target sequences in the hDMPK transcript outside the repeat 
did not have a silencing effect (data not shown) [8]. The lack of activity of the (CAG)4 AON 
is best explained by assuming that a minimum oligo length is necessary for effective 
hybridization to the (CUG)n target needed for AON activity.
We wondered whether the nature of the nucleotide residue at the 5’ or 3’ end of the AON 
might be crucial for silencing and tested a repeat-shifted version, 2’-OMe-modified (AGC)7 
(PS259). PS259 treatment resulted in a significant reduction of 85% of (CUG)500 transcripts 
without silencing mDmpk mRNA (Figure 1A).
Finally, a 2’-OMe-modified (CIG)7 AON was tested. The inosine residues should enable 
this AON, PS261, to hybridize to (CUG)n, (CAG)n, (CCG)n repeats and any combination of 
these triplets. Similar to PS58, PS261 induced 85% reduction of expanded mRNA (Figure 1A). 
Notably, endogenous mDmpk mRNA was also significantly reduced, albeit with only ~35% 
efficiency. This effect may be best explained by binding of (CIG)7 to the CCG(CUG)2(CAG)2CUG 
sequence in mDmpk mRNA. Besides, three low-affinity binding sites were identified 
that could have a cooperative, additive effect (11-13 nucleotides match; not present in 
hDMPK transcripts).
Silencing of expanded hDMPK transcripts by triplet repeat 2’-OMe AONs in DM500 
myotubes was independently confirmed by RT-qPCR analysis (Figure 1D). The lower silencing 
efficiency measured by RT-qPCR (60-90%, versus 85-95% detected by Northern blotting) is 
attributed to technical differences in sensitivity intrinsic to the methods.
Morpholino phosphorodiamidate (CAG)n AONs
Morpholino phosphorodiamidate oligos are uncharged AONs widely used as blocking oligos 
for selective inhibition of gene expression [14]. A (CAG)8 morpholino (PS304) was tested 
for its ability to silence expanded hDMPK RNA in DM500 myotubes. The morpholino was 
coupled to an octaguanidine dendrimer (so-called Vivo-Porter) to facilitate cellular uptake. 
PS304 treatment caused a 70% reduction of (CUG)500 transcripts, leaving mDmpk mRNA 
intact (Figure 1A).
2’-O,4’-C-ethylene-bridged-nucleic-acid modified (CAG)n AONs
The bicyclic modification in 2’-O,4’-C-ethylene-bridged nucleic acid (ENA) confers strong 
nuclease resistance and high binding affinity to complementary single stranded RNA 
(average ΔTm/modification = 5.5
oC versus 1.3oC for 2’-OMe) [15] (Supplementary Figure S1). 
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We tested two fully ENA-modified AONs consisting of three and four CAG triplets, and three 
ENA/2’-OMe gapmers of five, seven and ten CAGs (PS139-135, Figure 1A). Only treatment 
with PS136 resulted in a small, yet significant reduction (30%) of hDMPK RNA expression.
The discrepancy in efficacy between ENA- and 2’-OMe-modified AONs may be caused 
by differences in subcellular targeting. To verify this possibility, we followed cellular uptake 
and routing of two fluorescently labeled AONs with these modifications. For these analyses 
we switched to the use of DM500 myoblasts, which display a rather flat morphology, 
rendering them more suitable for live cell imaging of AON localization than myotubes. Forty 
minutes after transfection, fluorescent PS58 oligo was present in the cell nucleus and signal 
intensity further increased up to 60 minutes (Supplementary Figure S3). This behavior was 
independent of the type of fluorophore used and fluorophore coupling did not affect PS58 
silencing activity (data not shown). In contrast, labeled PS138, as a representative of the ENA 
AON collection, was concentrated in vesicle-like structures and rarely present in the nucleus 
itself. This pattern remained unchanged up to 48 hours after transfection (data not shown). 
We conclude that lower silencing efficiency of ENA-modified (CAG)n AONs observed in this 
study is due to their inability to reach muscle cell nuclei, where most expanded (CUG)n 
transcripts reside.
Triplet repeat siRNAs
Krol et al. [16] reported that (CXG)n triplet repeat hairpins in mRNAs are substrates for Dicer 
and produce short repeat RNAs that in turn may act as siRNAs against complementary 
repeats. We wanted to investigate whether in our cell model expanded hDMPK mRNAs 
could be silenced by introducing synthetic (CAG)n/(CUG)n siRNAs. Two different RNA 
duplexes were transfected in DM500 myotubes, PI-01 ((CAG)7/(GCU)7) and PI-02 
((GCA)7/(CUG)7) (Supplementary Table S1). An unrelated siRNA and PS58 were included as 
controls. RT-qPCR analysis demonstrated that none of the repeat siRNAs silenced hDMPK 
mRNA expression (Figure 2). From our AON stability assay, we conclude that it is unlikely that 
Figure 2. RT-qPCR analysis of hDMPK (CUG)500 RNA levels in DM500 myotubes after treatment with 
siRNAs (50 nM) targeting the (CUG)n repeat (n=6). PS58 (50 nM) was used as a control. Sequences 
of PI-01 [(CAG)7/(GCU)7 duplex], PI-02 [(GCA)7/(CUG)7 duplex] and control siRNA are listed in 
Supplementary Table S1.
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the inability to reduce expanded hDMPK transcripts is due to rapid intracellular degradation 
of the chemically unprotected siRNAs (Supplementary Figure S1).
Mouse transcripts containing a small (CUG)n segment
Transcripts that contain a (CUG)n segment, other than encoded by the hDMPK transgene, 
may also serve as targets for (CAG)n AONs in DM500 cells. Genes carrying a (CTG)n 
segment are rare, but at least nine transcripts in the mouse transcriptome contain a repeat 
of more than six triplets [8]. We investigated whether 2’-OMe/PS AONs of variable length 
and sequence ((CAG)5, (CAG)7, (CAG)10 and (CIG)7) acted on a subset of these transcripts 
expressed in DM500 myotubes. We analyzed transcript levels by RT-qPCR based on 
amplicons next to the repeat tracts (Figure 3; primer locations are depicted in more detail in 
A B C
Figure 3. Expression of three mouse transcripts, carrying a small (CUG)n repeat, after transfecting 
DM500 myotubes with a selection of AONs: (A) Ptbp1 (CUG)6, (B) Txlnb (CUG)9 and (C) Mapkap1 
(CUG)26. RNA levels were analyzed by RT-qPCR amplifying segments flanking the triplet repeat (n=3). 
Schemes illustrate exon-exon junctions, locations of PCR primers and amplicons. Dashed lines indicate 
100% levels (mock samples).
Supplementary Figure S4). Ptbp1 (CUG)6, Txlnb (CUG)9 and Mapkap1 (CUG)26 - the longest 
(CUG)n tract in the mouse transcriptome - showed no significant changes in expression after 
AON treatment (Figure 3). Note that due to the location of the (CUG)9 tract in the very 5’ end 
of the Txlnb gene, no suitable 5’ amplicon could be designed to measure Txlnb transcripts.
We also wanted to analyze RNA expression via amplification across the (CUG)n triplet 
repeat. Semi-quantitative RT-PCR for Ptbp1 and Txlnb transcripts confirmed the RT-qPCR 
findings and showed no significant change in expression (Supplementary Figure S5A,B). 
Remarkably, quantification across the Mapkap1 (CUG)26 repeat did record significant 
silencing after AON treatment, especially by PS146 (CAG)10 (Supplementary Figure S5C). 
This effect was not seen, however, when segments flanking the (CUG)26 tract were amplified 
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in the same assay. Also Northern blotting, visualizing two types of Mapkap1 transcripts as 
a result of alternative polyadenylation [17] (Supplementary Figure S4), revealed only a minor 
reduction in RNA expression, while Western blotting revealed no significant changes 
in Mapkap1 protein expression (Supplementary Figure S5D,E). We therefore decided 
that PCR-based quantification should not rely on amplification across a medium-sized 
(CUG)n tract.
Given these observations, we wanted to exclude the possibility that traces of AONs 
that might still be present in purified RNA samples would interfere with RT-PCR analysis. 
Using a hybridization-ligation method, we determined that free AON concentration in our 
RNA preparations was less than 0.2 nM. To rule out interference of (CAG)n AONs with RT 
or PCR amplification, untreated DM500 RNA samples were spiked with 0.1-10 nM PS147, 
PS58 or PS146 and correspondingly used in RT-PCR analysis. Presence of AONs during 
RT-PCR amplification did not have an effect on Mapkap1 (CUG)26 levels nor on quantification 
of hDMPK (CUG)500 RNA (Supplementary Figure S6). In sum, we conclude that transcripts 
containing small (CUG)n tracts were largely unaffected by the (CAG)n and (CIG)n repeat 
oligos tested.
Mouse transcripts carrying a small (CAG)n segment
To examine the possibility that oligo-mediated hDMPK RNA breakdown would generate 
short (CUG)n RNAs that in turn might act as siRNAs on complementary (CAG)n transcripts 
(compare [16]), we measured levels of mouse transcripts with a small (CAG)n segment: Sec24b 
(CAG)15, Hcn1 (CAG)7+(CAG)20 and Nr3c1 (CAG)17. After treatment with PS147, PS58, PS146 
and PS261 no significant change in expression of any of these transcripts was detectable 
by RT-qPCR analysis (Figure 4) ruling out an indirect effect of (CAG)n AONs on transcripts 
bearing a (CAG)n segment in the transcriptome.
(CUG)n length selectivity in DM1 patient myoblasts
A safe, antisense strategy for DM1 should differentiate between expanded and normal-
sized hDMPK transcripts. To test this requirement, we used two DM1 myoblast cultures: 
one expressing hDMPK transcripts with 21 (normal) and 200 (mutant) triplets (abbreviated 
21/200) and another with 5 and 1400 CUG triplets (abbreviated 5/1400) [18]. Activities 
of three 2’-OMe AONs, PS147, PS58 and PS146 were examined in these cultures, with 
use of Northern blotting to discriminate between normal and mutant hDMPK RNA. 
The three pure 2’-OMe/PS AONs behaved equally (Figure 5A): levels of (CUG)1400 and 
(CUG)200 transcripts were strongly decreased (65-95%). (CUG)21 transcripts appeared 
less susceptible to breakdown (45-55%) and as expected, (CUG)5 hDMPK mRNA was 
left intact. Silencing efficacy significantly correlated with the number of CUG triplets in 
the transcripts (Figure 5B).
Western blot analysis showed that silencing of hDMPK transcripts by PS146 (CAG)10 
resulted in around 50% loss of DMPK protein after 72 h in 21/200 myoblasts (Figure 6). No 
effect of PS147 (CAG)5 or PS58 (CAG)7 treatment was observed at this time point.
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Human transcripts containing a small (CUG)n segment
Also in the human transcriptome (CUG)n tracts are relatively rare [8,19]. Effects of a subset of 
2’-OMe/PS AONs on transcripts bearing a (CUG)n repeat expressed in 5/1400 myoblasts were 
examined for two transcripts: BPGM (CUG)8 and MAP3K4 (CUG)10 by RT-qPCR. No reduction 
of BPGM transcripts was detected after treatment with PS147 and PS146, while only a small 
effect was seen with PS58 (25% reduction) (Figure 7A). Similar effects for BPGM (CUG)8 were 
detected in 21/200 myoblast cultures (data not shown).
Total MAP3K4 mRNA levels were not affected by 2’-OMe AON treatment (Figure 7B). 
A conspicuous observation was made with regard to an effect on MAP3K4 pre-mRNA 
processing. Analysis of the fate of alternative exon 17 [20], which contains the short (CUG)10 
repeat that might serve as target, revealed that PS146 (CAG)10 was able to enhance exon 17 
skipping (Supplementary Figure S7). Effects on alternative splicing by shorter (CAG)n oligos 
were only minor.
Investigating potential mechanisms of expanded hDMPK transcript silencing
We wondered whether exon skipping could also be the underlying or initiating mechanism 
of PS58-induced silencing of expanded hDMPK transcripts. Human DMPK pre-mRNAs 
are subject to extensive alternative splicing and events involving final exon 15, in which 
the (CUG)n tract is located, have been reported [21,22]. For analysis of fate of different 
A B C
Figure 4. Analysis of expression levels of three mouse transcripts, containing a (CAG)n repeat, in 
DM500 myotubes after transfection with a selection of AONs: (A) Sec24b (CAG)15, (B) Hcn1 carrying 
a (CAG)7 and a (CAG)20 repeat located close together (see Supplementary Figure S4) and (C) Nr3c1 
(CAG)17. Expression was analyzed by RT-qPCR amplifying segments flanking the triplet repeat (n=3). 
Schemes illustrate exon-exon junctions, locations of PCR primers and amplicons. Dashed lines indicate 
100% levels (mock samples).
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A
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Figure 5. (CUG)n length selectivity in DM1 myoblasts. (A) Human myoblasts expressing either hDMPK 
(CUG)21 and (CUG)200 transcripts (21/200) or hDMPK (CUG)5 and (CUG)1400 transcripts (5/1400) were 
treated with a selection of CAG AONs. Northern blot analysis indicated that expanded hDMPK transcripts 
(‘exp’, arrow heads) were efficiently silenced by all AONs. (CUG)21 transcripts (‘normal’, double arrow 
heads) were moderately silenced. Only RNase-H recruiting PS260 substantially degraded (CUG)5 
transcripts (‘normal’, double arrow head). One representative blot of three independent experiments 
is shown for each cell culture. Quantification of signals is summarized in the graphs at the bottom. (B) 
A significant correlation was demonstrated between the number of CTG triplets and silencing activity 
of PS147, PS58 and PS146 (P<0.05, Pearson’s correlation, r = -0,98), but not PS260.
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Figure 6. Analysis of DMPK protein expression after AON treatment. Human myoblasts (21/200) 
expressing hDMPK (CUG)21 and (CUG)200 transcripts were treated with a selection of (CAG)n AONs. 
After 72 hours, protein lysates were made and DMPK protein (arrow head) levels were analyzed by 
Western blotting (n=3). Tubulin protein was used as a loading control. Lysate from Dmpk knock-out 
myoblasts served as reference (right two lanes).
Figure 7. Analysis of expression of two transcripts, each containing a small (CUG)n repeat, in DM1 
patient myoblasts (5/1400) after transfection with a selection of AONs. RNA levels of (A) BPGM (CUG)8 
and (B) MAP3K4 (CUG)10 were measured by RT-qPCR (n=3). Schemes illustrate exon-exon junctions and 
locations of PCR primers and amplicons. Dashed lines indicate 100% levels (mock samples).
A B
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hDMPK RNA segments in presence of AONs, we used a transcript scanning RT-qPCR approach 
for amplicons along the expanded hDMPK transcript in DM500 myotubes. Amplicons were 
designed in the 5’ end of the gene (exon 1 - exon 2, exon 4 - exon 5) and on either side of 
the (CUG)n tract in exon 15 (Figure 8). No significant differences were found in signal strength 
for any of these hDMPK segments (70-85% reduction for all segments across the transcript, 
compared to mock-treated samples). This finding indicates that PS58-induced skipping of 
the (CUG)n tract during hDMPK pre-mRNA splicing is unlikely to be mechanistically involved.
Test-tube incubation of radioactively labeled, in vitro transcribed (CUG)90 RNA with 
a concentration series of PS58 (CAG)7 caused a mobility shift illustrating direct oligo-RNA 
association (Supplementary Figure S8). Similar shifts were seen after incubation of different 
(CAG)n and (CUG)n AONs with (CUG)90 or (CAG)90 RNAs (Supplementary Figure S8). To 
exclude that triplet-repeat 2’-OMe AONs had an intrinsic RNase activity, similar to ribozymes 
or DNAzymes [23], (CUG)n RNA was incubated with a series of different AONs in the presence 
of various concentrations of Mg2+, Mn2+ or Zn2+ (Supplementary Figure S8; data not shown). 
No (CUG)n breakdown products could be detected, indicating that under the conditions 
tested none of these AONs displayed RNase-like activity when complexed to (CUG)n RNA.
Using the same (CUG)90 RNA template, we could confirm that PS58, a fully modified 
2’-OMe AON, was unable to induce RNase-H mediated degradation of expanded (CUG)n 
transcripts in vitro (Supplementary Figure S8). As positive controls, we used DNA-type AON 
PS142 and gapmer PS260, which both were able to recruit RNase-H to cleave (CUG)90 RNA. 
Figure 8. Human DMPK (CUG)500 RNA expression in DM500 myoblasts after transfection with PS58 
or scrambled-PS58. Expression of four different transcript segments (little black bars) was analyzed by 
RT-qPCR (n=3): two in the 5’ end of the transcript and two flanking the triplet repeat in the 3’ end of 
the transcript. Scheme illustrates exon composition (numbered boxes) of hDMPK transcript, arrowhead 
indicates reported cryptic splicing site 3’ to the triplet repeat [22]. Dashed lines indicate 100% 
levels (mock samples). No significant differences in response to the oligos were observed between 
the four segments.
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Activity of gapmer PS260 was also examined in human myoblasts, but with an apparent 
lack of specificity (Figures 5 and 6). More than 60% of both expanded and normal-sized 
hDMPK transcripts was degraded. Similar lack of specificity was observed for BPGM (CUG)8 
and MAP3K4 (CUG)10 RNAs, for which a 40% reduction in steady-state copy number was 
observed (Figure 7). Since the MAP3K4 exon17+ variant and the exon17- variant (which 
lacks the AON target site) were equally reduced by PS260, we conclude that RNase-H 
dependent degradation must have occurred in the nucleus, prior to exon 17 splicing 
(Supplementary Figure S7).
Complement activation by triplet repeat AONs
All triplet repeat oligos were well tolerated by cells in culture and essentially no toxic 
effects on growth or behavior were observed (data not shown). A well-known toxic side 
effect of antisense oligonucleotides in vivo, especially phosphorothioate-modified versions, 
is activation of the complement pathway [24]. As a prelude to later pre-clinical studies 
in animals and humans, we tested a selection of our PS-modified AONs with different 
chemistries and sequences for their ability to activate complement in plasma in vitro: full 
2’-OMe (PS58, PS146, PS147, PS261), chimeric 2’-OMe/DNA (PS260) and pure DNA (PS142). 
A first generation oligonucleotide known to activate the complement pathway was 
included as a positive control [25]. Formation of complement split products C3a (marker 
for the classical and alternative pathway) and Bb (marker for the alternative complement 
pathway) was measured in plasma from cynomolgus monkeys and humans after addition 
of AONs (Supplementary Figure S9). In particular PS261 (CIG)7, and to a lesser extent PS146, 
PS147 and PS260, caused a significant dose-dependent increase in the concentration of Bb 
in cynomolgus plasma. Only PS261 and PS260 activated C3a formation in human plasma. 
Other AONs showed no significant or minor effects.
 | D I S C U S S I O N
This study demonstrates that a range of triplet repeat AONs is capable of silencing expanded 
hDMPK transcripts. The long (CUG)n target that characterizes toxic hDMPK transcripts is 
a special RNA sequence in the sense that it can form a stem-loop structure that folds almost 
like an antiparallel double-stranded helix, despite the periodic U•U mismatches [26]. We 
conclude that the thermodynamically stable hairpin structure, known to sequester members 
of the MBNL protein family, does not hamper accessibility of antisense repeat AONs, when 
in the cellular context. The (CUG)n repeat, whose length differs between normal-short and 
mutant-expanded hDMPK transcripts, is therefore an attractive therapeutic target.
Chemical modifications of the sugar phosphate backbone of AONs serve to confer 
resistance against nucleases to extend cellular half-life [13]. The silencing activity of 
modified AONs PS142 and PS260 versus the inability of pure DNA AON PS56 to induce 
breakdown clearly illustrates the relationship between stability and efficacy. Oligo chemistry 
may also determine nucleocytoplasmic distribution of AONs. As target transcripts in DM1 
are concentrated in the nucleus, an AON must be capable to enter this compartment to 
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become useful. Microscopic evidence is provided that ENA-modified AONs remain in 
vesicular structures and only inefficiently reach the nucleus, rendering them a poor choice 
for repeat-directed antisense DM1 strategies. We have no simple explanation for this finding, 
as similarly modified 2’-OMe RNA/ENA chimeras have shown activity in the nucleus during 
exon skipping for Duchenne muscular dystrophy [27]. Effects of nucleotide sequence on 
subcellular oligo localization cannot be excluded at this point. Also the type of cell model 
and transfection method used may have an effect.
Not all types of AONs were equally efficient and specific, but as we compared only 
triplet repeat oligos here, some conspicuous observations are worth mentioning. First, 
as an explanation for the failure of (CUG)n/(CAG)n triplet repeat siRNAs to induce an 
RNAi response, we assume that a combination of chemistry and oligo sequence must 
be responsible. The poor performance of the two duplexes tested can be the result of 
unfavorable subcellular distribution of siRNAs, although the RNAi machinery is known to 
be active in the nucleus [28]. Alternatively, the (CUG)n RNA hairpin may be insufficiently 
accessible to certain components of the RNAi pathway in our myogenic cell model. Very 
recently, a comparable triplet repeat siRNA was successfully tested in vivo in skeletal muscle 
in a mouse model for DM1. (CUG)220 expanded RNA and also Txlnb (CUG)9 transcripts were 
reduced, but not Mapkap1 (CUG)25 RNA [29]. 
Secondly, oligo PS261 (CIG)7 was initially considered a promising new lead compound, 
because of its predicted ability to bind to (CUG)n as well as (CAG)n transcripts, with 
potential for treatment of DM1 and polyQ diseases like Huntington’s disease and several 
spinocerebellar ataxias. From the complement activation assay we learned, however, that 
this AON activated the complement cascade, rendering it a less favorable candidate for 
further development. Virtually none of the other AONs showed major adverse effects in vitro, 
with the best performing oligo being PS58. Screening for toxicity profiles in animals in vivo 
will be a logical next step.
Thirdly, RNase-H recruiting AON PS260 appeared to have prominent silencing capacity, 
but also suffered of lack of target specificity. Further characteristics of these DNA-type AONs 
will be discussed below in the context of mechanistic considerations. 
The main focus of our study had to do with AONs based on 2’-OMe/PS chemistry. For 
these AONs we demonstrated that oligo length may provide a means to introduce selectivity 
between expanded transcripts from a mutated hDMPK allele and RNA containing a normal, 
short (CUG)n tract. The shortest variant in our series of four to thirteen CAG triplets was 
unable to knockdown expanded transcripts in DM500 myotubes. The hybridization strength 
of the four CAG triplet AON may have been insufficient for a stable interaction with a (CUG)n 
segment in the living cell, even though the theoretical Tm for this interaction is around 39
oC.
AONs longer than four triplets all very efficiently silenced transgenic (CUG)500 transcripts. 
Significant (CUG)n-repeat length dependent activity in patient cells was displayed by (CAG)5, 
(CAG)7 and (CAG)10 2’-OMe/PS AONs. Between them they showed no significant difference 
in activity towards normal-sized hDMPK transcripts: (CUG)5 transcripts, expressed by ~40% 
of the Caucasian population [4], were left intact and (CUG)21 transcripts were ~50% reduced 
by all three AONs. In contrast, differential effects were observed at the DMPK protein level, 
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which might indicate a correlation with translation efficiency of remaining hDMPK transcripts. 
It should be noted that we cannot predict at the moment whether partial reduction 
of normal-sized transcripts will have any adverse consequences. We know that Dmpk 
knock-out mice have relatively mild phenotypes [30], hence a low level of remaining Dmpk 
protein might be sufficient to protect functional and structural integrity of cells in which it 
is expressed. Another still unresolved issue is the minimum efficacy needed for a beneficial 
effect. Partial suppression of toxic (CUG)n RNA may already be of clinical relevance 
in DM1 patients.
Expression of genes with a small (CTG)n repeat in myogenic cells was essentially 
unchanged upon treatment with 2’-OMe/PS AONs, except for MAP3K4. PS146 (CAG)10 
enhanced skipping of MAP3K4 exon 17 in which the (CUG)10 repeat is located. This (CUG)10 
repeat is unusual as it is located in an alternative exon, where it might function as an exon 
splicing enhancer [31]. To what extent exon 17+ and exon 17- transcript variants contribute 
to protein production is unknown. More importantly, it is unclear whether a shift in MAP3K4 
isoform ratio would have a biological effect. Nothing is known about functional differentiation 
generated by inclusion of the 50 amino-acid stretch encoded by in-frame exon 17 (including 
10 alanines encoded by the repeat tract). The minor shift in MAP3K4 variant ratio induced by 
smaller (CAG)n AONs is essentially within the normal variation observed in mock samples. 
Note that since splicing is a nuclear process, we can conclude that PS146 (CAG)10 must have 
been active inside the nucleus.
It is difficult to reconcile all observations regarding Mapkap1 (CUG)26 transcripts. First, as 
also seen with MAP3K4 transcripts, oligo length is an important parameter for AON activity 
and side effects seem to intensify with increased oligo length. Secondly, we provide ample 
evidence that our oligos did not interfere with RT-PCR quantification. Third, we propose that 
special care should be taken with RNA quantification based on amplicons covering a triplet 
repeat of more than ten units. These amplicons will never meet requirements for RT-qPCR 
analysis, but they may also be useless in semi-quantitative RT-PCR. For that reason, we 
generally used segments outside the repeat region for PCR quantification. Similar warnings 
regarding RT-PCR and use of AONs have been issued by others [32]. Given the location of 
the (CTG)26 repeat in between two alternative polyadenylation sites of the Mapkap1 gene 
[17], we cannot exclude length-dependent AON effects on splicing, transcription termination 
or polyadenylation. Clearly, more work is needed to be able to unequivocally interpret 
these data.
What do we know about the molecular mechanism underlying silencing activity of 
hDMPK transcripts by triplet repeat AONs examined here? Although the goal of this study 
was not to identify distinct pathways or describe novel interference principles, our findings 
provide important new insight in potential activities of triplet repeat AONs.
In a series of simple biochemical test tube experiments, we first investigated whether 
triplet repeat 2’-OMe/PS AONs might carry intrinsic endoribonuclease activity, similar to 
ribozymes or DNAzymes [23]. In none of the experiments RNase activity was detected. 
Although we also tested several cell-free or protein-free conditions (data not shown), it 
cannot be excluded that the right cellular reaction conditions were not fully reproduced.
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We provide evidence that PS260, a (CAG)7 gapmer, efficiently reached various 
(CUG)n RNA targets, irrespective of repeat length, and recruited endogenous RNase H for 
a first endonucleolytic cleavage. We expect that unprotected 5’ and 3’ RNA segments will be 
degraded after initial cleavage by conventional exonucleases as part of the quality control 
system in the cell [33]. Surprisingly, PS260 showed only little selectivity between expanded 
and normal-sized hDMPK transcripts in patient cells, suggesting that either RNase H activity 
took place in both the nucleus and the cytosol, or that degradation already occurred swiftly, 
during or shortly after RNA synthesis in the nucleus. Our observations contrast with a report 
that an LNA-based repeat gapmer did cleave hDMPK (CUG)40, but not (CUG)12 transcripts 
[10]; and also with a study in which a (CAG)6 LNA gapmer did not reduce CASK (CUG)16 
RNA [34]. The reason for these discrepancies should probably be found in oligo chemistry, 
concentration or model system used. 
Nucleotide analogs like morpholinos or modifications like 2’-OMe do not support RNase-H 
dependent degradation. These AONs must therefore use distinct pathways, explaining 
why PS58, a 2’-OMe/PS (CAG)7 AON, and PS260, displayed differential (CUG)n-length 
dependent silencing.
The RNAi pathway is unlikely to be involved in activity of fully 2’-OMe/PS AONs or 
(CAG)n morpholinos. Imperfect hybrids of 2’-OMe/PS or morpholino (CAG)n AONs, or perfect 
hybrids that these AONs may form with (CUG)n transcripts, will not be recognized by the RNAi 
machinery [35-37]. Furthermore, the size of the shortest effective AON (15 nucleotides) and 
tolerated 5’ modifications like a fluorescent group (as in FAM-PS58) or a peptide (data not 
shown) render involvement of the RNAi pathway highly unlikely [38,39]. Also, we did not find 
evidence for AON-induced processing of expanded hDMPK transcripts into (CUG)n siRNAs 
that could trigger degradation of (CAG)n transcripts.
Fully 2’-OMe/PS-modified AONs, like PS58, and morpholinos are usually designed and 
employed to serve as blocking oligos to modulate splicing or prevent translation [13,40]. As 
discussed above, PS146, a 30 nt-long 2’-OMe/PS AON, exhibits splicing modulating activity. 
We could not detect a similar activity of (CAG)n AONs towards hDMPK (CUG)500 transcripts. 
The most logical explanation for this observation is the location of the (CUG)n repeat in 
the final exon of the hDMPK gene. The only reported splice acceptor, located around 35 nt 
3’ of the (CUG)n tract, is only rarely used [22,41] and probably too weak to be amenable 
to manipulation. 
A (AGC)8A morpholino reportedly blocked Mbnl1 protein binding to transgenic 
(CUG)250 transcripts in a mouse model for DM1-related RNA toxicity [9]. In that study, 
cytoplasmic levels of expanded transcripts raised upon treatment, but the total amount 
of (CUG)250 transcripts was ~50% reduced. A comparable reduction was reported for 
expanded Huntingtin (CAG)n RNA using a (GCT)6G LNA-type blocking oligonucleotide [42]. 
The molecular mechanism underlying activity of the AGC morpholino is unknown, but it 
was suggested that the displacement of expanded transcripts to the cytoplasm may have 
induced hDMPK mRNA decay. We propose that a similar mechanism may be at play for our 
(CAG)n morpholino and the 2’-OMe/PS AONs examined here. Alternatively, this class of AONs 
may activate a yet to be identified RNase or RNA decay program in nucleus or cytoplasm. 
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Our current working hypotheses are that the interaction between (CAG)n AONs and 
the (CUG)n repeat attracts proteins involved in RNA degradation or that AON binding 
displaces RNA protecting proteins resulting in naked RNA, which is extremely sensitive to 
RNases. Further detailed studies into these interesting possibilities are warranted.
In sum, we provide further evidence that the expanded (CUG)n segment in hDMPK 
mRNA, being the product from the only known mutation in DM1, forms an attractive target 
for antisense oligonucleotide therapy. For development of future treatment modalities, 
chemical structure and oligo length in combination with the rather special sequence content 
needed – i.e., the complementary (CAG)n repeat character – have now been identified 
as crucial determinants. By extrapolation of findings, our results also open up interesting 
possibilities for therapy of other triplet repeat diseases.
 | M AT E R I A L S  A N D  M E T H O D S
Cell culture
Immortalized DM500 myoblasts were derived from DM300-328 mice [43] and cultured and 
differentiated to myotubes as described [8]. Human DM1 myoblast lines were derived and 
cultured as described [18].
Oligonucleotides
AONs and siRNAs were complementary to the (CUG)n repeat. Their sequence and chemistry 
are listed in Figure 1A and Supplementary Table S1, except for control oligos scrambled-PS58: 
5’-CAGAGGACCACCAGACCAAGG-3’; and PS57: 5’-CUGCUGCUGCUGCUGCUGCUG-3’ (both 
fully 2’-OMe/PS-modified). All AONs and siRNAs were provided by Prosensa (Leiden, NL), 
except morpholino PS304, which was purchased coupled to an octaguanidine dendrimer 
from Gene Tools (Philomath, OR, USA) and control siRNA was purchased from Thermo 
Scientific Dharmacon (Lafayette, CO, USA).
Oligo transfection
AONs were transfected using polyethyleneimine (PEI; ExGen 500, Fermentas, Glen Burnie, 
MD, USA) according to manufacturer’s instructions. Typically, 5 μl PEI/μg AON was added at 
a final AON concentration of 200 nM in differentiation medium to myotubes on day five of 
myogenesis or in Opti-MEM (Invitrogen, Carlsbad, CA, USA) to myoblasts. For concentration-
response experiments, oligo concentrations between 0.01 nM and 500 nM were applied. Four 
hours later fresh medium was supplemented to a maximum volume of 2 ml medium/well. 
Medium was changed 20 hours later. RNA was isolated 48 hours after start of transfection. 
PS304 was tested following the same protocol with the exception that no transfection 
reagent was used.
SiRNAs were administered twice (on subsequent days: day four and five of myogenesis) 
using a Lipofectamine 2000-based transfection protocol (Invitrogen) according to 
manufacturer’s instructions, at a final concentration of 50 nM. Four hours following addition 
of the transfection mix and 24 hours after start of the second transfection medium was 
changed. RNA was isolated 48 hours after the second transfection.
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Oligo stability
AONs (7.5 pmoles) were radioactively labeled by T4 polynucleotide kinase in the presence of 
[γ-32P]-ATP and then purified on G50 columns followed by ethanol precipitation.
DM500 myoblast whole cell extract was prepared by scraping approx. 1x106 cells per well 
in PBS containing 1 mM EDTA. Cells were collected via centrifugation (1000 rpm, 5 min), 
packed cell volume (PCV) was estimated and cells were resuspended in 1x PCV of 10 mM 
Tris-HCl pH 8.0, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT and 1x Protease Inhibitory Cocktail 
(Roche, Almere, NL). Cell suspensions were placed on ice for 15 min and homogenized using 
a pestle. Whole cell lysate was collected after centrifugation (14,000g, 10 min).
AONs (approx. 2 pmoles) were incubated with 5 µl whole cell lysate at 37°C for 0, 3 or 24 
hours, reaction was stopped by adding 140 mM sodium acetate, pH 5.0, phenol/CHCI3 and 
water phase was collected (14,000g, 10 min, 4°C). Oligo was precipitated by the addition 
of three volumes of ethanol. The oligo precipitate was washed with 70% (v/v) ethanol, air 
dried and dissolved in sample buffer (75% deionized formamide, 25% glycerol). Samples 
were loaded on a 12% (w/v) acrylamide/ bisacrylamide (37.5:1) denaturing-urea (8 M) PAGE 
gel in 1x MOPS buffer. After running, gels were dried at 70°C for 2 hours and exposed to X-ray 
film (X-Omat AR, Kodak, Rochester, USA).
RNA isolation
RNA was isolated using the Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA, USA), according 
to the manufacturer’s protocol.
Northern blotting
Northern blotting was done as described [8]. Random-primed 32P-labelled human DMPK 
(2.6 kb cDNA), rat Gapdh (1.1 kb cDNA) and mouse Mapkap1 (1.1 kb cDNA) probes were 
used. Signals were quantified by phospho-imager analysis (GS-505 or Molecular Imager FX, 
Bio-Rad) and analyzed with Quantity One (Bio-Rad) or ImageJ software. Gapdh levels were 
used for normalization. RNA levels of control samples were set at 100%.
RT-PCR 
Primer sets for PCR were designed using Primer-BLAST [44] in the NCBI database and 
validated in silico using OligoAnalyzer 3.1 [45] to prevent formation of hairpins and 
dimers during amplification. Resulting products were visualized on agarose gels and 
sequenced to verify identity and triplet repeat length. Primer sequences are listed in 
Supplementary Table S2.
For reverse transcription (RT), typically 0.5 μg RNA was subjected to cDNA synthesis using 
the SuperScript first-strand synthesis system with random hexamer primers in a total 
volume of 20 μl. For RT-PCR experiments in presence of AONs, AONs were added to the RNA 
to reach the indicated final concentration and incubated for 15 min on ice before starting 
the RT reaction.
For semi-quantitative RT-PCR, one μl of cDNA preparation was used in a PCR according 
to standard procedures. In RT- control experiments, reverse transcriptase was omitted. 
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The signal for β-actin was used for normalization. Cycle number was 18 for β-actin and 
22-31 for other primer sets. PCR products were analyzed on 1.5-2.5% agarose gels stained 
by ethidium bromide. Quantification of signals was done using Labworks 4.0 software (UVP 
BioImaging Systems, Cambridge, UK). Values for control samples were set at 100%.
For real-time RT-PCR (RT-qPCR), all procedures were performed following the Minimum 
Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines 
[46]. Amplification efficiency of primer sets was determined using standard curves (serial 
dilutions; 10- 5000 fold range). Primers sets displaying less than 90% efficiency in product 
amplification were ruled out and re-designed. cDNA preparations (see RT reaction 
above) were diluted 200-500 fold to avoid PCR inhibition by RT components. 3 µl of this 
dilution was mixed in a final volume of 10 µl containing 5 µl 2X Sybr Green mix (Roche 
Applied Science, Almere, NL) and 400 nM of each primer using the CAS-1200 automated 
pipetting system (Corbett Life Science/Qiagen, Venlo, NL). No template control (NTC) and 
no reverse transcriptase control (RT_) were included in each qPCR run to detect possible 
contaminations. Samples were analyzed using the Rotor-Gene 6000 (Corbett Life Science) 
or CFX96TM Real-time System (Bio-Rad). A melting curve was obtained for each sample in 
order to confirm single product amplification. Relative mRNA levels were calculated using 
the ΔΔCt method [47]. Both Actb and Gapdh were used for normalization. We validated that 
these reference genes were not affected by the treatment and had an optimal M stability 
value [48] under all experimental conditions. Values of control samples were set at 100%.
AON hybridization ligation assay
PS58 concentrations were determined by a hybridization-ligation assay as published 
by Yu et al. [49] with a few modifications: Template DNA probe (5’-GAATAGACGCTGCTGC 
TGCTGCTGCTGCTG-biotin-3’) and ligation DNA probe (5’-P-CGTCTATTC-digoxigenin 
(DIG)-3’) were used. Samples were incubated with the template probe (50 nM) at 37°C for 1 
hour and hybridized samples were transferred to streptavidin-coated plates. Subsequently, 
plates were washed four times and the DIG-labeled ligation probe (2 nM) was added and 
incubated for 30 min at ambient temperature. DIG label was detected using an anti-DIG-
POD (1:7,500; Roche Diagnostics), visualized with a 3,3’,5,5’-tetramethylbenzidine substrate 
(Sigma Aldrich, Zwijndrecht, the Netherlands). The reaction was stopped using maleic acid 
(345 mM, Sigma Aldrich). Absorption was measured at 450 nm using a BioTek Synergy HT 
plate reader (Beun de Ronde, Abcoude, NL). All samples and calibration curves were diluted 
(fit to criteria of the assay) in PBS. Absorption was read against a calibration curve of PS58 in 
PBS. A sample containing only PBS was used as correction for background.
Live cell imaging
DM500 myoblasts were cultured on gelatin-coated glass-bottom Willco dishes (Willco Wells, 
Amsterdam, NL). Cells were analyzed directly after addition of the transfection mix containing 
FAM-PS58 or Cy3-PS138 in RPMI medium without phenol red and including 10 mM HEPES 
and 10% FCS, (Invitrogen). A Zeiss LSM510meta confocal laser-scanning microscope was 
used, equipped with a temperature controlled CO2 incubator (type S) and sample stage. For 
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recording of oligo uptake, we used a PlanApochromatic 63x, 1.4 NA oil immersion DIC lens 
(Carl Zeiss GmbH, Jena, Germany).
Western Blotting
DM1 patient 21/200 myoblasts or DM500 mouse myotubes were transfected with PS147, 
PS58, PS146, PS260 or PS261 as indicated (200 nM) or mock transfected and 72 h later 
lysed in lysis buffer (TBS, 1% Nonidet P-40, 1 mM PMSF and Protease Inhibitory Mixture 
(Roche, Almere, The Netherlands)) on ice. Cleared lysates were separated on an 8% SDS/
PAGE gel and transferred to PVDF (Amersham Pharmacia Biotech). Blots were incubated with 
DMPK-specific antibody B79 [21] or anti-SIN1/Mapkap1 antibody (ab71152, Abcam, 
Cambridge, UK) and β-tubulin monoclonal antibody E7 (Developmental Studies Hybridoma 
Bank, University of Iowa), followed by ECL detection. Quantification of signals was done 
using ImageJ software. Values for mock-treated samples were set at 100%.
Experiments using in vitro transcribed triplet repeat RNA
(CUG)n and (CAG)n RNA was generated by in vitro transcription of a hDMPK (CTG)90 DNA 
template carrying flanking T7 and SP6 promoters. The hDMPK (CTG)90 template was 
generated by PCR using a hDMPK cDNA construct bearing a (CTG)90 repeat [50], T7-hDMPK 
forward primer 5’-GAATTTAATACGACTCACTATAGGGAGAACGGGGCTCGAAGGGT-3’ and 
SP6-hDMPK reverse primer 5’-ATTTAGGTGACACTATAGAAGGGCGTCATGCACAAGAAA-3’ and 
sequenced to verify triplet repeat number. (CUG)90 and (CAG)90 RNAs were synthesized in 
presence of [α-32P]GTP, using the MEGAscript® in vitro transcription kit (Applied Biosystems/
Ambion, Austin, TX, USA) according to manufacturer’s protocol.
To confirm AON binding to expanded triplet repeat RNA, (CUG)90 RNA was incubated 
with a concentration series (1, 10 and 100 μM) of PS58 in 50 mM Tris-HCl, pH 7.5 and 25 mM 
MgCl2 for 2 hours at 37°C. Sample buffer was added to a final concentration of 50% deionized 
formamide and 30% glycerol and samples were run at room temperature on a denaturing 
polyacrylamide gel (5% acryl/bisacryl, 8 M urea) in 1x MOPS. Gels were dried and exposed to 
X-ray film (X-Omat AR, Kodak).
To reveal binding specificity, (CUG)90 and (CAG)90 RNAs were incubated with 100 μM 
AONs in the presence of 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 25 mM MgCl2 and 1 mM EDTA 
for 2 hours at 37°C. Samples were next analyzed by electrophoresis as described above.
To examine RNase-H dependent activity, (CUG)n RNA was dissolved in 50 mM Tris-HCl, 
pH 7.5, 50 mM KCl, 5 mM MgCl2 and 1 mM DTT and incubated with 60-100 μM AON in 
the presence of 20 U/ml RNase H for 1 hour at 37°C. Samples were analyzed by electrophoresis 
as described above with the exception that the 1x MOPS running buffer was heated to 70°C 
before start of electrophoresis to induce dissociation between AONs and (CUG)n RNA.
To examine intrinsic oligo catalytic activity, (CUG)n RNA was dissolved in 100 mM 
Tris-HCl, pH 7.5, 100 mM NaCl and 1 mM EDTA and incubated with 100 μM AON for 2 hours 
at 37°C in the presence of 3.5 or 25 mM MgCl2. Samples were analyzed by electrophoresis 
as described above.
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Complement activation assay 
The potency of AONs to activate the complement pathway was demonstrated using 
Li+-heparin plasma from cynomolgus monkeys (kindly provided by CIT, France) and 
Li+-heparin plasma from healthy human donors (Sanquin, The Netherlands). AONs were 
added to plasma in various concentrations (25, 50, 150 and 300 µg/ml in a dilution of 
approx. 1:20 (volume AON/volume plasma)) and the samples were incubated at 37°C for 
30 min. The reaction was terminated by putting the samples on ice and adding ice-cold 
diluents according to the manufacturer’s protocol (Quidel, San Diego, CA, USA). Bb and 
C3a concentrations were determined by ELISA (Quidel). First generation oligonucleotide 
PS455 (ISIS 5132) was included as a positive control, as this oligo has been shown to activate 
the complement pathway [25].
Statistical Analysis
Northern blot and PCR signals were analyzed using an unpaired Student’s t-test or a one-way 
ANOVA. All values in graphs are presented as the mean ± SEM. Pearson’s correlation was 
applied to evaluate whether a correlation exists between silencing efficacy and number 
of CTG triplets in hDMPK alleles in human myoblasts. Differences between groups were 
considered significant when P<0.05: *, P<0.05; **, P<0.01; ***, P<0.001. Statistical analyses 
and sigmoidal concentration curve fitting were performed with GraphPad Prism 4 software 
(GraphPad Software, Inc., La Jolla, CA, USA).
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Figure S1. AON stability in cell extract. AONs were end-labeled with [γ-32P] ATP, incubated in DM500 
whole cell extract for 0, 3 or 24 hours and then analyzed by polyacrylamide gel electrophoresis. PS56 
was almost completely degraded after 24 hours. Chemically modified AONs PS58 and PS136, and siRNA 
PI-02 were still present after 24 hours incubation. Numerals at the bottom indicate quantification by 
phosphoimager analysis.
Figure S2. Concentration-response curve of PS142 including raw data. DM500 myotubes were treated 
with a concentration series of 0.01-500 nM of this AON. RNA was isolated 48 hours post-transfection 
and hDMPK transcript levels were analyzed by Northern blotting. Data points are the mean of at least 
three measurements.
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Figure S3. Differential uptake and localization of AONs in DM500 myoblasts. DM500 myoblasts 
were transfected with (a-f) FAM-PS58 or (g-l) Cy3-PS138. Uptake was visualized by live cell imaging. 
Time points indicate minutes after addition of the oligo-transfection reagent complex to the culture 
medium. Phase contrast (e, k) and dashed lines help to recognize cell boundaries (see also merge). 
Essentially no nuclear localization was detected for ENA-modified PS138, whereas 2’-OMe/PS-modified 
PS58 showed prominent nuclear localization. Intense signals in panels a-f represent FAM-PS58-
polyethyleneimine complexes in the medium. Representative images of two independent experiments 
are shown. The type of fluorophore used did not affect AON behaviour (data not shown). Bars: 20 µm.
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Figure S4. Schematic representation of triplet repeat transcripts and segments thereof, analyzed by 
RT-(q)PCR. Boxes indicate exons. (CUG)n and (CAG)n tracts are highlighted in red and blue, respectively. 
PCR primers are represented by arrows. Transcript lengths are based on NCBI Reference Sequences and 
indicate nucleotides. pA indicates alternative polyadenylation site in Mapkap1.
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Supplementary Figure S5.
Expression of mouse transcripts, carrying a small (CUG)n repeat, after transfecting DM500 myotubes 
with a selection of AONs: (A) Ptbp1 (CUG)6, (B) Txlnb (CUG)9 and (C) Mapkap1 (CUG)26. 
Semi-quantitative RT-PCR was used to be able to amplify a segment across the repeat. Schemes on top 
illustrate exon-exon junctions, locations of PCR primers and amplicons. Dashed lines indicate 100% 
levels (mock samples). (D) Northern blot containing RNA isolated from DM500 myotubes treated with 
repeat AONs or mock-treated. The blot was incubated with a Mapkap1 probe and a Gapdh probe for 
normalization. Two Mapkap1 transcripts were detected which result from alternative polyadenylation 
(Schroder et al. (2004) Gene, 339, 17-23). The (CUG)26 tract is only present in the long form 
(Supplemental Figure S4). Only a minor reduction in the level of both transcripts was observed upon AON 
treatment (indicated at the bottom). (E) Mapkap1 protein levels were measured by Western blotting 72 h 
after mock or AON treatment (n=3). No significant changes in expression were observed.
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Figure S5. Expression of mouse transcripts, carrying a small (CUG)n repeat, after transfecting DM500 
myotubes with a selection of AONs: (A) Ptbp1 (CUG)6, (B) Txlnb (CUG)9 and (C) Mapkap1 (CUG)26. 
Semi-quantitative RT-PCR was used to be able to amplify a segment across the repeat. Schemes on top 
illustrate exon-exon junctions, locations of PCR primers and amplicons. Dashed lines indicate 100% 
levels (mock samples). (D) Northern blot containing RNA isolated from DM500 myotubes treated with 
repeat AONs or mock-treated. The blot was incubated with a Mapkap1 probe and a Gapdh probe for 
normalization. Two Mapkap1 transcripts were detected which result from alternative polyadenylation 
(Schroder et al. (2004) Gene, 339, 17-23). The (CUG)26 tract is only present in the long form (Supplemental 
Figure S4). Only a minor reduction in the level of both transcripts was observed upon AON treatment 
(indicated at the bottom). (E) Mapkap1 protein levels were measured by Western blotting 72 h after 
mock or AON treatment (n=3). No significant changes in expression were observed.
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Figure S6. Control experiments to exclude perturbing effects of AONs during RT-PCR quantification. 
(A) Purified RNA from DM500 myotubes was incubated with PS147, PS58 or PS146 (0 - 10 nM) 
and subsequently used in a semi-quantitative RT-PCR assay based on an amplicon containing 
the (CUG)26 tract to measure Mapkap1 (CUG)26 levels. Actb RNA was used for normalization (see 
numerals at the bottom). None of the three AONs influenced RT-PCR efficiency, not even at high 
concentration. (B) The same RNA samples were used in a RT-qPCR assay to measure hDMPK (CUG)500 
RNA levels. Amplicons were located in exon 15, 5’ and 3’ of the (CUG)500 tract. Again, no effect of 
(CAG)n AON pre-incubation on RT-PCR efficiency was observed. Dashed lines indicate 100% level 
(mock samples).
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Figure S7. (CAG)n oligos can modulate alternative splicing of the (CUG)n-containing exon in 
the MAP3K4 primary transcript. (A) DM1 patient 5/1400 myoblasts were transfected with a selection 
of AONs followed by semi-quantitative RT-PCR amplifying a segment containing MAP3K4 exon 17, 
including the (CUG)10 repeat. The ex17- variant increased upon PS146 (CAG)10 treatment, while 
the level of the ex17+ variant decreased. Gapmer PS260 (CAG)7 reduced expression of both MAP3K4 
variants. Quantification of results obtained with all four AONs are shown in B (ex17- fraction) and C 
(total MAP3K4 RNA levels). Dashed line indicates 100% level (mock sample).
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Figure S8. Test-tube experiments using in vitro synthesized RNA bearing a (CUG)90 or (CAG)90 tract. 
(A) Schematic representation of the hDMPK gene segment flanked by T7 and SP6 promoters, obtained 
by PCR, used for the synthesis of RNAs with a (CUG)90 or (CAG)90 tract. (B) (CUG)90 RNA was incubated 
for 2 hours at 37°C with different concentrations of PS58 (CAG)7 and then loaded on a polyacylamide 
gel. A concentration-dependent mobility shift was observed revealing oligo-RNA binding. (C) The same 
approach was followed with different (CAG)n or (CUG)n AONs and with (CUG)90 RNA and (CAG)90 RNA, 
with comparable results. (D) Incubation of (CUG)90 RNA with 2’-OMe/PS (CAG)n AONs in presence of 
3.5 or 25 mM Mg2+ for 2 hours at 37°C did not show any proof of ribozyme activity. (E) (CUG)90 RNA was 
incubated with PS58 (2’-OMe/PS), PS260 (2’-OMe/DNA/PS) or PS142 (DNA/PS) in presence of RNase 
H for 1 hour at 37°C. RNase H only degraded RNA in a RNA-DNA duplex (stable products indicated by 
arrowheads). Chemistry and sequence of AONs is listed in Figure 1A. W=position of the wells; F= front.
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Figure S9. Complement activation assay. Complement activation by a selection of AONs was examined 
in plasma from (A) cynomolgus monkeys or (B) humans. Formation of split products Bb (left panels) and 
C3a (right panels) was determined by ELISA. See Figure 1A for AON sequence and chemistry. ISIS 5132 
was used as a positive control (Rudin et al. (2001) Clin. Cancer Res., 7, 1214-1220).
Table S1. SiRNAs (RNA duplexes) used in this study.
PI-01:
5’-CAGCAGCAGCAGCAGCAGCAG-3’ + 5’-GCUGCUGCUGCUGCUGCUGCU -3’
PI-02:
5’-GCAGCAGCAGCAGCAGCAGCA-3’ + 5’-CUGCUGCUGCUGCUGCUGCUG-3’
Control:
5’-CAAGAACGAUUUGCUGACATT-3’ + 5’-UGUCAGCAAAUCGUUCUUGTT-3’
Capital: DNA. Capital, underlined: RNA.
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Table S2. PCR primers used in this study (5’ -> 3’):
qPCR
mActb Fw GCTCTGGCTCCTAGCACCAT
mActb Rv GCCACCGATCCACACAGAGT
mGapdh Fw GTCGGTGTGAACGGATTTG
mGapdh Rv GAACATGTAGACCATGTAGTTG
mPtbp1 (5’) Fw GCATAATGTCAGCCTCTCCGTAT
mPtbp1 (5’) Rv CTCCATGGACATTAGGGACAGAG
mPtbp1 (3’) Fw TGTCCTTTTGGTCAGCAATCTG
mPtbp1 (3’) Rv ACATCACCGTAGACGCCGA
mTxlnb (3’) Fw TTCCTGCTTAGCTCCCTTCCT
mTxlnb (3’) Rv GAGTTGGGTGCTCCACTGAGAG
mSec24b (5’) Fw GGCACCGCCGCAGCAGAA
mSec24b (5’) Rv TGATGAGGCAGCCCATACCCAGAT
mSec24b (3’) Fw GATCCTTGGCTACAGCGAACAGC
mSec24b (3’) Rv AACTGGGTGACTTGGAGCAGGT
mHcn1 (5’) Fw GAGACAGTTGCTATTGACCGACTCG
mHcn1 (5’) Rv GTCATGCTTCACGATCTGCTTCAGG
mNr3c1 (5’) Fw AGTCCCCAGCAGTTTGCTTGGC
mNr3c1 (5’) Rv CGCAGAAACCTTGACTGTAGCTCCA
mNr3c1 (3’) Fw AACTTCGCAGGCCGCTCAGTGT
mNr3c1 (3’) Rv CAGGCAGAGTTTGGGAGGTGGTC
mMapkap1 (5’) Fw GCACCTGTACTTCGAGTCCGA
mMapkap1 (5’) Rv CTCGCTCGTGATTCCAGGAT
mMapkap1 (3’) Fw AGGGAGAAGGAGAGCAAGCC
mMapkap1 (3’) Rv GCATCTGGTGTAGACAGAGGTGTG
hDMPK e1-e2 Fw ACTGGCCCAGGACAAGTACG
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Table S2. (continued)
qPCR
hDMPK e1-e2 Rv CCTCCTTAAGCCTCACCACG
hDMPK e4-e5 Fw GACCGGCGGTGGATCACG
hDMPK e4-e5 Rv GGTCCCCGCCCACGTAATAC
hDMPK e15(5’) Fw AGAACTGTCTTCGACTCCGGG
hDMPK e15(5’) Rv TCGGAGCGGTTGTGAACTG
hDMPK e15(3’) Fw TGCCTGCTTACTCGGGAAATT
hDMPK e15(3’) Rv GAGCAGCGCAAGTGAGGAG
hACTB Fw CGGGCCGTCTTCCCCTCCAT
hACTB Rv TGGGCCTCGTCGCCCACATA
hGAPDH Fw CCCGCTTCGCTCTCTGCTCC
hGAPDH Rv CCTTCCCCATGGTGTCTGAGCG
hMAP3K4 e16-e17 Fw TCGGAACAGCCCCCGTCCTATGA
hMAP3K4 e16-e17 Rv CCGCGCGTCGGAAGGCAT
hMAP3K4 e17-e18 Fw CCCTCTGGTGGTGACTCTGTGCT
hMAP3K4 e17-e18 Rv GGGCTTGAGTGACGACTCAGGGAC
hMAP3K4 e3-e4 Fw TGCAAAGGGCACGTATAGCATTGG
hMAP3K4 e3-e4 Rv GCTCCTCCCACGACACAGCA
hBPGM (3’) Fw AGGGCACTCCTAAAACACCTGGAAG
hBPGM (3’) Rv CCAACAGCACGCAGGTTTTCATCC
Primers for mGapdh were described earlier (Fu et al. (2007) J. Biomed. Mater. Res. A, 83, 770-778).
Semi-quantitative PCR: Primers for Ptbp1, Txlnb and Mapkap1 were described earlier (Mulders et al. (2009) 
Proc. Natl. Acad. Sci. USA, 106, 13915-13920).
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 | I N T R O D U C T I O N
The data included in this appendix are aimed confirm experimentally whether PS58 employs 
the RNA interference (RNAi) pathway to silence expanded DMPK transcripts. We tested this 
AON in DM1 patient myoblasts where levels of Argonaute2 (AGO2) were reduced by means 
of siRNAs. The AGO2 protein is required by the RNA-induced silencing complex (RISC) to 
perform the endonucleolytic cleavage of target mRNA in the RNAi pathway [1].  We expect 
that, if PS58 works via this pathway, reduced levels of AGO2 protein will decrease the silencing 
activity towards expanded DMPK transcripts.
 | M AT E R I A L  A N D  M E T H O D S
Cell culture
Primary human myoblasts from a DM1 patient expressing DMPK transcripts with 13 (healthy 
allele) and 800 (expanded allele) CUG triplets were cultured on gelatin-coated plates. 
The proliferation medium used consisted of Ham F10 medium with GlutaMAX™ and 20% 
HyClone grow serum.
siRNA nucleofection
For AGO2 knock-down experiments, SMART-pool siRNA targeting human AGO2 
(previously named EIF2C2) and control siRNA targeting mouse Mypt1 (Ppp1r12a) were 
purchased from Thermo Scientific Dharmacon (Lafayette, CO, USA). The target sequences 
of AGO2 siRNAs are (5’>3’) CAAGCAGGCCUUCGCACUA, GGUCUAAAGGUGGAGAUAA, 
CCAAGGCGGUCCAGGUUCA and GCACGACUGUGGACACGAA. The target sequence for 
control siRNA is (5’>3’) UGUCAGCAAAUCGUUCUUG. SiRNA transfection was performed 
using Amaxa™ P5 Primary Cell 4D-Nucleofector™ X Kit L (Lonza, Basel, Switzerland) following 
manufacturer’s instructions: human myoblasts were trypsinized after reaching 70-80% 
confluency, centrifuged and re-suspended in 100 ml P5 Nucleofection solution in presence of 
13.5 mg/ml of corresponding siRNA. Cells were then transferred to Amaxa certified cuvettes 
(typically ~2 x 106 cells per cuvette) and exposed to an electric shock, following program 
EY-100 of Nucleofector. Immediately after the shock, cells were re-suspended in pre-warmed 
fresh proliferation medium and plated in 6-well plates for subsequent analysis.
Oligo transfection
AONs were transfected using polyethyleneimine (PEI; ExGen 500, Fermentas, Glen Burnie, 
MD, USA) according to the manufacturer’s instructions. Five µL PEI/µg AON was added 
at a final AON concentration of 200 nM in Opti-MEM (Invitrogen, Carlsbad, CA, USA) to 
the myoblasts in culture. Four hours later fresh medium was supplemented to a maximum 
volume of 2 ml medium/well. Medium was changed 24 hours later. RNA was isolated 48 
hours after start of transfection.
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Western blotting
Protein lysates from DM1 patient 13/800 myoblasts were prepared at the indicated time 
points. Wells were washed with cold phosphate buffered saline (PBS) and incubated with 
100 ml RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 1 mM PMSF, 0.5% 
sodium deoxycholate, 0.1% SDS, 25 mM NaF, 1 mM Na4P2O7, 0.1 mM Na3VO4 and Protease 
Inhibitory Mixture [Roche, Basel, Switzerland]) for 10 minutes on ice. Cells were disrupted 
by scraping to collect protein lysates and centrifuged for 10 minutes at 15,000 rpm and 4⁰C 
of temperature. Cleared lysates (supernatant) were separated on an 8% SDS/PAGE gel and 
transferred to PVDF (Amersham Pharmacia Biotech, Piscataway, NJ). Blots were blocked in 
blocking solution (5% milk in PBST 0.05% Tween20) o/n at 4⁰C and incubated with 1:3200 
dilution in blocking solution of monoclonal 11A9 anti-AGO2 antibody (Sigma, St. Louis, 
MO, USA) o/n at 4⁰C. Then the membrane was washed 3 times in phosphate buffered 
saline 0.1% Tween20 (PBST) and incubated for 1 hour at room temperature in the dark with 
1:10,000 dilution of the secondary antibody IRDye800 anti-Rat IgG in blocking solution. For 
normalization, membrane was washed again an incubated in 1:1000 dilution of β-tubulin 
monoclonal antibody E7 (Developmental Studies Hybridoma Bank, University of Iowa, 
Iowa City, IA) and 1:20,000 dilution of GaM680 secondary antibody. Infrared fluorescence 
detection and quantification of the secondary antibodies were performed using Odyssey® 
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Average value of control 
samples was set at 100%.
RNA isolation
RNA from cultured cells was isolated using the Aurum™ Total RNA Mini Kit (guanidine-
HCl/mercaptoethanol-based lysis, silica membrane binding; Bio-Rad), according to 
manufacturer’s protocol.
Northern blotting
To follow DMPK mRNA expression and breakdown fate Northern blotting was performed 
as described [2]. Random-primed 32P-labelled cDNAs for human DMPK (2.6 kb cDNA) and 
rat Gapdh (1.1 kb cDNA) were used as probes. Signals were quantified by phospho-imager 
analysis (GS-505 or Molecular Imager FX, Bio-Rad) and analyzed with Quantity One (Bio-Rad) 
or ImageJ software. Gapdh levels were used for normalization. RNA levels of control samples 
were set at 100%.
 | R E S U LT S  A N D  C O N C LU S I O N S
Analysis by Western blot showed that AGO2 levels were reduced to less than 30% of normal 
levels 72 hours after AGO2 siRNA nucleofection, and this level of reduction was maintained 
during at least 2 more days (Figure 1A).
Cells were transfected with PS58 or PS589 (scrambled PS58 control) 72 hours after AGO2 
siRNA nucleofection and RNA was isolated for DMPK analysis 48 hours later. Therefore, 
during the entire period of AON treatment these cells lacked more than 70% of total AGO2 
protein levels (Figure 1B). RNA samples were run on a Northern blot to evaluate PS58 activity 
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towards DMPK transcripts (Figure 2). PS58 treatment affected DMPK expression by inducing 
~25% reduction of levels from normal allele products and ~70% reduction of expanded 
transcripts, compared to scrambled control. This pattern of reduction was the same between 
cells with reduced AGO2 levels (treated with AGO2 siRNA) and cells with normal AGO2 levels 
(treated with control siRNA). 
Figure 1. Western blot analysis of human AGO2 knock-down. (A) Blot developed by infrared detection 
of secondary antibodies. Green signal corresponds to antibody against AGO2, red signal to β-tubulin 
and protein ladder (M). The specific AGO2 bands can be seen at ~80 kD. For the quantification 
(see numerals below the bands), each signal was normalized with the corresponding β-tubulin 
band. Average values of control samples were set at 100%. (B) Quantification of AGO2 knock-down 
including all time points after siRNA transfection. Data from the 72 hour time point was obtained from 
a separate blot.
A
B
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Some studies using similar siRNA SMART-pools to reduce AGO2 expression have shown 
that knocking-down mRNA levels of this gene by ~70% is already sufficient to impair its 
activity [3,4]. In fact, a study using triplet-repeat AONs designed to target the CAG repeat of 
HTT transcripts by the RNAi pathway also showed lack of AON activity when AGO2 expression 
was reduced [5]. Taking all these observations together, we conclude that RNAi is probably 
not involved in PS58-mediated silencing of expanded DMPK transcripts.
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Figure 2. Northern blot analysis of DMPK transcripts. Signals corresponding to products from normal 
(Norm.) and expanded (Exp.) alleles are indicated by arrow heads. For the quantification (see graph), 
each signal was normalized to corresponding GAPDH band. Average values of control samples (Scrm: 
scrambled control AON) were set at 100%.
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 | A B S T R A C T
Myotonic Dystrophy type 1 (DM1) is posited to be caused by toxicity of an expanded, 
noncoding (CUG)n tract in mRNA transcripts from the DMPK gene. Triplet-repeat specific 
2’-O-methyl phosphorothioate-modified (CAG)n antisense oligonucleotides (2’-OMe 
PS AONs) have been shown to efficiently reduce levels of expanded DMPK transcripts, both 
in vitro and in vivo. These AONs are therefore considered promising tools in therapeutic 
strategies for reversal of RNA toxicity in DM1. Knowledge of the mechanism of 2’-OMe 
PS repeat AON mediated breakdown of (CUG)n-containing RNAs is a prerequisite for 
the development of safe therapy for patients, for prediction of non-obvious side effects 
and for optimizing currently available lead compounds. Here, we present the first data from 
a study wherein we explored the use of the (CAG)7 2’-OMe PS AON (PS58) for the isolation 
of proteins that may serve as mediators of knock-down of DMPK (CUG)n RNA. Pull down 
of ribonucleoprotein complexes formed by association of PS58 to its target (CUG)n RNA 
in presence of myoblast protein extracts, followed by proteome analyses of captured 
complexes, helped us to identify proteins with a possible role in DMPK RNA fate specification. 
Among the candidate proteins identified were members of the DDX family of RNA helicases, 
known to control stability of expanded DMPK transcripts and proteins with intrinsic nuclease 
activity, including Fen1 (flap structure-specific endonuclease 1). From follow-up studies in 
in vitro assays with repeat RNA substrate and purified recombinant protein, we conclude, 
however, that FEN1 likely has no direct role in PS58-mediated breakdown of (CUG)n RNA. 
Other candidate proteins still await functional characterization. Availability of a list of 
proteins that associate with (CUG)n RNA upon PS58 binding will undoubtedly help us in 
further work toward mechanistic understanding of 2’-OMe PS AON-mediated breakdown of 
RNAs with triplet repeat expansions.
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 | I N T R O D U C T I O N
Myotonic Dystrophy type 1 (DM1), is a frequent autosomal dominant disorder with highly 
variable and complex manifestation. Typical disease features consist of a combination of 
muscular, neurological and endocrine problems, each of which may vary in severity and 
age of onset. Problems in DM1 are caused by expansion of an unstable trinucleotide (CTG)n 
repeat in the 3’ untranslated region of the DMPK gene on chromosome 19q [1]. Production 
of long-repeat containing transcripts from this gene leads to abnormal binding of RNA splice 
and transport factors, like members of the MBNL family of proteins, causing factor titration 
and formation of anomalous ribonucleoprotein (RNP) aggregates [2-5]. In turn, these events 
lead to distortion in trans of alternative splicing and polyadenylation, maturation and 
nuclear export of numerous other mRNAs [6,7]. Also formation of homopolymeric proteins 
is possible, by so-called RAN translation across the repeat tract in mutant DMPK mRNAs 
or anti-sense transcripts produced from the same locus [8]. Altogether, these toxic events 
culminate into a global imbalance of proteostasis, ultimately causing cell stress with loss of 
physiological integrity.
Current strategies to achieve reversal of pathobiological effects in DM1 aim at 
complete removal of mutant DMPK mRNA or blockage of anomalous binding of proteins to 
the (CUG)n repeat tract. Approaches with use of repeat antisense oligonucleotides or small 
organic compounds that promote selective cleavage at the repeat tract and subsequent 
breakdown of mutant DMPK mRNA or prevent its abnormal association with members of 
the MBNL family of proteins have therefore been developed [9-15]. Ameliorating effects 
have also been reported from use of antisense oligos or shRNAs that are not repeat-selective, 
but promote breakdown of all DMPK mRNAs, produced from both wt and mutant DMPK 
alleles [16,17]. Our group has focussed on the use of 2’-O-methyl (2’-OMe) phosphorothioate 
(PS) modified (CAG)n AONs, to induce degradation of toxic (CUG)n transcripts [10,18]. With 
PS58, a 21-mer lead compound, and derivatives thereof, we achieved a 50-90% reduction 
in the level of DMPK (CUG)n mRNA transcripts in myoblast cells derived from the DM500 
transgenic mouse model [19,20]. Additional experiments demonstrated that 2’-OMe PS 
(CAG)n AONs also induced a relatively fast and specific silencing of transcripts with expanded 
(CUG)n repeats in vitro (in DM1 patient-derived myoblasts) and in vivo (in DM500 and HSALR 
DM1 mouse models). Removal of toxic RNA also lead to normalization of aberrant pre-mRNA 
splicing in these models [10].
Until now, the mechanism of action underlying the silencing capacity of 2’-OMe PS 
(CAG)n AONs has not been fully understood (see [18] and chapter 2). This situation is in 
contrast to that for AONs with other types of chemistry [21], whereby breakdown of target 
RNAs is based on RNAse H- [11] or RNAi-mediated mechanisms [22] (although usually 
not experimentally proven for each individual case). Here, we followed a RNA pull-down 
strategy to disclose protein-based events that could be involved in binding and degradation 
of expanded (CUG)n DMPK transcripts by PS58. We report on the identification of several 
candidate proteins with a possible mechanistic role in RNA targeting and breakdown and 
present follow-up studies with one candidate, FEN1. The hypothetical involvement of other 
candidate proteins is discussed.
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Isolation of DM500 protein extract
DM500 myoblasts were derived as described [10] from a DM1 mouse model that express 
human DMPK (CUG)500 transcripts, the disease-causing agent in myotonic dystrophy type 
1 [19]. These cells were cultured on 0.1% (w/v) gelatin-coated dishes in DMEM (GibcoBRL, 
Gaithersburg, MD) supplemented with 20% (v/v) FCS, 50 µg/ml gentamycin, 10 U/ml IFN-γ 
(BD Biosciences, San Jose, CA) and 2% (v/v) chicken embryo extract (Sera Laboratories 
International, Bolney, UK) at 33°C and 5% CO2.
Protein isolation was started when DM500 myoblasts reached 90% confluency. Cells 
were washed twice in phosphate-buffered saline (PBS) and collected in 5 ml PBS containing 
1 mM EDTA by scraping with a pliable rubber policeman. The cell pellet was collected by 
centrifugation at 250x g for 8 minutes and resuspended in 3 times packed cell volume (PCV) 
of ice-cold Hypotonic Buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, 
supplemented with Protease Inhibitor Cocktail at a concentration as specified by the vendor 
(Roche, Almere, The Netherlands)). Cells were then incubated for 15 min on ice. Aliquots were 
taken at different intervals to follow the loss of cell integrity by exclusion-staining with trypan 
blue and microscope monitoring. If cells were not completely disrupted after the incubation 
period, they were transferred to a glass Dounce homogenizer and homogenized on ice with 
10-15 up-and-down strokes using a loose-fitting pestle. This procedure was stopped when 
more than 90% cells appeared trypan-blue positive and intact free nuclei became visible. To 
obtain the cytoplasmic fraction, the lysate was centrifuged for 15 min at 4°C and 3300x g and 
the supernatant was collected (nuclei are in the pellet). For the isolation of nuclear proteins, 
the nuclear pellet was resuspended in 200-500 µl Hypotonic Buffer to wash away possible 
traces of cytosolic proteins and recollected by centrifugation for 15 min at 4°C and 3300x g. 
The supernatant was removed and 1 PCV of ice-cold Nuclear Extraction Buffer (10 mM HEPES 
pH 7.9, 1 mM EDTA, 400 mM NaCl, 1 mM DTT and 1X Protease Inhibitor Cocktail (Roche, 
Almere, The Netherlands)) was added to the pellet. The pellet was resuspended thoroughly 
and incubated for 30 min on ice. The suspension was mixed by vortexing every 5 min.
Finally, cytosolic and nuclear extracts were centrifuged for 15 min at 4°C and 21,000x g 
to remove debris and the supernatants were collected. Glycerol was added to a final 
concentration of 10% (v/v). Protein concentration of the extracts was measured using 
a standard Bradford protocol and extracts were stored at -80°C until further use. Where 
indicated, cytosol and nuclear extracts were mixed to obtain a purified DM500 protein 
mixture of 1 mg/ml.
PS58-DMPK transcript pull-down
DMPK (CUG)90 RNA was generated by in vitro transcription of a DMPK (CTG)90 DNA 
template carrying flanking T7 and SP6 promoters (Supplementary Figure S1). This DMPK 
(CTG)90 template was generated by PCR using a human DMPK cDNA construct bearing 
a (CTG)90 repeat [23], T7-DMPK forward primer 5’-GAATTTAATACGACTCACTATAGG 
GAGAACGGGGCTCGAAGGGT-3’ and SP6-DMPK reverse primer 5’-ATTTAGGTGACACTATAGAAG 
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GGCGTCATGCACAAGAAA-3’, and was sequenced to verify triplet repeat number. (CUG)90 
RNAs were synthesized in presence of [α-32P]GTP, using MEGAscript® in vitro transcription 
kit (Applied Biosystems/Ambion, Austin, TX, USA) according to manufacturer’s instructions, 
using 200 ng DMPK (CTG)90 template. In vitro 3’-end biotinylation was performed using 
the Pierce® RNA 3’ End Biotinylation Kit (Thermo Scientific, Rockford, IL, USA) following 
manufacturer’s instructions. Biotinylated DMPK (CUG)90 RNA was purified using the Aurum 
Total RNA Mini Kit (Bio-Rad).
For the pull down, approximately 2 μg biotin-(CUG)90 RNA was incubated with 
5 μM PS58 in a total volume of 20 μl of PBS-buffered reaction mix for 5 min on ice. This 
mixture was then added to 100 µl pre-washed Dynabeads® MyOneTM Streptavidin T1 
(Invitrogen, Oslo, Norway) and incubated on ice for 2 hours to allow binding. Beads were 
collected using a magnet to perform the washing steps. Samples were washed 3 times in 
PBS 0.1% Tween®20 (PBST) to remove excess biotin-(CUG)90/PS58 not bound to the beads. 
Next, 200 μl of whole cell protein extract (1 mg/mL) from DM500 myoblasts was mixed 
with the beads and incubated for 40 min on ice. Beads were washed 5 times with PBST. To 
release (CUG)90 RNA and bound proteins from the beads, beads were resuspended in 40 
μl of 60 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol and the mixture was 
incubated at 95°C for 5 minutes. Beads were immediately removed by magnetic force and 
the supernatant containing RNA and proteins was collected, snap frozen in liquid nitrogen 
and stored at -80°C until further use. Proteins and RNA were separated by electrophoresis 
in 10% SDS/PAGE gels. Proteins were visualized by silver staining [24], whereas RNA was 
detected by gel exposure to X-ray film (X-Omat AR, Kodak).
Mass spectrometry
Samples were incubated at 95°C for 5 minutes and loaded on a 10% SDS/PAGE gel. 
Electrophoresis was carried out for 30 minutes at 80 V. The gel was stained with Coomassie 
Blue and each lane excised and divided with a clean scalpel in small pieces of ~1 mm3. Gel 
pieces were equilibrated with 50 mM ammonium bicarbonate, dehydrated with acetonitrile 
and dried overnight. Next day, samples were transferred to the Radboud Proteomics Center 
(Radboudumc) for further processing and analysis, essentially as described in [25]. Gel 
pieces were washed successively three times with 50 mM ammonium bicarbonate, 50% (v/v) 
acetonitrile and 100% (v/v) acetonitrile for 5 minutes. Gel particles were swelled in 10 mM 
dithiotreitol and incubated for 20 minutes at 56°C under gentle agitation to reduce protein 
disulfide bonds. After removal of the reduction buffer, gel particles were shrunk in 100% 
acetonitrile for 5 minutes at room temperature. Alkylation of reduced cysteine residues 
was performed by incubating the gel particles for 20 minutes in alkylation buffer (50 mM 
chloroacetamide in 50 mM ammonium bicarbonate) at room temperature in the dark. 
Following the alkylation step, gel particles were washed successively with 50 mM ammonium 
bicarbonate and acetonitrile three times prior to the addition of 50 μl 12.5 ng/μl trypsin in 
50 mM ammonium bicarbonate (Promega) and overnight protein digestion at 37°C. Then, 
50 μl 2% triflouroacetic acid was added to each sample followed by a 20 minute incubation 
under gentle agitation. The supernatant was transferred to a clean tube. Remaining 
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proteolytical peptides in the gel pieces were recovered by shrinking the gel particles in 80% 
acetonitrile/0.1% formic acid for 20 minutes at room temperature under gentle agitation 
and subsequently the peptide-containing acetonitrile supernatant was transferred to 
the sample tube. The combined peptide extracts were subjected to in vacuo centrifugation 
to remove acetonitrile. After peptide extraction, the digested samples were loaded on 
STAGE-tips (Stop-And-Go Elution [26]) for clean-up, desalting and concentration prior to 
LC-MS analysis. The resulting peptide mixtures were analyzed by nanoflow C18 reversed 
phase liquid chromatography coupled online to a 7 Tesla Linear Ion Trap Fourier-Transform 
Ion Cyclotron Resonance mass spectrometer (LTQ FT Ultra; Thermo Fisher Scientific). 
The samples were measured with CID (Collision Induced Dissociation) as fragmentation 
technique and chromatographic separation was achieved via a linear gradient of 5% to 35% 
acetonitrile using 0.1% formic acid as ion pair reagent. Peptide and protein identifications 
were extracted from the data by means of the search program Mascot (Matrix Science). In 
this case, a custom RefSeq55 database was used with Mus musculus as specified taxonomy. 
The following modifications were allowed in the search: carbamidomethylation of cysteines 
(fixed), oxidation of methionine (variable) and acetylation of the N-terminus (variable). 
Protein identification validation was performed by an in-house developed script. Briefly, 
the software classifies protein identifications based on the number of uniquely identified 
peptide sequences and clusters proteins sharing the same set of peptides. Exponentially 
Modified Protein Abundance Index (emPAI) scores are used to indicate protein abundance 
[27]. The emPAI value is based on the correlation between the number of acquired spectra 
and protein abundance with a correction for the number of theoretically detectable peptides 
by the approach. As such, emPAI values can be compared between different proteins 
and samples.
FEN1 activity assay
To test the possible role of FEN1 activity, (CUG)90 RNA was labeled by synthesis in presence 
of [α-32P]GTP, using MEGAscript® in vitro transcription kit (Applied Biosystems/Ambion, 
Austin, TX, USA) according to manufacturer’s instructions. Approximately 500 ng of repeat 
RNA was dissolved in 50 mM Tris-HCl pH 8.0, 2 mM DTT, 30 mM NaCl, 0.1 mg/ml BSA, 5% 
glycerol, 2 mM MgCl2 and 4 mM ATP. PS58 was added to a final 100 μM concentration 
(5 μM PS58 was also tested with identical results) and incubated for 1 hour at 37˚C to allow 
binding. Then, human purified FEN1 recombinant enzyme (ProSpec, Ness Ziona, Israel) was 
added to a final 100 nM concentration in 20 μl final solution and incubated at 30˚C for 45 
minutes. To stop the reaction, 20 μl 2X termination dye (90% formamide, 10 mM EDTA, 2X 
bromophenol blue) was added to the mixture.
A FEN1 substrate was used as a positive control as described [28]. 100 pmole of 
FEN1-cleavable oligo (downstream primer (D1) 5’-CCAAGGCCACCCGTCCACCCGACGCCACC 
TCCTG-3’) was 5’-end labeled with 32P by T4 Kinase, by incubation for 3.5 hours at 37°C in 
presence of [g32-P] ATP. The reaction was stopped by heating at 72˚C for 10 min. To anneal 
the required other oligos to the substrate, 200 mL of annealing buffer (10 mM Tris-HCl pH 8, 50 
mM NaCl) was added to the mixture. 500 pmole of template primer (T1) 3’-GCTGGCACGGTCGG
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ATTTAAAGTTAGGTGGGCAGGTGGGCTGCGGTGGAGGACG-5’was added and the reaction mix 
was incubated at 70˚C for 5 min and then cooled down slowly to 25˚C. Annealing of upstream 
primer (U3) was performed by adding 2 nmole of 5’-CGACCGTGCCAGCCTAAATTTCAATA-3’ 
oligo and incubating the mixture at 37˚C for 30 min. Complete FEN1 substrate was 
precipitated in 100% EtOH and resuspended again in annealing buffer. FEN1 substrate was 
assayed in parallel using the same conditions as described for (CUG)90 RNA. All samples 
were heated at 100˚C for 5 min and run on a acrylamide/bisacrylamide (19:1 w/w, 5% for 
(CUG)90 RNA and 15% for FEN1 substrate) 8 M urea denaturing gels for 1 hour in MOPS 
running buffer at 70°C. Gels were dried and exposed to X-ray film (X-Omat AR, Kodak).
 | R E S U LT S  A N D  D I S C U S S I O N
Previous studies have shown that distinct proteins can be recruited specifically to an RNA 
target by AONs of different chemistries, triggering diverse mechanisms of RNA breakdown or 
modulation [29,30]. We hypothesized that PS58, by binding to expanded DMPK transcripts, 
will attract ribonucleoproteins (RNPs) to activate an RNA decay program in the nucleus 
Figure 1. Working hypothesis for PS58-mediated degradation of expanded DMPK transcripts. (A) 
Expanded DMPK mRNA forms a (CUG)n hairpin structure that binds MBNL1 proteins. (B) PS58 binds 
to the (CUG)n repeat opening the structure and releasing MBNL1 proteins. (C) Unknown proteins are 
recruited to the PS58-DMPK duplex, possibly mediating a first endonucleolytic cleavage. (D) DMPK 
mRNA is completely degraded by exonucleases present in the cell.
A
D
C
B
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or in the cytoplasm (Figure 1). Here we aimed to isolate and identify these proteins from 
a myoblast protein extract using a pull-down approach.
To establish a reliable procedure for protein capture and pull-down of RNP complexes 
several protocols for AON binding to (CUG)n expanded mRNA, incubation of AON-RNA 
complexes in myoblast lysate, and purification of bound proteins, were tested in pilot 
experiments. Use of biotinylated PS58 as bait resulted in a too high background of bound 
proteins in the eluate, probably due to non-specific protein binding to free 2’-OMe 
PS-modified AON without concurrent association to (CUG)90 RNA (data not shown). 
Ultimately, we chose for use of 3’-end biotinylation of the (CUG)90 RNA target, prior to hybrid 
formation and protein binding (Figure 2A) as the method of choice. Check-up of recovery 
of radiolabeled DMPK specific RNA segments that were used as bait revealed that 
pull down with streptavidin-coated magnetobeads was highly specific and efficient (Figure 
2B lanes 3-5 versus lane 2), as anticipated. By using (CUG)n fragments of the RNA as bait and 
anchor, we thus certified that candidate proteins in the pull-down fraction must have been 
truly hybrid-bound at the moment that complexes were captured and are not proteins that 
only have avidity for free AON molecules.
Analysis of protein content of captured complexes by SDS-polyacrylamide gel 
electrophoresis and silver staining of gels enabled us to identify a distinct subpopulation 
of proteins with the ability to bind to biotin-(CUG)90 RNA-PS58 hybrids (Figure 2C, lane 
5). Firstly, proteins binding aspecifically to beads alone (lane 1) or to beads in presence 
of the naked non-biotinylated (CUG)90 RNA (lane 2) could be easily differentiated and 
considered as background. Secondly, proteins with avidity for binding to ssRNA, as seen in 
the bound fractions from the mixtures that received biotin-labelled RNA, either alone (lane 
3) or in presence of a control AON -with other type of chemistry and sequence- (lane 4), 
resulted in a very distinct profile of proteins, allowing us to identify those that were recruited 
to the (CUG)90 RNA-PS58 hybrid specifically (compare Figure 2C, lanes 3-5). Specific-bound 
proteins may be a mixture of (a) proteins that bound to free PS58 first, were shuttled by 
the oligo, and remained present upon hybridization-binding to the RNA and (b) proteins 
that bound later, i.e. those with avidity for double-stranded AON-RNA hybrids. From 
a mechanistic perspective, both classes of proteins in this mixture are equally interesting, so 
we did not adapt our pull-down isolation procedure further.
Next, proteins isolated by this pull down procedure (lanes 3, 4 and 5 in Figure 2B) were 
separated by polyacrylamide gel electrophoresis, excised in slices from the gel slab and 
subjected to proteomic analysis by mass spectroscopy. Among a total of 415 validated 
proteins (Figure 3), 103 (25%) were only identified in the sample wherein PS58-DMPK mRNA 
hybrids were formed (Supplementary Table S1). An additional 62 (15%) proteins appeared at 
least two-fold more abundant in the pull-down from the PS58-DMPK mRNA lysate mixture 
than in the mixtures that had received no AON or a control AON (Supplementary Table S2). 
Conspicuously, 57 (14%) proteins were pulled-down from the reaction mixture that received 
DMPK mRNA only, but were no longer seen when PS58 was also present. In this case, possibly 
these proteins associate loosely with the repeat segment in the RNA bait and are actually 
directly displaced by PS58 hybridization, or get detached by changes in RNA conformation, 
induced by PS58 binding.
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Figure 2. DMPK (CUG)90 PS58 pull-down in presence of myoblast protein extract. (A) An in vitro-
synthetized DMPK RNA segment containing 90 CUG triplets was 3’-biotinylated and used as bait in 
presence of PS58 and myoblast protein extract. Using this approach, the aim was to identify proteins 
that interact specifically with the RNA AON duplex (group I of proteins) or were already bound to 
free PS58, prior to hybridization but remained present when duplexes were formed (II). Additionally, 
some proteins might bind to (CUG)n RNA independently (III). Using streptavidin-coated magnetic 
beads these complexes were isolated with a magnet. The washing procedure was optimized to reduce 
the background of proteins binding aspecifically to the beads (IV). (B) Visualization of radioactively 
labeled DMPK RNA that was recovered during the pull down. No RNA was used in lane 1. In lane 2, as 
expected, non-biotinylated RNA was not recovered. In lanes 3, 4 and 5, biotin-conjugated DMPK RNA 
was recovered. The intensity in lane 5 (PS58 incubation) is rather low, suggesting that PS58-mediated 
degradation may have occurred during the procedure. (C) Visualization of pulled-down proteins by 
silver staining. Proteins in the first two lanes correspond to non-specific binding to the beads (IV). 
Proteins in lane 3 bound to biotin-DMPK RNA only (III). In lane 4, a control AON of different chemistry 
and sequence was used (PS1242, 2’-F PS (CUG)7). In lane 5 (PS58 incubation), we could see some bands 
not present in the previous lanes, corresponding to proteins specifically recruited by PS58 bound to 
biotin-(CUG)90 RNA before (I) or after (II) hybridization.
A
B
106
3
Chapter 3
As expected on the basis of similarities in electrophoresis profiles in lanes 3-5 of Figure 
2B-C, a relatively large number of proteins remained present in the isolates from all mixtures, 
even after washing of the complexes. Altogether this group comprised 193 proteins, 46% 
of all proteins identified. As these proteins must represent non-specifically bead-bound 
proteins or proteins with a strong tendency to bind to RNA, irrespective of binding of 
PS58, we excluded them from further analysis. For further study we therefore focused on 
the remaining group of 222 proteins (54%), as we considered these the most interesting 
candidates for being implicated in the antisense activity of PS58.
Strikingly, although members of the MBNL family of splicing factors are centrally 
implicated in DM1 pathology and able to bind (CUG)n or (CCUG)n sequences [31], they were 
not identified in our samples. Similar studies using (CUG)n RNA as a bait for the identification 
of binding proteins, also failed to detect MBNL1 [32,33]. Maybe partial disassembly of 
the RNP complexes occurs under the salt and buffer conditions used for binding, pull-down 
and washing of the complexes. The inability of us and others to find MBNL proteins may thus 
indicate that loss of candidate proteins with selective binding properties may have occurred 
in the pull-down and isolation procedure, particularly for proteins that where only loosely 
bound in the (CUG)n RNA-AON-protein complexes. 
As a first step towards the disclosure of functional clues for these candidates a gene 
ontology (GO) analysis was performed using String [34] and David [35,36] as bioinformatics 
tools. Not entirely unexpected, most of the proteins isolated from the lysate via the RNA-PS58 
duplex pull-down have a role in RNA-related processes (Table 1). Furthermore, most of these 
proteins fitted into functional clusters in which they can strongly interact and influence each 
other (Supplementary Figure S2). It is thus possible that PS58 silencing activity is mediated 
via interference with only one or few proteins, but that this interference modulates the entire 
pathway in which these proteins are involved.
It was already shown in our previous studies that PS58 is able to reduce the number and 
size of insoluble/visible RNP foci present in the nucleus of DM1 muscle fibers [10]. Proteins 
with RNA helicase activity recruited by PS58 could be directly implicated in unwinding 
Only found in PS58 lane
193
62
103
57
Enriched >2-fold by PS58
Equally present in all samples
Displaced by PS58 binding
Figure 3. Distribution of 415 proteins identified by mass spectrometry that were recovered after 
pull-down experiment. Four protein groups were made according to their relative abundance in 
control and PS58 samples
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the hairpin structure of the long (CUG)n repeat (Figure 1B) and thus be implemented in 
the structural modulation of these RNP aggregates. Although this might not directly trigger 
a RNA degradation process, it may be a necessary first step in the silencing event (Figure 1C). 
It is therefore of note that we identified several members of the DDX family of RNA helicases 
among the group of proteins that were enriched more than two-fold by PS58 binding to 
the repeat (Table 2). If present in fairly high abundance we expected to see these proteins as 
distinct bands in the PS58 lane in Figure 2C. Indeed in this lane bands appeared at positions 
around 55, 70 and 83 kDa, corresponding with the predicted MWs for DDX3x, DDXy, DDX5 or 
DDX6. These proteins are implicated in a number of cellular processes, related to alteration 
of RNA secondary structure. DDX helicases have been reported to interfere with (CUG)n 
hairpin formation and MBNL binding [33,37], leading to foci disruption and improvement 
of DM1 molecular pathology, as recently reported for DDX6 [37]. Thus, to explain possible 
involvement in AON-mediated breakdown of expanded mRNA, we have to assume that 
DDX helicases have a facilitating role after AON binding by enhancing mRNA release from 
abnormal RNP complexes and entry in mRNA decay pathways, either in the nucleoplasm 
or – upon further transport – in the cytosol. Experimental follow up studies are necessary to 
confirm the hypothetic involvement of DDX candidates now identified.
For completion of the actual silencing by breakdown of the RNA, helicases must act in 
conjunction with accessory endo- or exonucleases. To substantiate this expectation and 
verify the validity of this idea, we specifically searched for proteins with nuclease activity. 
Among the candidates on our list five proteins with nuclease activity were identified: Rps3, 
Xrn2, Snd1, Dis3 and Fen1 (Table 3). Rps3 is a ribosomal protein for which an additional 
(moonlighting) role in DNA repair has been described. Involvement of this protein in 
the degradation of DMPK transcripts is unlikely since it does not have endonuclease 
Table 1. Summary of molecular functions associated to proteins enriched in the presence of PS58. 
Information of annotation clusters based on DAVID’s output for the ontology analysis of 165 proteins.
Cluster Number Percentage
Nucleic acid binding 79 48%
RNA-binding 41 25%
Ribonucleoprotein 29 18%
Ribosomal protein 17 10%
mRNA processing 16 10%
mRNA splicing 14 8%
Helicase activity 11 7%
Nuclease activity 5 3%
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activity for RNA [38]. Xrn2 has been found important for efficient degradation of RNA by 
RNase H-dependent AONs [39]. However, this protein is a 5’-3’ exoribonuclease, requiring 
a 5’-terminal monophosphate in the RNA for its activity [40]. Therefore, an additional 
protein might be required to perform the first endonucleolytic cleavage (Figure 1C) before 
Xrn2 can continue degrading a transcript (Figure 1D). Snd1 is a reported component of RISC 
[41] with a nuclease domain involved in the degradation of hyperedited (inosine modified) 
dsRNA [42]. However, any direct involvement in mRNA degradation has not been proven 
so far for this protein. Dis3 has both 3’-5’ exonuclease and endonuclease activities and it is 
a putative catalytic component of the RNA exosome complex [43]. This complex is responsible 
for proper maturation of stable RNA species such as rRNA or snRNA, for the elimination of 
mRNA with defects and for processing of by-products [44,45]. Although Dis3 would be an 
interesting candidate to pursue further, we gave its study no priority here because it was 
only marginally enriched in the pull-down preparation that was obtained in presence of 
PS58 (see Table 3).
Finally, Fen1 was recruited specifically in presence of PS58 and was completely absent in 
control samples (Table 3 and maybe the specific band at ~43 kDa in lane 5 of Figure 2C). Fen1, 
with both RNase and endonuclease activity, is involved in the removal of Okazaki fragments 
during DNA replication of the lagging strand [46]. During this process, when synthesis 
from one Okazaki fragment encounters the next, the elongating DNA strand displaces 
the 5’-end of the downstream segment and a non-annealed flap, containing the initiator 
RNA primer, is created. Fen1 is a structure-specific nuclease that participates in the removal 
of the flap structure, which is necessary to allow completion of lagging-strand synthesis. 
As an endonuclease, Fen1 specifically recognizes a double-stranded structure (RNA/DNA or 
DNA/DNA) with a 5’-unannealed flap (RNA or DNA) and makes a cleavage at the base [47]. 
We hypothesised that Fen1 might recognize, bind and cleave any branched ds AON-RNA 
structures that may be potentially formed upon PS58 binding to the repeat [48]. Upon 
Fen1-induced endonucleolytic cleavage, the mRNA might get further degraded by other 
exonucleases in the cell [39,49]. Such a model is supported by the observation that Xrn2, 
Table 2. Proteins enriched in the presence of PS58 which are associated with RNA helicase activity in 
GO analysis. Colour coding: green (high abundance) > yellow (medium abundance) > red (low abundance).
PROTEIN Name Mw (kDa)
Control 
AON No AON PS58
ATP-dependent RNA helicase DDX1 Ddx1 83 0.07 0.03 0.25
ATP-dependent RNA helicase DDX3X Ddx3x 73 0.42 0.42 1.15
ATP-dependent RNA helicase DDX3Y Ddx3y 73 0.34 0.34 0.98
probable ATP-dependent RNA helicase DDX5 Ddx5 69 0.57 0.57 1.47
probable ATP-dependent RNA helicase DDX6 Ddx6 54 0.00 0.00 0.53
pre-mRNA-splicing factor ATP-dependent RNA 
helicase PRP16
Dhx38 141 0.00 0.00 0.09
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Table 3. Proteins enriched in the presence of PS58 which are associated with ribonuclease (RNase) or 
endonuclease (Endo) activity in GO analysis. Colour coding: green (high abundance) > yellow (medium 
abundance) > red (low abundance).
PROTEIN Cluster Name Mw (kDa)
Control 
AON No AON PS58
Staphylococcal nuclease domain-
containing protein 1
RNase 
& Endo
Snd1 102 0.37 0.33 1.19
40S ribosomal protein S3 Endo Rps3 27 0.53 0.41 2.03
5’-3’ exoribonuclease 2 RNase Xrn2 109 0.00 0.00 0.21
Exosome complex exonuclease RRP44
RNase 
& Endo
Dis3 109 0.00 0.05 0.08
Flap endonuclease 1
RNase 
& Endo
Fen1 43 0.00 0.00 0.23
a 5’-3’ exoribonuclease, was recruited in PS58-DMPK mRNA hybrids at very comparable 
levels to Fen1. To test the potential efficacy of this putative mechanism, we incubated 
PS58 with the in vitro synthetized DMPK (CUG)90  RNA, in presence of human FEN1 enzyme 
(Figure 4). As a positive control for FEN1 activity, we used a combination of DNA oligos 
that form the required flap structure (see material and methods), which is recognized and 
cleaved by the enzyme [28]. Under the same conditions whereby FEN1 cleaved its natural 
substrate, it failed to cleave (CUG)90 RNA in combination with PS58. Although we do not 
know whether our reaction mimic the right cellular conditions needed for breakdown of 
the (CUG)90 hairpin, we consider this fairly strong evidence against an initiating role of Fen1 
in PS58-mediated RNA breakdown.
-
FEN1 
substrates
(CUG)90 RNA
--
FEN1
FE
N1
PS
58
PS
58
Figure 4. FEN1 does not cleave (CUG)90 RNA substrate in presence of PS58. FEN1 is able to cleave its 
substrate in vitro (positive control, left panel). A similar incubation of (CUG)90 RNA in the presence of 
PS58 and FEN1 did not lead to degradation (right panel).
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Concluding remarks
Since previous studies showed that the mechanism of mRNA silencing by triplet-repeat 
2-OMe-PS modified AONs shares no overt features with described events in antisense 
technology (like splicing modulation, RNAse H mediated RNA degradation, siRNA silencing 
or ribozyme activity) it is clear that the working mechanism of PS58 will thus remain subject 
for further study. 
We discard the possibility that FEN1 acts as a mediator of RNA silencing during PS58 
treatment. However, the now available list of remaining candidates will help in guidance 
of other mechanistic studies in the future. For instance, ribosomal proteins like Rps9, 
Rps24, Rpl11 or Rps4x and mRNA processing proteins like Hnrnpa3, Hnrnpa1 or Hnrnpa2b1 
(Supplementary Figure S2) do not have known nuclease activity, but were highly enriched in 
PS58-DMPK mRNA hybrids (Supplementary Tables S2 and S3). Some of these proteins could 
have nuclease activity not described to date or form a scaffold that attracts other proteins to 
build up complexes with nuclease activity. To perform tests for such speculative functions, 
f.e. with use of protein-RNA crosslinking assays we would ultimately need a complete 
new toolbox to study RNP proteins, with access to expression constructs for recombinant 
proteins, appropriate host cells and antibodies. These analyses go clearly beyond the scope 
of the work as described in this thesis chapter.
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Table S1. Proteins recruited only in presence of PS58, and absent in other conditions (continues on next 
page). Proteins present in PS58 sample but not present in control conditions were sorted according to 
abundance in the first. The cut-off score for this list was set at 0.03 (PS58 emPAI value). Colour coding: 
green (high abundance) > yellow (medium abundance) > red (low abundance).
Protein name Mw (kDa) Control AON No AON PS58
Rps9 223 0.00 0.00 1.74
Rps24 15 0.00 0.00 1.37
Rpl11 20 0.00 0.00 1.03
Nudt16l1 23 0.00 0.00 0.96
Alyref 27 0.00 0.00 0.85
Ddx6 54 0.00 0.00 0.53
Rpa1 69 0.00 0.00 0.45
Rpl10,Rpl10-ps1 25 0.00 0.00 0.43
Csnk1a1 38 0.00 0.00 0.39
Kif5b 110 0.00 0.00 0.38
Hmga2 12 0.00 0.00 0.33
Eif4g2 98 0.00 0.00 0.32
Elavl1 36 0.00 0.00 0.29
Mcm3 92 0.00 0.00 0.25
Cdc73 61 0.00 0.00 0.24
Fen1 43 0.00 0.00 0.23
Nudt21 26 0.00 0.00 0.23
Kif2a 81 0.00 0.00 0.23
Xrn2 109 0.00 0.00 0.21
Cirbp 19 0.00 0.00 0.19
Eif2b4 58 0.00 0.00 0.18
Cope 35 0.00 0.00 0.18
Mpg 37 0.00 0.00 0.18
D10Wsu52e 55 0.00 0.00 0.17
Mcm4 97 0.00 0.00 0.17
Pes1 68 0.00 0.00 0.17
Api5 57 0.00 0.00 0.16
Shmt2 56 0.00 0.00 0.15
Plrg1 57 0.00 0.00 0.15
Dimt1 35 0.00 0.00 0.15
Gm5409 27 0.00 0.00 0.15
Rpa2 29 0.00 0.00 0.15
Csnk1d 47 0.00 0.00 0.14
Dera 35 0.00 0.00 0.13
Usp10 87 0.00 0.00 0.13
Glt25d1 71 0.00 0.00 0.12
Hnrnpl 64 0.00 0.00 0.12
 | S U P P L E M E N TA R Y  M AT E R I A L S
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Table S1. (continued)
Protein name Mw (kDa) Control AON No AON PS58
Eif3d 64 0.00 0.00 0.12
Snrpa1 28 0.00 0.00 0.12
Prpf6 107 0.00 0.00 0.11
Srp54a,Srp54b 56 0.00 0.00 0.10
Map4k5 95 0.00 0.00 0.10
Cct5 60 0.00 0.00 0.10
Dhx38 141 0.00 0.00 0.09
Abce1 673 0.00 0.00 0.09
Parp3 60 0.00 0.00 0.09
Emg1 27 0.00 0.00 0.09
Wdr61 34 0.00 0.00 0.09
Hnrnpr 71 0.00 0.00 0.09
Atxn2l 111 0.00 0.00 0.08
Rqcd1 34 0.00 0.00 0.08
Ctc1 134 0.00 0.00 0.08
Sac3d1 46 0.00 0.00 0.08
Dock7 238 0.00 0.00 0.08
2310022A10Rik 45 0.00 0.00 0.07
Kifc5b 74 0.00 0.00 0.07
Mta2 75 0.00 0.00 0.07
Fam98b 45 0.00 0.00 0.07
Rfc2 39 0.00 0.00 0.07
Cc2d1a 104 0.00 0.00 0.07
Actr3 47 0.00 0.00 0.06
Ssb 48 0.00 0.00 0.06
Fam98a 55 0.00 0.00 0.06
Gtf2i 112 0.00 0.00 0.06
Tubgcp3 104 0.00 0.00 0.06
Igf2bp2 66 0.00 0.00 0.05
Larp4b 82 0.00 0.00 0.05
Elp4 46 0.00 0.00 0.05
Smu1 58 0.00 0.00 0.05
Dkc1 57 0.00 0.00 0.05
Acly 120 0.00 0.00 0.05
Prim2 58 0.00 0.00 0.05
Tsr1 92 0.00 0.00 0.04
Fbxw8 68 0.00 0.00 0.04
Gtse1 79 0.00 0.00 0.04
Mtap1s 103 0.00 0.00 0.04
Kif22 73 0.00 0.00 0.04
Tpx2 86 0.00 0.00 0.03
Atxn2 137 0.00 0.00 0.03
Fam115a 103 0.00 0.00 0.03
Kank2 90 0.00 0.00 0.03
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Table S1. (continued)
Protein name Mw (kDa) Control AON No AON PS58
Clasp1 169 0.00 0.00 0.03
Hells 95 0.00 0.00 0.03
Otud4 123 0.00 0.00 0.03
Copg 98 0.00 0.00 0.03
Rasa3 96 0.00 0.00 0.03
Eftud2 110 0.00 0.00 0.03
Table S2. Proteins present in control conditions but more than 2-fold abundant in PS58 lane (continues 
on next page). Proteins were sorted according to fold change increase in “PS58” compared to the average 
of “control AON” and “no AON” values. Only proteins more than 2-fold enriched were considered. Colour 
coding: green (high abundance) > yellow (medium abundance) > red (low abundance).
Protein name Mw (kDa) Control AON No AON PS58 Fold change
Hnrnpa3 37 0.00 0.17 1.59 18.51
Hnrnpa1 34 0.17 0.08 1.59 12.51
Rps4x 30 0.00 0.30 1.42 9.36
Hnrnpa2b1 33 0.17 0.17 1.59 9.26
Pabpc4 72 0.00 0.04 0.13 6.26
Hmmr 92 0.00 0.03 0.09 6.17
2700060E02Rik 28 0.09 0.09 0.53 5.97
Caprin1 78 0.22 0.14 1.06 5.92
Rps2-ps13,Rps2 31 0.00 0.19 0.53 5.72
Cct2 58 0.00 0.09 0.23 5.33
Ddx1 83 0.07 0.03 0.25 5.10
Strap 38 0.22 0.07 0.69 4.84
Rbm3 17 0.52 0.52 2.51 4.83
Hnrnpd 33 0.25 0.25 1.15 4.71
Ncl 77 0.35 0.42 1.72 4.47
Eif4g1 175 0.07 0.07 0.31 4.44
Rps7 22 0.17 0.36 1.15 4.40
Rps3 27 0.53 0.41 2.03 4.33
Dclk1 84 0.04 0.04 0.17 4.24
Eef1a1 50 0.32 0.32 1.31 4.07
Actr1a 43 0.07 0.15 0.40 3.75
Snd1 102 0.37 0.33 1.19 3.40
Pabpc1 71 0.18 0.08 0.44 3.38
Copa 138 0.02 0.08 0.17 3.35
Rps3a 30 0.10 0.10 0.33 3.31
Csde1 89 0.10 0.10 0.32 3.30
Taf15 59 0.09 0.09 0.30 3.29
Cnot1 266 0.04 0.01 0.09 3.28
Rpl17-ps5,Rpl17 21 0.00 0.36 0.58 3.26
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Table s2. (continued)
Protein name Mw (kDa) Control AON No AON PS58 Fold change
Rbm14 69 0.06 0.06 0.19 3.18
Fus 53 0.47 0.67 1.78 3.14
Rps16,Rps16-ps2 16 0.93 1.28 3.39 3.08
Dis3 109 0.00 0.05 0.08 3.04
Hnrnpa0 31 0.26 0.26 0.78 3.01
Hnrpll 64 0.09 0.19 0.42 2.96
Ybx1 36 0.23 0.23 0.69 2.95
Mcm5 82 0.15 0.07 0.31 2.89
Ddx3y 73 0.34 0.34 0.98 2.88
Ddx3x 73 0.42 0.42 1.15 2.77
Chd4 218 0.00 0.05 0.06 2.69
Cct8 60 0.08 0.08 0.20 2.64
G3bp2 54 0.27 0.34 0.80 2.64
Fubp1 67 0.10 0.15 0.32 2.60
Ubap2l 107 0.15 0.09 0.31 2.60
Sfpq 75 0.17 0.31 0.62 2.57
Ddx5 69 0.57 0.57 1.47 2.57
Rps19 16 0.70 0.43 1.42 2.53
Samhd1 76 0.11 0.15 0.31 2.47
Rps18 18 1.28 1.68 3.39 2.29
Iqgap1 189 0.13 0.11 0.28 2.28
Rcc1 45 0.26 0.26 0.58 2.26
Eif2s3x 51 0.21 0.28 0.55 2.24
Rps5 23 0.15 0.33 0.54 2.21
Plec 534 0.06 0.05 0.12 2.15
Poldip3 46 0.12 0.18 0.32 2.14
LOC100045999 Ran 24 0.14 0.14 0.29 2.14
Rbfox2 47 0.09 0.19 0.30 2.13
Mat2a 44 0.08 0.08 0.16 2.08
Syncrip 70 0.09 0.05 0.14 2.06
Dync1li1 57 0.05 0.05 0.10 2.05
Eef2 95 0.03 0.06 0.09 2.04
Ppfibp1 109 0.02 0.05 0.08 2.03
118
3
Chapter 3
Figure S2. String analysis for interactions between proteins enriched in the presence of PS58. 
The identified protein networks have defined functional clusters (surrounded by red lines). For 
a description of the interactions attributed between proteins (spheres), see colour key in the figure. 
Figure S1. Schematic representation of the DMPK construct used to generate (CUG)90 RNA for 
test tube experiments. Using T7 RNA polymerase RNA containing 90 CUG repeats flanked by part of 
the endogenous human DMPK sequence was generated. 


C H A P T E R
W H O L E - T R A N S C R I P TO M E  A N A LY S I S  
O F  D M 1  A N D  C O N T R O L  M YO B L A S T S 
T R E AT E D  W I T H  A  ( C A G ) 7  
A N T I S E N S E  O L I G O N U C L E OT I D E
Anchel González-Barriga1,2, Melvin M. Evers3, Ingeborg D. G. van Kessel1, Jeroen F. J. Laros4, 
Judith C. T. van Deutekom2, Willeke M. C. van Roon-Mom3, Susan A. M. Mulders2, 
Bé Wieringa1 and Derick G. Wansink1
1 Department of Cell Biology, Radboud Institute for Molecular Life Sciences, 
Radboud university medical center, Nijmegen, The Netherlands 
2 BioMarin Nederland B.V., Leiden, The Netherlands 
3 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands 
4 Leiden Genome Technology Center, Leiden University Medical Center, Leiden, The Netherlands
Unpublished data
4
122
4
Chapter 4
 | A B S T R A C T
To develop a safe antisense oligonucleotide (AON) therapy for myotonic dystrophy patients, 
based on modulation of toxicity of the (CUG)n repeat in RNA from the mutant DMPK gene, it 
is essential to get insight in the genome-wide effects that treatment with (CAG)n-AONs have 
on the cellular transcriptome. In the analysis of these effects we need to distinguish between 
transcriptome changes that result from genuine disease-correction and collateral changes 
evoked by in trans side effects. 
Here, we report on parallel and comparative use of RNA sequencing (RNA-Seq) and 
serial analysis of gene expression (SAGE) for profiling of gene expression after treatment 
of myoblasts with an AON consisting of seven CAG triplets, a fully 2’-O-methylribose 
phosphorothioate backbone and 5-methylcytosines (named “(mCAG)7” in this study). 
Bioinformatics analysis of the transcriptome of myoblasts from DM1 patients and unaffected 
individuals revealed that treatment with the (mCAG)7 AON did not affect expression of 
transcripts with short (CUG)n repeats (6-25 triplets). AON treatment did, however, smoothen 
out differences in gene expression between patients and controls. Remarkably, correction of 
characteristic splicing abnormalities previously reported in DM1 was not observed.
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 | I N T R O D U C T I O N
Myotonic dystrophy type 1 (DM1) is a disease caused by a mutant expansion of a (CTG·CAG)
n repeat in one of the two parental DMPK genes, associated with a toxic gain of function 
in the 3’-UTR of the mRNA from the mutant allele. DMPK transcripts become pathogenic 
(toxic), when the unstable repeat expands to above approximately 150-200 triplets. It 
is postulated that long (CUG)n repeats in mutant DMPK transcripts promotes abnormal 
binding and, ultimately, aggregation of protein factors that function in alternative RNA 
splicing, polyadenylation and nucleocytoplasmic transport [1], leading to global cellular 
ribostasis and proteostasis problems in cis and in trans. In turn, these problems cause cell 
stress and loss of integrity of physiological functions of many tissues and organs [2]. There 
is no cure for DM1, but several therapeutic strategies are currently under development 
[3-14]. In previous studies, we explored different aspects of use of triplet-repeat antisense 
oligonucleotides (AONs), which directly bind to the (CUG)n repeat of DMPK transcripts and 
silence their expression [14,15].
An important aspect in the pre-clinical evaluation of (CAG)n AONs is the characterization 
of their safety profile. AONs of this sequence can bind specifically to DMPK mRNA, but 
potentially also to any other transcript in the cell that carries a (CUG)n stretch. In addition, 
(CAG)n AONs perhaps interact with regulatory proteins that may lead to unexpected 
alterations in the cellular transcriptome.  As a first step towards identification of – and 
discrimination between - undesired adverse effects and genuine effects caused by 
elimination of mutant DMPK transcripts, we compared whole-transcriptome profiles of DM1 
and control myoblasts that were transfected with (CAG)n AONs, and performed extensive 
gene expression profiling (GEP) and subsequent bioinformatics analyses of the data 
obtained. Concomitantly, the analysis may give new clues about DM1 pathology by studying 
what happens with the transcription profile of these cells after reducing toxic effects of 
expanded DMPK transcripts.
GEP is nowadays commonly used for the characterization of activity or expression of genes 
in a given cell or organism, made possible by the identification and quantification of mRNA 
sequences. Profiles generated can be compared and analyzed to reveal differences between 
cell populations, indicative of relevant features like cell type, cell cycle, differentiation stage 
and response to stress, environment or treatments. The first widely used GEP methodology 
was the DNA microarray technology [16], which measures the relative expression of 
a predefined set of previously identified genes by hybridizing mRNA/cDNA samples to 
a large number of DNA sequences (probes) immobilized on a solid surface in an ordered 
array [17]. More recently, sequencing techniques have allowed GEP of all genes expressed 
in a particular specimen, not just from a predefined set. The most relevant example among 
the first sequencing technologies that were applied with this purpose is serial analysis of 
gene expression (SAGE). This method is based on the concatenation of small sequences of 
nucleotides, so-called tags of about 11 bp in size, derived from the 3’ part of polyadenylated 
mRNAs present in a given sample [18]. These tags can then be analyzed by means 
of high-throughput DNA sequencers. Nowadays, the advent of next generation 
sequencing (NGS), sometimes performed on individual RNA molecules within the entire 
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population, allows for whole-transcriptome characterization, giving an accurate qualitative 
and quantitative profile of all RNA entities present in a given sample [19]. This approach, 
also known as RNA sequencing (RNA-Seq), has the advantage of offering near-full sequence 
coverage of all transcripts present in the cell, allowing to study certain aspects that were 
not covered with previous technologies, such as novel alternative splice modes or antisense 
transcription [20].
In this study, we performed GEP by combining RNA-Seq and SAGE approaches with 
extensive bioinformatics analysis of the data. We monitored transcriptome changes after 
treating myoblasts (from unaffected individuals and patients suffering from DM1) with 
a (CAG)7 AON containing a fully modified 2’-O-methylribose phosphorothioate backbone 
and 5-methyl cytosines (named “(mCAG)7” here) or a control AON based on the scrambled 
sequence of (mCAG)7. This study may help to validate outcome and predict or identify any 
possible side effects of (CAG)n AON treatment.
 | M AT E R I A L S  A N D  M E T H O D S
Cell culture
Myoblast cell lines from DM1 patients carrying a (CTG)760, a (CTG)800 or a (CTG)1200 
repeat in the DMPK gene and control myoblast cell lines from three unaffected individuals 
(control 1, control 2 and control 3) were kindly provided by Dr. D. Furling (Institut de 
Myologie, Inserm, Paris, France) and Dr. J. Puymirat (Centre Hospitalier de l’Université Laval, 
Québec, Canada). Cells were cultured at 37°C and 5% CO2 in growth medium (Ham F10 
medium with GlutaMAX™ (Thermo Scientific) supplemented with 20% HyClone® Bovine 
Growth Serum (Thermo Scientific) and 25 μg/ml gentamicin. When cells reached 100% 
confluency, the differentiation process was started by changing to differentiation medium 
(DMEM supplemented with 4 mM L-glutamine, 1 mM pyruvate, 10 μg/ml insulin [Sigma], 
100 μg/ml apo-transferrin [Sigma] and 25 μg/ml gentamicin) and incubating for 7 days. 
AON treatment
Cells were transfected in duplicate with (mCAG)7, a chemically modified AON with 
the sequence 5’-CAGCAGCAGCAGCAGCAGCAG-3’, containing modifications in all 
nucleotides: 2’-O-methylriboses, phosphorothioate backbone and 5-methyl cytosines, or 
with a scrambled control AON, 5’-CAGAGGACCACCAGGCCAAGG-3’, with the same chemical 
modifications. Transfections were performed by means of polyethyleneimine (PEI; ExGen 
500, Fermentas) according to the manufacturer’s instructions. Typically, 5 μl of PEI per μg of 
AON was added in Opti-MEM medium (Invitrogen) to myoblasts two days before reaching 
100% confluency or in differentiation medium to myotubes on day 5 of myogenesis 
(Fig. 1A), in both cases at a final oligo concentration of 200 nM. Fresh medium was 
supplemented after 4 hours and medium was changed 24 hours later. RNA was isolated 
at the specified time points (for Northern blotting) or 48 h after transfection in myotubes 
(for SAGE and RNA-Seq).
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RNA isolation
RNA was isolated using the Aurum Total RNA Mini Kit (Bio-Rad), following the manufacturer’s 
protocol with an extended on-column DNase I treatment. RNA quantity and quality 
was determined by RNA Nano LabChip (Agilent) measurements, for the calculation of 
concentrations and RNA integrity number (RIN) values per sample [21]. The concentrations 
were verified by spectrophotometry in a Nanodrop apparatus (Thermo Scientific). Samples 
were stored at -80°C until further use.
RNA sequencing (RNA-Seq)
Strand specific RNA-Seq libraries were generated using the method described by 
Parkhomchuk et al. [22] with minor modifications. In short, mRNA was isolated from 1 µg 
total RNA using oligo-dT Dynabeads (Life Technologies) and fragmented to 150-200 nt in 
first strand buffer for 3 minutes at 94°C. Random hexamer primed first strand was generated 
in presence of dATP, dGTP, dCTP and cTTP. Second strand was generated using dUTP instead 
of dTTP to tag the second strand. Subsequent steps to generate the sequencing libraries 
were performed with the KAPA HTP Library Preparation Kit for Illumina sequencing with 
minor modifications, i.e., after indexed adapter ligation to the dsDNA fragments, the library 
was treated with USER enzyme (New England Biolabs) in order to digest the second 
strand derived fragments. After amplification of the libraries, samples with unique sample 
indexes were pooled. Sequencing of the DNA fragments was performed in both directions 
(paired-end sequencing) using 2x100 bp read lengths on a HiSeq2000 system (Illumina), 
following standard manufacturer guidelines.
Serial analysis of gene expression (SAGE)
SAGE libraries were produced as described previously [23]. In short, 500 ng total RNA was 
hybridized to Dynabeads poly-dT magnetic beads (Invitrogen). First and second strand 
synthesis was performed on the beads. Bound DNA was digested with NlaIII endonuclease 
to leave short dsDNA segments, spanning the sequence between the most downstream 
NlaIII recognition site (CATG) and the poly(A) tail. Next, GEX adapter 1 was ligated and 
the DNA segment was digested with MmeI to create a 21 base pair fragment downstream 
of this adapter. This fragment was then ligated to GEX adapter 2 to complete the cassette 
and purified using Dynabeads streptavidin C1 magnetic beads (Invitrogen). Adaptor 
ligated DNA fragments were amplified by 25 cycles and PCR products were loaded on 6% 
Novex Tris/Borate/EDTA acrylamide gels (Invitrogen). The 96 base pair band corresponding 
to the complete cassette was excised and purified from the gel, followed by ethanol 
precipitation. Sample quality was checked on a DNA 1000 Lab-on-a-Chip (Agilent).
Sequencing was performed at the Leiden Genome Technology Center on an Illumina 
GA2 sequencer (Illumina). Purified samples were diluted to 10 nM and loaded on a single 
lane of the flow cell where, after cluster amplification, samples were put through an ultra-
short 18 cycle sequencing run. Illumina Pipeline Software version 1.5 was used for data 
sequence processing. The FASTQ files were analysed using the open source GAPSS_B(v2) 
pipeline http://www.lgtc.nl/GAPSS. All sequences were trimmed to 17 base pairs to 
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remove the first lower quality base pair from the 3’ end of the sequences. After trimming, 
the NlaIII recognition site (CATG) was added to the 5’ end of the sequence to create 
the complete 21-22 mer nucleotide sequences. Sequences were aligned using the Bowtie 
short read aligner (version 0.12.7) against the UCSC hg19 reference genome, allowing for 
a maximum of one mismatch and a maximum of two possible positions in the genome 
(options: -k 1 -m 2 -n 1 --best --strata -solexa1.3-quals).
Northern blotting
To examine DMPK mRNA expression and silencing, Northern blotting was performed as 
described [14]. Random-primed 32P-labelled cDNAs for human DMPK (2.6 kb cDNA) and 
rat Gapdh (1.1 kb cDNA) were used as probes. Signals were quantified by phospho-imager 
analysis (GS-505 or Molecular Imager FX, Bio-Rad) and analyzed with Quantity One (Bio-Rad) 
or ImageJ software. Gapdh levels were used for normalization.
Data analysis and statistics
Data quality control (QC) of RNA-Seq data was assessed with the FastQC tool kit [24], giving 
QC information including GC content, sequence quality and overrepresented k-mers. Then, 
the FastX tool kit [25] was used to filter low quality data by clipping low quality bases from 
the reads and the FastQC tool kit was run again to assess the improvement in quality. Reads 
were aligned with a specialised RNA aligner, GSNAP [26]. This aligner is able to split reads that 
cross exon-exon boundaries. The output of this aligner was converted to a standard format 
(BAM) with SAMtools [27]. To exploit the strand-specific nature of the data, the read pairs 
originating from the transcripts located on the forward strand were separated from those 
located on the reverse strand. After data splitting, BEDtools was used to count numbers of 
reads mapping to individual exons [28]. Gene expression and transcript assembly analysis 
was done by Cufflinks [29]. Then, for later downstream analysis, a list of exact absolute counts 
per exon was generated.
Analysis of SAGE data was done using the R programming package [30]. Data was filtered 
for at least 0.5 counts per million, in at least half of the samples. To perform the comparison 
between groups we used the libraries “limma”, “edge R”, “org.Hs.eg.db” and “biomaRt”. R was 
also used to generate the volcano plots and the multidimensional scaling (MDS) analysis of 
the RNA-Seq data. Specific threshold limits (0.05 for the q-value and 2 for the fold change) 
were applied to generate the volcano plots, using the library “metabolomics” in addition to 
the ones previously mentioned. The MDS analysis was performed using the “edge R” library. 
MDS represents the samples on a two-dimensional scatterplot according to the pairwise 
expression distances of the typical log2 fold changes of the top 100 genes that best 
distinguish the samples.
To gain further insight into the biology behind certain genes subsets in our dataset, 
the Gene Set Enrichment Analysis (GSEA) method was used to compute overlap with gene 
ontology signatures and test whether they were significantly enriched [31].
For all these analyses, either p-value or q-value functions were used (indicated in each 
experiment) for the estimation of statistical significance. The q-value is the false discovery 
rate analog of hypergeometric p-value after correction for multiple hypothesis testing [32].
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Evaluation of DMPK silencing after (mCAG)7 AON treatment
We used six different myoblast cell lines (three from DM1 patients and three from unaffected 
controls) to perform gene expression profiling by RNA-Seq and/or SAGE (Table 1). Cells were 
analyzed after seven days of differentiation to myotubes in order to achieve a transcriptome 
profile that optimally matched the profile of adult muscle. Since we were interested in 
possible changes of gene expression caused by (mCAG)7 AON treatment that may arise 
already at myoblast stage but also have consequences for later steps in myogenesis, we 
used a protocol with first transfection before onset of differentiation (Fig. 1A). To monitor 
DMPK silencing during the entire course of differentiation, we performed Northern blot 
analysis of RNA samples obtained at day -1 (one day before onset of differentiation) and 
at days 1, 3 and 5 after medium switch for differentiation (Fig. 1A). Hybridization with 
a 32P-labeled DMPK probe revealed that strong silencing of expanded DMPK transcripts 
occurred in myoblasts before the medium switch for differentiation and that silencing was 
stably maintained in myotubes during the initial five days of differentiation (Fig. 1B). At 
day 5, cells did undergo a second round of transfection to make sure DMPK levels would 
remain low until day 7, the time point used for RNA-Seq and SAGE analysis. As expected, 
we could confirm a significant reduction in DMPK transcripts in the DM1 cell line, whereas 
DMPK transcripts of the control cell line appeared not affected (Fig. 1C, note that these two 
methods cannot discriminate between expanded and normal-sized allele products). We 
performed additional SAGE analysis in the other two DM1 and control cell lines (Table 1). In 
all cases comparable DMPK silencing effects were observed in DM1 cells, with no effects on 
DMPK expression seen in controls (Fig. 1D).
Effects of (mCAG)7 treatment on expression of (CTG)n-repeat containing genes
One anticipated but undesired effect of (mCAG)7 treatment would be silencing of other 
(CTG.CAG)n-repeat containing genes than DMPK that produce transcripts with a (CUG)n 
Table 1. Cell lines used in this study. Overview of control and DM1 myoblast cell lines including DMPK 
(CTG)n repeat lengths. The transcriptome profiling technique(s) used for analysis of each cell line are 
given in the last column. 
Cell line (CTG) repeat length Analysis
Control 1 5/10 SAGE and RNA-Seq
Control 2 5/5 SAGE
Control 3 5/5 SAGE
(CTG)760 11/760 SAGE
(CTG)800 13/800 SAGE and RNA-Seq
(CTG)1200 5/1200 SAGE
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Figure 1. DMPK silencing in (mCAG)7-treated DM1 myoblasts. (A) Experimental scheme for myoblast-
myotube culture and AON administration. DM1 and control myoblasts were grown until confluence 
and then differentiated to myotubes for 7 days. Cells were transfected twice with either (mCAG)7 
or scrambled control AON: first transfection was performed in the myoblast phase (2 days before 
reaching confluence) and the second transfection in the myotube phase (day 5 of differentiation). †: 
Time points of RNA isolation for Northern blotting. ‡: Time point of RNA isolation for RNA-Seq and 
SAGE. (B) DMPK expression in one control and one DM1 cell line analyzed by Northern blotting using 
RNA samples isolated at indicated time points prior and during differentiation. GAPDH expression 
was used for normalization, see quantification underneath the upper image. Samples corresponding 
to scrambled AON treatment were set to 100% for each allele product and time point independently 
to better appreciate (mCAG)7 AON effect. We observed a strong and specific silencing of expanded 
DMPK transcripts during the entire course of the experiment. (C) Quantification of DMPK fragments 
per kilobase of exon per million fragments mapped (FPKM) by RNA-Seq (day 7 of differentiation). (D) 
Quantification of DMPK counts by SAGE (day 7 of differentiation).
repeat sequence, of which there are several in the human genome. For a complete listing of 
these genes see refs. [14,33]. Here, we studied expression of fourteen representatives of this 
group of genes with repeats of 6 to 25 (CTG.CAG) triplets (Table 2). Very encouragingly, we 
found that only DMPK was consistently silenced in all DM1 cell lines. Other (CUG)n-containing 
transcripts were not or only mildly affected, whereby no consistent effects across all cell 
lines were seen (e.g. LTBP3 and STEAP3). Importantly, there was no correlation between 
the level of reduction and (CUG)n repeat length for the repeat range (6-25 CUG triplets) 
analyzed (Fig. 2).
Transcriptome effects of (mCAG)7 AON treatment
To obtain better insight in the overall effects of (mCAG)7 AON activity we first made 
a comparison between the transcriptomes of DM1 and control myotubes that received 
treatment with (mCAG)7 or with the scrambled control AON (Fig. 3). RNA-Seq data analysis 
revealed 266 genes whose expression changed significantly after (mCAG)7 treatment in 
the (CTG)800 cell line (q<0.05 threshold; 113 upregulated and 153 downregulated) and 
484 that had undergone expression change in the control cell line 1 (q<0.05 threshold; 412 
upregulated and 72 downregulated). SAGE analysis also showed statistically significant 
changes in gene expression of the (CTG)800 cell line after (mCAG)7 treatment (q<0.05 
threshold; 452 genes: 293 upregulated and 159 downregulated), but not in control cell 
lines. Comparing these three lists of genes, there was an overlap of four genes that were 
significantly dysregulated in all datasets after (mCAG)7 treatment (INHBE, MYL4 and EGR2 
with enhanced expression; TMEM158 with reduced expression). SAGE expression analysis 
in the other cell lines (the three control cell lines, (CTG)760 and (CTG)1200) showed no 
statistically significant change for any gene. Given that RNA-Seq and SAGE analysis were 
powered in the same way for all cell lines (n=2), we conclude that RNA-Seq is more sensitive 
and thus provides a better ability to detect significant changes in gene expression. 
Next, we attempted to deconvolute complexity in our dataset, needed because changes 
in gene expression observed in some cell lines could be caused by either (i) unspecific cellular 
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response to triplet-repeat AONs and/or (ii) downstream effects of reduction of expanded 
DMPK gene expression (only applicable to DM1 cell lines) or superposition of these effects.
As we may assume that non-specific side effects (i) occur in both the control and DM1 
cell populations, we took RNA-Seq data of these cells to compare the genes that significantly 
changed expression with (mCAG)7 treatment in both (CTG)800 and control cell line 1. Out 
of the total set of genes that had undergone expression change (see Fig. 3), altogether 
27 genes were identified that showed congruent changes in expression in both cell lines 
(Table 3). Twenty genes appeared upregulated (p value of overlap < 1.015e-14) and 7 
were downregulated (p value of overlap < 4.763e-07). From this list of genes, only six were 
Table 2. Expression analysis of genes containing a (CTG)n repeat (n>5). Several transcripts with more 
than 5 CUG triplets were included in the analysis. 1(CTG)n: number of CTG triplets in the gene. Please note 
that the number of CTG triplets indicated (given as variable for DMPK) for each gene does not indicate 
a fixed repeat length. Most repeats occur as polymorphic DNA segments and occur with variable length 
throughout the human population. 2Loc.: location of the repeat in the gene. If the repeat is part of the coding 
sequence (CDS), the exon number containing the repeat is given, followed by the total amount of exons 
in the gene between brackets. 3F.C.: fold change of expression between (mCAG)7 AON and scrambled 
control. 4Sig.: statistical analysis of the comparison indicating p value/q value. The q value is adjusted 
for the total amount of comparisons. Comparisons were considered significant when (p or q)<0.05: 
*(p or q)<0.05, **(p or q)<0.01, ***(p or q)<0.001 and, in those cases, corresponding values 
are highlighted in bold. 5Assay: color key used to indicate the type of assay used for RNA analysis; yellow 
indicates RNA-Seq, blue indicates SAGE.
   
 
1 
 
 
 
 
 Gene (CTG)n1 Loc.2 F.C.3 Sig.4 F.C.3 Sig.4 F.C.3 Sig.4 Assay5 F.C.3 Sig.4 F.C.3 Sig.4 F.C.3 Sig.4
0.67 ***/* RNA‐Seq 1.07 n.s./n.s.
0.55 */n.s. SAGE 0.69 n.s./n.s.
1.04 n.s./n.s. RNA‐Seq 1.06 n.s./n.s.
1.16 n.s./n.s. SAGE 0.74 n.s./n.s.
0.81 **/n.s. RNA‐Seq 0.83 */n.s.
0.67 n.s./n.s. SAGE 0.62 n.s./n.s.
1.11 n.s./n.s. RNA‐Seq 1.03 n.s./n.s.
1.78 **/n.s. SAGE 1.27 n.s./n.s.
1.19 n.s./n.s. RNA‐Seq 0.96 n.s./n.s.
1.27 n.s./n.s. SAGE 1.24 n.s./n.s.
0.77 */n.s. RNA‐Seq 0.92 n.s./n.s.
0.42 n.s./n.s. SAGE 0.73 n.s./n.s.
0.99 n.s./n.s. RNA‐Seq 0.99 n.s./n.s.
1.18 */n.s. SAGE 0.74 n.s./n.s.
0.81 **/n.s. RNA‐Seq 1.02 n.s./n.s.
0.73 n.s./n.s. SAGE 0.71 n.s./n.s.
1.03 n.s./n.s. RNA‐Seq 1.05 n.s./n.s.
0.70 n.s./n.s. SAGE 1.05 n.s./n.s.
0.89 n.s./n.s. RNA‐Seq 0.96 n.s./n.s.
0.83 n.s./n.s. SAGE 0.83 n.s./n.s.
1.09 n.s./n.s. RNA‐Seq 0.94 n.s./n.s.
1.36 n.s./n.s. SAGE 1.48 n.s./n.s.
0.96 n.s./n.s. RNA‐Seq 1.10 n.s./n.s.
0.75 n.s./n.s. SAGE 1.20 n.s./n.s.
1.34 n.s./n.s. RNA‐Seq 0.89 n.s./n.s.
1.11 n.s./n.s. SAGE 0.93 n.s./n.s.
0.96 n.s./n.s. RNA‐Seq 1.00 n.s./n.s.
0.75 n.s./n.s. SAGE 0.92 n.s./n.s.
0.91 n.s./n.s. RNA‐Seq 0.94 n.s./n.s.
0.46 */n.s. SAGE 1.44 n.s./n.s.
0.80 n.s./n.s.1.66 n.s./n.s.
0.81 n.s./n.s.0.99 n.s./n.s.
1.39 n.s./n.s.0.71 n.s./n.s.
1.33 n.s./n.s.1.25 n.s./n.s.
0.88 n.s./n.s.0.91 n.s./n.s.
0.98 n.s./n.s.0.71 n.s./n.s.
0.75 n.s./n.s.2.03 */n.s.
1.50 n.s./n.s.1.24 n.s./n.s.
0.37 n.s./n.s.1.72 n.s./n.s.
0.94 n.s./n.s.0.75 n.s./n.s.
0.87 n.s./n.s.1.11 n.s./n.s.
0.93 n.s./n.s.0.88 n.s./n.s.
1.04 n.s./n.s.1.30 n.s./n.s.
0.90 n.s./n.s.0.94 n.s./n.s.
Control cell lines
Control 1 Control 2 Control  2
0.72 n.s./n.s.0.80 n.s./n.s.
 STEAP3 6 0.89 n.s./n.s. 0.63 n.s./n.s.
 RBM23 6 1.16 n.s./n.s. 0.63 n.s./n.s.12 (14)
Intron 1
 CHRNA3 7 1.06 n.s./n.s. 0.98 n.s./n.s.
 EIF2AK3 8 0.97 n.s./n.s. 1.37 n.s./n.s.1 (17)
1 (6)
 BPGM 8 1.06 n.s./n.s. 0.91 n.s./n.s.
 BRI3BP 9 1.13 n.s./n.s. 1.22 n.s./n.s.1 (3)
5'UTR
 PAPSS2 10 1.19 n.s./n.s. 1.47 n.s./n.s.
 LTBP3 10 1.63 n.s./n.s. 0.58 n.s./n.s.1 (28)
5'UTR
 MAP3K4 11 1.30 n.s./n.s. 1.72 n.s./n.s.
 LRP8 12 0.84 n.s./n.s. 0.34 n.s./n.s.1 (19)
17 (27)
 NOTCH4 13 1.13 n.s./n.s. 1.21 n.s./n.s.
 JPH3 15 1.23 n.s./n.s. 1.61 n.s./n.s.Intron 1
1 (30)
 RPL14 20 0.87 n.s./n.s. 0.43 */n.s.
 TCF4 25 1.27 n.s./n.s. 1.14 n.s./n.s.Intron 3
6 (6)
DM1 cell lines
DM1 (CTG)760 DM1 (CTG)1200 DM1 (CTG)800
 DMPK Variable 0.46 */n.s. 0.18 **/n.s.3'UTR
 
 
Table 2. Expression analysis of genes containing a (CTG)n repeat (n>5). Several transcripts with 
more than 5 CUG riplets were included in the analysis. 1(CTG)n: number of CTG triplets in the g ne. 
Please note that the number of CTG triplets indicated (given as variable for DMPK) for each gene 
does not indicate a fixed repeat length. Most repeats occur as polymorphic DNA segments and occur 
with variable length throughout the human population. 2Loc.: location of the repeat in the gene. If the 
repeat is part of the coding sequence (CDS), the exon number containing the repeat is given, followed 
by the total amount of exons in the gene between brackets. 3F.C.: fold change of expression between
(mCAG)7 AON and scrambled control. 4Sig.: statistical analysis of the comparison indicating p 
value/q value. The q value is adjusted for the total amount of comparisons. Comparisons were 
considered significant when (p or q)<0.05: *(p or q)<0.05, **(p or q)<0.01, ***(p or q)<0.001 and, in 
those cases, corresponding values re highlighted in bold. 5Ass y: col r key used to indicate the type 
of assay used for RNA analysis; yellow indicates RNA-Seq, blue indicates SAGE. 
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Figure 2. (mCAG)7 AON activity in relation to target repeat length between 6 and 25 CUG triplets. 
The graphs show a linear regression analysis of (mCAG)7 AON effect versus number of CUG triplets 
in the target RNA as analyzed by (A) RNA-Seq for one control and one DM1 cell line or by (B) SAGE 
for three control and three DM1 cells (merged). No significant correlations were found (α=0.05) using 
either Spearman or Pearson tests.
upregulated more than two-fold in both cell lines (TAS1R3, UCKL1-AS1, FBXO39, ZNF619, 
MMRN2 and TREX1) and only two were downregulated more than 2-fold in both cell lines 
(NPTX1 and CD79A). 
We next attempted to identify genes that underwent specific change in 
expression – directly, or indirectly - in response to knock-down of toxic DMPK transcripts. 
We therefore specifically searched for genes that did undergo expression change in 
the (CTG)800 cell line upon treatment with the (mCAG)7 AON, in the entire RNA-Seq and 
SAGE dataset (Fig. 3). Out of a total of 75 genes which showed change in both the RNA-Seq 
and SAGE analysis, 45 were significantly upregulated (p value of overlap < 3.389e-56) and 
30 were significantly downregulated (p value of overlap < 1.868e-35) in both data sets. We 
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Figure 3. Genes whose expression was significantly changed by (mCAG)7 AON treatment: 
comparison between different cell groups and techniques. Analysis was performed separately for 
upregulated and downregulated genes. The threshold to include a gene in this analysis was q<0.05 
(for the comparison (mCAG)7 AON treatment versus scrambled AON treatment). In DM1 cell lines, 
the overlap of these genes between RNA-Seq and SAGE genes was statistically significant, both in 
upregulated and downregulated genes (note that there were no significant gene expression changes 
detected by SAGE for the control cell line, so no overlap could be tested between techniques in that 
case. When comparing genes with overlap between DM1 and control cell lines, there was also significant 
overlap in both upregulated and downregulated genes. The genes that were significantly upregulated 
or downregulated in both control and DM1 cell line (as determined by RNA-Seq) are depicted in Table 
3. Asterisks indicate whether the overlap between gene sets in the intersection between pairs of circles 
is significant (i.e. not representing the result of random intersection **: p<0.01, ***: p<0.001). Note 
that three upregulated genes and one downregulated gene appear at the intersection of the three 
circles for unregulated and downregulated genes respectively, and thus they are also included in each 
comparisons between gene sets.
performed a Gene ontology (GO) analysis of these genes using a Gene Set Enrichment Analysis 
(GSEA) tool [31]. When looking at genes that were upregulated after (mCAG)7 treatment in 
the DM1 cell line, GSEA found a significant enrichment (q=1.05E-09) of eight genes involved 
in development of skeletal muscle or myogenesis (ACTC1, PPFIA4, COL15A1, MYL4, DES, 
MYOG, KLF5 and TNNT1). GSEA analysis of genes downregulated by AON treatment resulted 
in a significant enrichment (q=1.71E-07) of six genes involved in epithelial-mesenchymal 
transition (TFPI2, MMP1, FBLN1, FMOD, ANPEP and SFRP1).
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Gene  Name Fold change q value Fold change q value
TAS1R3  Taste receptor, type 1, member 3 6.687 5.16E‐03 4.469 6.92E‐03
UCKL1‐AS1  Uridine‐cytidine kinase 1‐like 1 Antisense 3.179 1.19E‐12 2.391 2.59E‐12
FBXO39  F‐box protein 39 2.565 1.00E‐02 2.464 9.52E‐05
ZNF619  Zinc finger protein 619 2.473 7.50E‐03 2.177 1.12E‐02
C19orf35  Chromosome 19 open reading frame 35 2.468 1.07E‐03 1.975 2.09E‐04
MMRN2  Multimerin 2 2.216 3.93E‐02 2.221 2.00E‐03
TREX1  Three prime repair exonuclease 1 2.055 8.51E‐03 2.810 2.74E‐02
INHBE *  Inhibin, beta E 1.648 5.69E‐04 1.451 4.43E‐05
SLC8A2  Solute carrier family 8 (sodium/calcium exchanger) 1.611 3.42E‐03 2.426 1.75E‐05
UCP3  Uncoupling protein 3 (mitochondrial, proton carrier) 1.572 4.45E‐02 1.560 2.49E‐02
MYOM3  Myomesin 3 1.549 2.19E‐02 1.298 9.87E‐03
EGR2 *  Early growth response 2 1.518 5.10E‐05 1.266 2.74E‐02
RPPH1  Ribonuclease P RNA component H1 1.472 3.42E‐03 1.435 9.52E‐04
CSNK1D  Casein kinase 1, delta 1.437 5.74E‐03 2.157 3.84E‐07
KRT7  Keratin 7 1.422 3.59E‐04 1.312 4.32E‐03
MYBPH  Myosin binding protein H 1.405 2.12E‐03 1.231 4.20E‐02
CTGF  Connective tissue growth factor 1.306 8.51E‐03 1.278 1.23E‐02
MYL4 *  Myosin, light chain 4, alkali; atrial, embryonic 1.296 3.73E‐02 1.336 3.03E‐03
TRIB3  Tribbles homolog 3 (Drosophila) 1.260 2.18E‐02 1.383 1.91E‐04
VCAM1  Vascular cell adhesion molecule 1 1.245 4.49E‐02 1.769 6.94E‐08
ALDH1A3  Aldehyde dehydrogenase 1 family, member A3 0.765 1.34E‐02 0.726 8.37E‐04
TMEM158 *  Transmembrane protein 158 0.722 3.32E‐05 0.742 6.68E‐03
CIT  Citron (rho‐interacting, serine/threonine kinase 21) 0.695 1.75E‐05 0.643 1.03E‐02
ITGA10  Integrin, alpha 10 0.676 1.35E‐02 0.613 3.75E‐05
AMH  Anti‐Mullerian hormone 0.4803 1.83E‐05 0.7842 4.66E‐02
NPTX1  Neuronal pentraxin 0.472 7.24E‐10 0.461 1.50E‐06
CD79A  Molecule, immunoglobulin‐associated alpha 0.389 2.98E‐02 0.324 5.22E‐03
DM1 cell line Control cell line
0.1 0.25 0.5 0.75 1 1.5 2 2.5 3
Fold change color key
<<< Dowregulated Upregulated >>>  
Table 3. RNA-Seq analysis of genes whose expression changed significantly in both control and 
DM1 cell lines by (mCAG)7 AON treatment. List of genes that are significantly upregulated or 
downregulated (q<0.05) in both DM1 and control cell line. *: genes indicated in bold lettering 
showed significant change in expression in both cell lines (as determined by RNA-Seq) and in 
addition were also significantly changed in the SAGE data (see triple overlap of the circles in Fig. 3). 
 
 
 
Table 3. RNA-Seq analysis of genes whose expression changed significantly in both control and DM1 
cell lines by (mCAG)7 AON treatment. List of genes that are significantly upregulated or downregulated 
(q<0.05) in both DM1 and control cell line. *: genes indicated in bold lettering showed significant change 
in expression in both cell lines (as determined by RNA-Seq) and in addition were also significantly changed 
in the SAGE data (see triple overlap of the circles in Fig. 3).
Reversal of DM1 expression pattern by (mCAG)7 treatment
The finding that a significant portion of genes that were upregulated after (mCAG)7 treatment 
are inv lved in myo enesis triggered us to hypothesize that expanded DMPK silenci g could 
have reverted (at least in part) the downstream effects of the repeat in gene expression, and 
consequently improving myoblast differentiation of the DM1 cell line. To provide a more 
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solid theoretical foundation for this hypothesis, we first tried to characterize the differences 
in expression between DM1 and control cell lines (independently of (mCAG)7 treatment) 
to generate a characteristic DM1 expression pattern of the cells used in our experiment. 
To do so, we analyzed differences in gene expression of the (CTG)800 cell line compared 
to a control cell line in the RNA-Seq data (Fig. 4A). For a q<0.05 threshold, we found 3339 
genes that differed more than two fold in expression between both cell lines. Since we are 
not using isogenic cell lines, we have to consider that some of these differences in gene 
expression may be due to genetic background differences between both cell lines, and not 
only are due to the pathogenic condition. Making a similar comparison with the SAGE data 
for the DM1 and control cell lines, we found 618 genes with significant different expression 
(this lower number of genes found by SAGE can be taken as an additional indication of 
the superior sensitivity of RNA-Seq). A significant portion of these genes (42%) overlapped 
with the list of genes found in the RNA-Seq analysis (p value of overlap < 7.152e-64).
We then continued with the analysis of the DM1 expression pattern found in the RNA-Seq 
data. From the 3339 genes with significant expression differences between (CTG)800 and 
control cell line, 2294 genes showed at least a >2-fold higher expression and 1045 genes 
showed at least <50% lower expression in DM1 compared control cells, respectively. GSEA 
analysis of overexpressed genes indicated a significant enrichment for pathways related 
to inflammatory response (50 genes, q=7.08E-23), with overlap for groups of genes that 
respond to signaling of certain cytokines, like IFNγ (88 genes, q=1.65E-62), IFNα (55 genes, 
q=3.36E-47), NFκβ/TNFα (69 genes, q=4.28E-41) and STAT5/IL2 (51 genes, q=1.1E-23), and 
genes for complement system proteins (58 genes, q=4.88E-30). Other relevant clusters in 
our list of overexpressed genes were for genes involved in apoptosis (38 genes, q= 5.99E-17) 
and epithelial-mesenchymal transition (75 genes, q=2.21E-47).  Groups of genes whose 
activity is lower in DM1 cells were significantly enriched for functioning in myogenesis (73 
genes, q=1.23E-67) and response to KRAS activation (26 genes, q= 5.30E-12).
Upon (mCAG)7 treatment, the number of overexpressed genes was reduced (from 2294 
to 1580) and the total number of underexpressed genes hardly changed (1045 vs 1138) 
(Fig. 4A). To us, the pattern of DM1 gene expression in the volcano plots, for both 
overexpressed and underexpressed genes, appeared more similar to control cells upon 
(mCAG)7 treatment, i.e. closer to Log2 fold expression difference = 0 (compare left and 
right graph of Fig. 4A). To verify this observation, we performed a classification of the genes 
according to the direction of expression change upon (mCAG)7 treatment (Fig. 4B). We 
inferred that out of a total of 2294 genes that showed differential overexpression originally, 
1039 genes (45%) showed a lower fold change in expression difference (i.e. had undergone 
partial normalization towards control-like expression); 93 (4%) underwent further 
upregulation and 1162 (51%) remained unchanged. Out of the group of underexpressed 
genes in DM1 cells (1045 genes altogether), 315 genes (30%) underwent upregulation as an 
effect of AON treatment, 95 (9%) were further downregulated and 635 (61%) did not change 
their expression. Therefore, in both cases, the majority of genes that did change, adapted 
their expression into the direction of the normal expression pattern, as found for the control 
cell line. It should be noted that, for some of these genes, although the fold change in 
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Figure 4. Partial correction of DM1 expression pattern after (mCAG)7 treatment as determined by 
RNA-Seq. (A) Volcano plots of gene expression. Genes in the (CTG)800 cell line are represented by dots 
plotted in comparison to their expression in the control cell line by fold change (x-axis) and significance 
(y-axis). Genes with q<0.05 and >2-fold change are indicated in blue (downregulated in DM1) or red 
(upregulated). Left graph shows the expression pattern after transfection with the scrambled control 
AON (DM1 signature), whereas right graph shows the expression pattern after transfection with 
(mCAG)7 AON ((mCAG)7 treatment). (B) Pie-charts representing the distribution of genes according to 
their change in expression after (mCAG)7 treatment. Genes that changed their expression >25% away 
from their value in the control cell line account for the dark grey area of the chart, genes that maintain 
the same levels (±25%) are included in the light grey sector and genes that change their expression 
>25% towards their value in the control cell line are represented in the green sector. (C) Representation 
of average fold-change between control and DM1 cells for the entire population of genes. The fold 
change is significantly lower in cells transfected with (mCAG)7 AON (treatment) compared to those 
transfected with the scrambled control AON (signature). ***: p<0.001. (D) Multidimensional scaling 
analysis of FPKM values of the entire dataset of genes detected in the RNA-Seq experiment. (E) 
Representation of expression differences for a selection of genes in DM1 cells whose levels were 
significantly closer to the healthy control after transfection with (mCAG)7 AON. aGenes that were 
expressed in the DM1 cell line but not in the control cell line were given an arbitrary log2FC value of 
6.64 (FC=100). bGenes that were expressed in the control cell line but not in the DM1 cell line were given 
an arbitrary log2FC value of -6.64 (FC=0.01). These genes are described in Table 4.
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expression was reduced, the deviation in their expression remained statistically significant. 
Nevertheless, the average magnitude of change came significantly closer to control cells 
(reference value of zero) after (mCAG)7 treatment, as assessed by comparing the mean 
fold change of expression difference between cell lines under scrambled AON treatment 
versus (mCAG)7 treatment (Fig. 4C). This was further confirmed by a multidimensional 
scaling analysis, which uses the most representative genes of each sample group to create 
a representative signature of the expression pattern (Fig. 4D).
To verify our expectation that the genes that recovered expression towards levels as 
found in the control cell line belong to the same group as those that were found dysregulated 
in DM1, we performed a new GSEA analysis with the genes whose expression level was 
partially or completely corrected by (mCAG)7 treatment (examples from these genes are 
depicted in Table 4 and Fig. 4E). Indeed, we found that a significant portion of the genes with 
reduced expression after (mCAG)7 treatment were also those that were found overexpressed 
in the previous analysis, i.e. the genes with a role in inflammatory responses (q=1.32E-21), 
IFNγ response (80, q=8.24E-80), IFNα response (55 genes, q=8.00E-66), NFκβ/TNFα signaling 
(45 genes, q=2.36E-32), STAT5/IL2 signaling (30 genes, q=1.05E-16), complement biology 
(43 genes, q=3.70E-30), apoptosis (27 genes, q=2.08E-16) and epithelial-mesenchymal 
transition (40 genes, q=7.08E-27).  Similarly, genes that were underexpressed in DM1, but 
recovered expression towards control levels with (mCAG)7 treatment, were again found 
significantly enriched for functioning in myogenesis (11 genes, q=2.10E-06) and expression 
induced by KRAS activation (12 genes, q=4.09E-07). This indeed confirms that genes that 
were found dysregulated in DM1 are also in majority the ones that recovered their expression 
to control values upon (mCUG)7 treatment.
One of the best characterized hallmarks of DM1 is the incorrect splicing that several 
gene transcripts undergo as a consequence of MBNL and CUGBP1 dysregulation [34,35]. We 
looked into the RNA-Seq data at a panel of genes reported to be incorrectly spliced in DM1 
[36]: CLCN1 (exon 7), DMD (exon 78), TTN (exon 5), LDB3 (exon 7), NFIX (exon 7), PHKA1 (exon 
18), INRS (exon 11) MBNL1 (exon 7), BIN1 (exon 11), SERCA1 (exon 22) and NCOR2 (exon 45). 
From all these genes, exon coverage was only sufficient to perform splicing analysis for BIN1, 
NCOR2, MBNL1 and NFIX (Fig. 5). The splicing pattern on BIN1, NCOR2 and MBNL1 was indeed 
significantly different between control and DM1 cells but, strikingly, there was no correction 
by (mCAG)7 AON treatment. Inclusion of exon 7 of NFIX was not affected in our DM1 cells as 
compared to the control. 
 | D I S C U S S I O N
This study aimed to monitor transcriptome changes that occurred in healthy and DM1 
myoblasts upon transfection with a (mCAG)7 AON. A gene expression profiling (GEP) 
analysis based on RNA-Seq and SAGE-based  quantitation and bioinformatics analysis of 
data was conducted to reveal different types of changes: (i) effects on the target transcripts 
for which the (mCAG)7 AON was intended, i.e. (CUG)n-expanded DMPK mRNA isoforms, (ii) 
effects on (CUG)n-containing mRNAs from other genes in the genome, (iii) collateral effects 
of AON treatment on gene expression, not necessarily due to direct hybridization activity of 
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Table 4. Genes with corrected expression after (mCAG)7 AON treatment. List of genes with their log2 
fold change (FC) expression in DM1 cells respective to control cells after transfection with scrambled 
AON (signature) or (mCAG)7 AON (treatment). aGenes that were expressed in the DM1 cell line but not in 
the control cell line were given an arbitrary log2FC value of 6.64 (FC=100). bGenes that were expressed in 
the control cell line but not in the DM1 cell line were given an arbitrary log2FC value of -6.64 (FC=0.01). 
The expression changes of these genes are represented in Fig. 4E.
Gene Description
Log2 fold change
Signature Treatment
SDCBP2 Syndecan Binding Protein (Syntenin) 2 6.64 a -0.40
IFI27L2 Interferon, Alpha-Inducible Protein 27-Like 2 6.64 a 1.49
KYNU Kynureninase 6.64 a 2.12
CASP12 Caspase 12 6.64 a 2.80
MIR492 MicroRNA 492 6.64 a 3.35
CD40 CD40 molecule, TNF receptor superfamily member 5 5.62 4.16
CD74 CD74 Molecule, Major Histocompatibility Complex, Class II 4.03 1.52
ZNF664-FAM101A Filamin-Interacting Protein FAM101A 3.97 1.16
BATF2 Basic Leucine Zipper Transcription Factor, ATF-Like 2 3.36 0.48
FAM100B UBA-Like Domain Containing 2 2.67 0.27
IFI35 Interferon-Induced Protein 35 2.35 -0.05
MX2 MX Dynamin-Like GTPase 2 2.05 -0.18
OASL 2’-5’-Oligoadenylate Synthetase-Like 1.85 -0.38
IRF1 Interferon regulatory factor 1 1.16 -0.07
PTGIS Prostaglandin I2 (Prostacyclin) Synthase -1.75 -0.33
MSTN Myostatin -2.71 -1.19
MYOZ1 Myozenin 1 -3.62 -1.93
TMEM233 Transmembrane Protein 233 -4.34 -2.55
RBPMS2 RNA Binding Protein With Multiple Splicing 2 -4.53 -1.92
PITPNM3 Phosphatidylinositol Transfer Protein, Membrane-Associated 3 -4.84 -3.00
EN2 Engrailed Homeobox 2 -4.99 -2.56
SLC16A9 Solute Carrier Family 16, Member 9 -6.10 -3.70
IL2RG Interleukin 2 Receptor, Gamma -6.64 b -4.35
MYL10 Myosin, Light Chain 10, Regulatory -6.64 b -1.97
C1QTNF3-AMACR C1QTNF3-AMACR Readthrough (NMD Candidate) -6.64 b -0.06
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Table 4. Genes with corrected expression after (mCAG)7 AON treatment. List of genes with 
their log2 fold change (FC) expression in DM1 cells respective to control cells after transfection with 
scrambled AON (signature) or (mCAG)7 AON (treatment). aGenes that were expressed in the DM1 
cell line but not in the control cell line were given an arbitrary log2FC value of 6.64 (FC=100). 
bGenes that were expressed in the control cell line but not in the DM1 cell line were given an 
arbitrary log2FC value of -6.64 (FC=0.01). The expression changes of these genes are represented in 
Fig. 4E. 
 
the AON, and (iv) expression changes that may be indicative for normalization of the genetic 
disease expression pattern upon silencing of the mutation (pathology reversal). The findings 
obtained can potentially serve to provide better insight in the type and magnitude 
of side effects of the oligo and also to understand the extent of reversal to a normal 
myoblast-myotube transcriptome expression pattern that can be achieved upon treatment 
of DM1 cells with this AON.
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The first obvious transcript to study was DMPK itself. We observed a significant reduction 
in DMPK RNA in all DM1 cell lines by both RNA-Seq and SAGE, but DMPK expression was not 
affected by treatment with (mCAG)7 AON in unaffected myoblasts. Moreover, we could show 
by Northern blotting that DMPK reduction in DM1 myoblasts corresponded specifically to 
the mutant products of the expanded allele.
In addition to DMPK, several other transcripts containing a small (CUG)n repeat occur 
in the transcriptome. None of these potential targets for (mCAG)7 appeared significantly 
silenced by the oligo. Furthermore, there was no significant correlation between the number 
of CUG triplets in the target and the level of reduction for a range between 6 to 25 triplets. 
Taking these findings together, we conclude that the impact of (mCAG)7 treatment on 
transcripts containing repeats in this range is negligible. This fits with our earlier observation 
Fig. 5. Analysis of DM1 splicing abnormalities. Quantification of read coverage for BIN1 exon 11, MBNL1 
exon 7, NCOR exon 45 and NFIX exon 7, comparing different cell lines and treatments. Normalization 
was performed by calculating the ratio of read counts for the particular exon compared to read 
counts of all other exons of the transcript. Values of scrambled-treated control cells were set to 100% 
for comparison.
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that (CAG)7 AONs works with selectively towards products of the mutant DMPK allele 
(containing >25 CUG triplets) leaving normal transcripts with ~5-15 CUG triplets largely 
unaffected (see Chapter 2 [15] and Fig. 1B).
Other potential side effects of (mCAG)7 treatment may not be dependent of direct binding 
to transcripts with (CUG)n repeats. For instance, (mCAG)7 could interact with cellular factors 
and trigger unexpected downstream gene expression responses. To explore this possibility, 
we looked at significant changes in global gene expression in control cell lines, again by 
comparing treatment with (mCAG)7 and scrambled AON. We took control cell lines instead 
of DM1 cell lines for this analysis to avoid identification of any changes that were directly 
or indirectly repeat-related. When looking at the fold change in gene expression between 
(mCAG)7 and scrambled AON treatment, we could only find significantly dysregulated genes 
in control cell line 1 by RNA-Seq, but not by SAGE in this one nor any of the two other control 
cell lines. We can exclude that the expression change of these genes is a downstream effect 
of DMPK silencing since we demonstrated that DMPK expression levels were not reduced in 
control cell line 1 upon AON treatment. 
Gene expression differences between (mCAG)7 and scrambled AON treatment in 
(CTG)800 DM1 cells revealed that twenty-seven genes changed expression as in the control 
cell line. However, only eight (out of a total of 1536 genes analyzed in both cell lines) showed 
more than two-fold change in expression, six of them being upregulated (Taste Receptor 
(TAS1R3), Uridine-Cytidine Kinase (UCKL1), F-Box Protein 39 (FBXO39), Zinc Finger Protein 
619 (ZNF619), Multimerin 2 (MMRN2) and Three Prime Repair Exonuclease (TREX1)) and two 
of them downregulated (Neuronal Pentraxin (NPTX1) and CD79a Molecule (CD79A)). These 
transcripts belong to very different functional classes of genes, according to our GSEA 
analysis, so it is difficult to give any statements on causal associations between (mCAG)7 
treatment and effects on their expression. Moreover, some of these genes, like TAS1R3, 
NPTX1 or CD79a, are not characteristic for myoblasts or muscle tissue and were indeed found 
to be expressed at a very low level. These observations led us to think that, at least for some 
of these genes, the changes observed (even when corrected for the false discovery rate) 
may be due in large part to stochastic variation in gene expression (culture or experimental 
context-dependent; perhaps under epigenetic regulation) rather than to a true biological 
effect. Taking together, the SAGE and RNA-Seq analyses yielded no evidence to support 
that (mCAG)7 AON induces unspecific off-target changes in the transcriptome or that these 
changes could lead to detrimental effects in the cell.  Further study is needed to substantiate 
this conclusion.
The key issue in the study described here is finding an answer on the question whether 
(mCAG)7 treatment could help restoring the DM1 transcription pattern to levels observed 
in control cell lines. To do just that, we generated a characteristic DM1 expression pattern 
profile of the transcriptome by comparing gene expression in DM1 cells with that in control 
cells (fold change and significance) in samples that were transfected with the scrambled 
control oligo. By performing GO analysis of genes whose expression was significantly 
different, we identified classes of genes involved in stress responses and inflammation, like 
apoptosis, complement activation, interferon response and cytokine signalling, including 
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TNFα, IL2 and IL6. Other transcriptome studies in DM1 have also reported overexpression 
of genes related to immune response and interferon activation [37]. Specifically, cytokines 
like TNFα and IL6, are known to be elevated in DM1 patients [38,39], probably due to 
the toxic effects exerted by the mutant (CUG)n expansion [40,41]. In addition, genes 
related to epithelial-mesenchymal transition were also overexpressed, whereas genes 
related to myogenesis were underexpressed. This could indicate a partially disrupted 
differentiation program in DM1 cells compared to healthy myoblasts [42], which may also 
be due to detrimental effects of the DMPK mutation as has been reported by others [43,44]. 
These observations indicate that indeed many of the genes in the DM1 cell line may show 
dysregulated expression due to the pathogenic condition of the cells.
Equally interesting and important from a therapeutic perspective, is the finding 
that (mCAG)7 AON treatment partially corrected abnormal gene expression in DM1 
patient myotubes. Among the responsive genes, we found several related to interferon 
and inflammation biology. For instance, IFI27L2, BATF2, IFI35, MX2, IRF1 and CD40 were 
overexpressed in DM1 cells, but expressed at the level of control cell line levels after 
(mCAG)7 treatment (see Table 4). Also the cluster of genes upregulated by IL6 showed 
expression correction. Likewise, genes related to myogenesis that we found underexpressed 
in DM1, like PTGIS, MYOZ1, MSTN and MYL10, partially recovered normal expression levels 
(see Table 4). Although our results are encouraging and provide new leads for study 
of DM pathology, we should be cautious with drawing too definite conclusions from 
this exploratory study, since most of the findings discussed here need to be validated 
by alternative techniques like qPCR and be corroborated in additional cell lines 
and experiments.
Commonly, aberrant splicing is considered by most researchers in the field as central 
and causative of the pathogenic features in DM1 [1,45-49]. Here, we report that reduction in 
the level of expanded DMPK transcripts is coupled to a partial normalization of the myogenic 
transcriptome, but that this is not overtly associated with correction of representative splice 
aberrations. Interestingly, in a GEP study in mice, other researchers found that dysregulation 
of gene expression caused by expanded (CUG)n repeats is not completely dependent on 
Mbnl loss, which is thought to be responsible for more than 80% of DM1 alternative splice 
changes [50]. Based on our preliminary findings and these literature observations (realizing 
that we still have to do a much more in depth study of effects on alternative splicing) it is 
tentative to speculate that these RNA processing alterations could be downstream of primary 
repeat effects. Distinction between primary and secondary effects in pathogenesis has also 
been suggested by others [51]. Part of the splicing changes observed in DM1 may therefore 
not be causal in development of the DM1 phenotype. Since most of these changes represent 
a switch from adult to embryonic splice forms [52,53], perhaps they can be explained as an 
repeat-mediated effect of transition of muscle cells to a less differentiated state [54].
141
4
Transcriptome analysis of cells treated with (CAG)7
 | A C K N O W L E D G E M E N T S
We thank Jeroen van de Giessen (BioMarin Nederland BV) for conducting initial attempts 
in the processing of RNA samples for SAGE; Henk Buermans (Leiden Genome Technology 
Center) for providing information about the RNA-Seq procedure. We thank members of 
the Department of Cell Biology and BioMarin Nederland for meaningful discussions.
142
4
Chapter 4
 | R E F E R E N C E S
1. Wheeler TM and Thornton CA (2007) 
Myotonic dystrophy: RNA-mediated muscle 
disease. Curr Opin Neurol, 20: 572-576.
2. Udd B and Krahe R (2012) The myotonic 
dystrophies: molecular, clinical, and therapeutic 
challenges. Lancet Neurol, 11: 891-905.
3. Wheeler TM, Sobczak K, Lueck JD, Osborne 
RJ, Lin X, Dirksen RT and Thornton CA 
(2009) Reversal of RNA dominance by 
displacement of protein sequestered on 
triplet repeat RNA. Science, 325: 336-339.
4. Lee JE, Bennett CF and Cooper TA (2012) 
RNase H-mediated degradation of toxic 
RNA in myotonic dystrophy type 1. Proc Natl 
Acad Sci USA, 109: 4221-4226.
5. Leger AJ, Mosquea LM, Clayton NP, Wu IH, 
Weeden T, Nelson CA, Phillips L, Roberts E, 
Piepenhagen PA, Cheng SH and Wentworth 
BM (2013) Systemic Delivery of a Peptide-
Linked Morpholino Oligonucleotide 
Neutralizes Mutant RNA Toxicity in a Mouse 
Model of Myotonic Dystrophy. Nucleic Acid 
Ther, 21: 109-117.
6. Wheeler TM, Leger AJ, Pandey SK, MacLeod 
AR, Nakamori M, Cheng SH, Wentworth 
BM, Bennett CF and Thornton CA (2012) 
Targeting nuclear RNA for in vivo correction 
of myotonic dystrophy. Nature, 488: 111-115.
7. Francois V, Klein AF, Beley C, Jollet A, 
Lemercier C, Garcia L and Furling D (2011) 
Selective silencing of mutated mRNAs in 
DM1 by using modified hU7-snRNAs. Nat 
Struct Mol Biol, 18: 85-87.
8. Sobczak K, Wheeler TM, Wang W and 
Thornton CA (2013) RNA interference 
targeting CUG repeats in a mouse model of 
myotonic dystrophy. Mol Ther, 21: 380-387.
9. Warf MB, Nakamori M, Matthys CM, 
Thornton CA and Berglund JA (2009) 
Pentamidine reverses the splicing defects 
associated with myotonic dystrophy. Proc 
Natl Acad Sci USA, 106: 18551-18556.
10. Garcia-Lopez A, Llamusi B, Orzaez M, 
Perez-Paya E and Artero RD (2011) In 
vivo discovery of a peptide that prevents 
CUG-RNA hairpin formation and reverses 
RNA toxicity in myotonic dystrophy models. 
Proc Natl Acad Sci USA, 108: 11866-11871.
11. Childs-Disney JL, Parkesh R, Nakamori M, 
Thornton CA and Disney MD (2012) Rational 
design of bioactive, modularly assembled 
aminoglycosides targeting the RNA that 
causes myotonic dystrophy type 1. ACS 
chemical biology, 7: 1984-1993.
12. Zhang W, Wang Y, Dong S, Choudhury R, 
Jin Y and Wang Z (2014) Treatment of type 
1 Myotonic Dystrophy by engineering site-
specific RNA endonucleases that target 
(CUG) repeats. Mol Ther, 22: 312-320.
13. Pandey SK et al. (2015) Identification and 
Characterization of Modified Antisense 
Oligonucleotides Targeting DMPK in Mice 
and Nonhuman Primates for the Treatment of 
Myotonic Dystrophy Type 1. J Pharmacol Exp Ther.
14. Mulders SA, van den Broek WJAA, Wheeler TM, 
Croes HJE, van Kuik-Romeijn P, de Kimpe SJ, 
Furling D, Platenburg GJ, Gourdon G, Thornton 
CA, Wieringa B and Wansink DG (2009) Triplet-
repeat oligonucleotide-mediated reversal of 
RNA toxicity in myotonic dystrophy. Proc Natl 
Acad Sci U S A, 106: 13915-13920.
15. Gonzalez-Barriga A, Mulders SAM, van de 
Giessen J, Hooijer JD, Bijl S, van Kessel ID, 
van Beers J, van Deutekom JC, Fransen JA, 
Wieringa B and Wansink DG (2013) Design 
and analysis of effects of triplet repeat 
oligonucleotides in cell models for myotonic 
dystrophy. Mol Ther Nucleic Acids, 2: e81.
16. Schulze A and Downward J (2001) 
Navigating gene expression using 
microarrays - a technology review. Nat Cell 
Biol, 3: E190-E195.
17. Schena M, Shalon D, Davis RW and Brown 
PO (1995) Quantitative Monitoring of Gene-
Expression Patterns with a Complementary-
DNA Microarray. Science, 270: 467-470.
18. Velculescu VE, Zhang L, Vogelstein B and 
Kinzler KW (1995) Serial Analysis of Gene-
Expression. Science, 270: 484-487.
19. Wang Z, Gerstein M and Snyder M (2009) 
RNA-Seq: a revolutionary tool for transcriptomics. 
Nature Reviews Genetics, 10: 57-63.
143
4
Transcriptome analysis of cells treated with (CAG)7
20. Ozsolak F and Milos PM (2011) RNA sequencing: 
advances, challenges and opportunities. 
Nature Reviews Genetics, 12: 87-98.
21. Schroeder A, Mueller O, Stocker S, Salowsky R, 
Leiber M, Gassmann M, Lightfoot S, Menzel W, 
Granzow M and Ragg T (2006) The RIN: an RNA 
integrity number for assigning integrity values 
to RNA measurements. BMC Mol Biol, 7: 3.
22. Parkhomchuk D, Borodina T, Amstislavskiy V, 
Banaru M, Hallen L, Krobitsch S, Lehrach H and 
Soldatov A (2009) Transcriptome analysis by 
strand-specific sequencing of complementary 
DNA. Nucleic Acids Res, 37: e123.
23. Mastrokolias A, den Dunnen JT, van 
Ommen GB, t Hoen PA and van Roon-Mom 
WM (2012) Increased sensitivity of next 
generation sequencing-based expression 
profiling after globin reduction in human 
blood RNA. BMC Genomics, 13: 28.
24. Leggett RM, Ramirez-Gonzalez RH, Clavijo 
BJ, Waite D and Davey RP (2013) Sequencing 
quality assessment tools to enable data-
driven informatics for high throughput 
genomics. Front Genet, 4: 288.
25. Pearson WR, Wood T, Zhang Z and Miller W 
(1997) Comparison of DNA sequences with 
protein sequences. Genomics, 46: 24-36.
26. Wu TD and Watanabe CK (2005) GMAP: 
a genomic mapping and alignment 
program for mRNA and EST sequences. 
Bioinformatics, 21: 1859-1875.
27. Li H, Handsaker B, Wysoker A, Fennell T, Ruan 
J, Homer N, Marth G, Abecasis G, Durbin 
R and Genome Project Data Processing S 
(2009) The Sequence Alignment/Map format 
and SAMtools. Bioinformatics, 25: 2078-2079.
28. Quinlan AR and Hall IM (2010) BEDTools: 
a flexible suite of utilities for comparing 
genomic features. Bioinformatics, 26: 841-842.
29. Trapnell C, Williams BA, Pertea G, Mortazavi 
A, Kwan G, van Baren MJ, Salzberg SL, Wold 
BJ and Pachter L (2010) Transcript assembly 
and quantification by RNA-Seq reveals 
unannotated transcripts and isoform 
switching during cell differentiation. Nat 
Biotechnol, 28: 511-515.
30. R Development Core Team. (2010). R 
Foundation for Statistical Computing, 
Vienna, Austria.
31. Subramanian A, Tamayo P, Mootha VK, 
Mukherjee S, Ebert BL, Gillette MA, 
Paulovich A, Pomeroy SL, Golub TR, 
Lander ES and Mesirov JP (2005) Gene set 
enrichment analysis: a knowledge-based 
approach for interpreting genome-wide 
expression profiles. Proc Natl Acad Sci 
USA, 102: 15545-15550.
32. Benjamini Y, Drai D, Elmer G, Kafkafi N 
and Golani I (2001) Controlling the false 
discovery rate in behavior genetics research. 
Behav Brain Res, 125: 279-284.
33. Kozlowski P, de Mezer M and Krzyzosiak WJ 
(2010) Trinucleotide repeats in human genome 
and exome. Nucleic Acids Res, 38: 4027-4039.
34. Pascual M, Vicente M, Monferrer L and 
Artero R (2006) The Muscleblind family of 
proteins: an emerging class of regulators of 
developmentally programmed alternative 
splicing. Differentiation, 74: 65-80.
35. Ladd AN, Charlet N and Cooper TA 
(2001) The CELF family of RNA binding 
proteins is implicated in cell-specific and 
developmentally regulated alternative 
splicing. Mol Cell Biol, 21: 1285-1296.
36. Nakamori M et al. (2013) Splicing biomarkers 
of disease severity in myotonic dystrophy. 
Ann Neurol, 74: 862-872.
37. Rhodes JD, Lott MC, Russell SL, Moulton V, 
Sanderson J, Wormstone IM and Broadway 
DC (2012) Activation of the innate immune 
response and interferon signalling in 
myotonic dystrophy type 1 and type 2 
cataracts. Hum Mol Genet, 21: 852-862.
38. Fernandez-Real JM, Molina A, Broch M, Ricart 
W, Gutierrez C, Casamitjana R, Vendrell J, 
Soler J and Gomez-Saez JM (1999) Tumor 
necrosis factor system activity is associated 
with insulin resistance and dyslipidemia in 
myotonic dystrophy. Diabetes, 48: 1108-1112.
39. Johansson A, Carlstrom K, Ahren B, 
Cederquist K, Krylborg E, Forsberg H and 
Olsson T (2000) Abnormal cytokine and 
adrenocortical hormone regulation in 
myotonic dystrophy. J Clin Endocrinol 
Metab, 85: 3169-3176.
40. Mammarella A, Ferroni P, Paradiso M, 
Martini F, Paoletti V, Morino S, Antonini G, 
Gazzaniga PP, Musca A and Basili S (2002) 
144
4
Chapter 4
Tumor necrosis factor-alpha and myocardial 
function in patients with myotonic 
dystrophy type 1. J Neurol Sci, 201: 59-64.
41. Zhang L, Lee JE, Wilusz J and Wilusz CJ (2008) 
The RNA-binding protein CUGBP1 regulates 
stability of tumor necrosis factor mRNA 
in muscle cells: implications for myotonic 
dystrophy. J Biol Chem, 283: 22457-22463.
42. Yokoyama S and Asahara H (2011) 
The myogenic transcriptional network. Cell 
Mol Life Sci, 68: 1843-1849.
43. Furling D, Lemieux D, Taneja K and Puymirat 
J (2001) Decreased levels of myotonic 
dystrophy protein kinase (DMPK) and delayed 
differentiation in human myotonic dystrophy 
myoblasts. Neuromuscul Disord, 11: 728-735.
44. Timchenko NA, Patel R, Iakova P, Cai ZJ, Quan 
L and Timchenko LT (2004) Overexpression 
of CUG triplet repeat-binding protein, 
CUGBP1, in mice inhibits myogenesis. J Biol 
Chem, 279: 13129-13139.
45. Philips AV, Timchenko LT and Cooper TA 
(1998) Disruption of splicing regulated 
by a CUG-binding protein in myotonic 
dystrophy. Science, 280: 737-741.
46. Ho TH, Charlet BN, Poulos MG, Singh 
G, Swanson MS and Cooper TA (2004) 
Muscleblind proteins regulate alternative 
splicing. EMBO J, 23: 3103-3112.
47. Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan 
Y, Moxley RT, Swanson MS and Thornton 
CA (2006) Failure of MBNL1-dependent 
post-natal splicing transitions in myotonic 
dystrophy. Hum Mol Genet, 15: 2087-2097.
48. Kuyumcu-Martinez NM, Wang GS and 
Cooper TA (2007) Increased steady-
state levels of CUGBP1 in myotonic 
dystrophy 1 are due to PKC-mediated 
hyperphosphorylation. Mol Cell, 28: 68-78.
49. Cooper TA (2006) A reversal of misfortune for 
myotonic dystrophy? N Engl J Med, 355: 1825-1827.
50. Du H, Cline MS, Osborne RJ, Tuttle DL, 
Clark TA, Donohue JP, Hall MP, Shiue L, 
Swanson MS, Thornton CA and Ares M, Jr. 
(2010) Aberrant alternative splicing and 
extracellular matrix gene expression in 
mouse models of myotonic dystrophy. Nat 
Struct Mol Biol, 17: 187-193.
51. Mahadevan MS (2012) Myotonic dystrophy: 
is a narrow focus obscuring the rest of 
the field? Curr Opin Neurol, 25: 609-613.
52. Wang ET, Ward AJ, Cherone JM, Giudice 
J, Wang TT, Treacy DJ, Lambert NJ, Freese 
P, Saxena T, Cooper TA and Burge CB 
(2015) Antagonistic regulation of mRNA 
expression and splicing by CELF and MBNL 
proteins. Genome Res, 25: 858-871.
53. Kalsotra A, Xiao X, Ward AJ, Castle JC, 
Johnson JM, Burge CB and Cooper TA 
(2008) A postnatal switch of CELF and MBNL 
proteins reprograms alternative splicing in 
the developing heart. Proc Natl Acad Sci U S 
A, 105: 20333-20338.
54. Bland CS, Wang ET, Vu A, David MP, Castle 
JC, Johnson JM, Burge CB and Cooper TA 
(2010) Global regulation of alternative 
splicing during myogenic differentiation. 
Nucleic Acids Res, 38: 7651-7664.


C H A P T E R
C E L L  M E M B R A N E  I N T E G R I T Y  I N  M YOTO N I C 
DY S T R O P H Y  T Y P E  1 :  
I M P L I C AT I O N S  F O R  T H E R A P Y
Anchel González-Barriga1,3, Julia Kranzen1, Huib J. E. Croes1, Suzanne Bijl3, 
Walther J. A. A. van den Broek1, Ingeborg D. G. van Kessel1, Baziel G. M. van Engelen2, 
Judith C. T. van Deutekom3, Bé Wieringa1, Susan A. M. Mulders1,3 and Derick G. Wansink1
1 Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical 
Center, Nijmegen, The Netherlands 
2 Department of Neurology, Donders Centre for Neuroscience, Radboud university medical center, 
Nijmegen, The Netherlands 
3 Prosensa Therapeutics B.V., Leiden, The Netherlands
Published in PLOS ONE (2015). DOI: 10.1371/journal.pone.0121556
5
Chapter 5
148
5
 | A B S T R A C T
Myotonic Dystrophy type 1 (DM1) is a multisystemic disease caused by toxic RNA from 
a DMPK gene carrying an expanded (CTG•CAG)n repeat. Promising strategies for treatment 
of DM1 patients are currently being tested. These include antisense oligonucleotides and 
drugs for elimination of expanded RNA or prevention of aberrant binding to RNP proteins. 
A significant hurdle for preclinical development along these lines is efficient systemic 
delivery of compounds across endothelial and target cell membranes. It has been reported 
that DM1 patients show elevated levels of markers of muscle damage or loss of sarcolemmal 
integrity in their serum and that splicing of dystrophin, an essential protein for muscle 
membrane structure, is abnormal. Therefore, we studied cell membrane integrity in DM1 
mouse models commonly used for preclinical testing. We found that membranes in skeletal 
muscle, heart and brain were impermeable to Evans Blue Dye. Creatine kinase levels in 
serum were similar to those in wild type mice and expression of dystrophin protein was 
unaffected. Also in patient muscle biopsies cell surface expression of dystrophin was normal 
and calcium-positive fibers, indicating elevated intracellular calcium levels, were only rarely 
seen. Combined, our findings indicate that cells in DM1 tissues do not display compromised 
membrane integrity. Hence, the cell membrane is a barrier that must be overcome in future 
work towards effective drug delivery in DM1 therapy.
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Myotonic Dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults. 
Patients with this disease carry an unstable (CTG)n repeat in the 3’ UTR of the DMPK gene, 
the length of which correlates with disease severity [1,2]. DM1’s molecular pathogenesis is 
complex. Firstly, mutant DMPK RNAs with a long (CUG)n repeat are retained in the cell nucleus, 
where they abnormally bind transcription and splicing factors, resulting in aberrant protein 
production and different downstream cellular effects [3]. Secondly, antisense transcripts 
from the mutant DM1 locus, which carry an expanded (CAG)n repeat, may contribute to 
the imbalance in proteostasis in DM1 by the production of homopolymeric proteins via 
a process called RAN translation [4]. Combined, these effects of (CTG•CAG)n expansion 
are thought to compromise functional development and cause wasting of skeletal muscle 
(myotonia and muscle weakness), heart (arrhythmia) and brain (mental retardation).
No cure for DM1 is available yet, but strategies for molecular therapy based on antisense 
RNA, siRNA or oligonucleotides (AONs) [5-11], compounds that inhibit aberrant (CUG)n 
RNA-protein interactions [12-14] or site-specific RNA endonucleases that target (CUG)n 
repeats [15] are currently under development. As essentially all these strategies require 
intracellular delivery of the therapeutic agents (oligonucleotides, high molecular weight 
organic compounds or proteins), sophisticated approaches may be needed to promote 
uptake across biological membranes and reach effective tissue concentrations [e.g. 16].
Typically, efficacy of drug uptake into cells is dominantly controlled by molecular 
characteristics of the cargo itself and by properties of the membranes. Functional changes 
in cell membranes are central in the pathogenesis of many diseases [17]. For example, 
membrane permeability can be altered by aberrant protein-membrane interactions, 
presence of aggregative proteins [18] or lack of integral membrane proteins, i.e. as seen with 
dystrophin in patients with Duchenne muscular dystrophy (DMD) [19].
Despite its importance as parameter for efficacy of drug delivery, not much is known 
about membrane integrity in tissues of DM1 patients. Abnormal red blood cell membranes 
in DM1 patients were noticed in the past [20-22]. Pathological features in skeletal muscles 
include internal nuclei, ring fibers, sarcoplasmic masses, type-I fiber predominance and 
atrophy, fibrosis and fatty infiltration, and a greatly increased number of intrafusal muscle 
fibers [23]. Potentially related to the myopathy, DM1 patients may show mildly elevated 
levels of markers of muscle damage in serum [24], with a possible impact of exercise 
regimen on these parameters [25]. Finally, aberrant splicing of dystrophin in DM1 patients 
has been reported [26], with as yet unknown effects on muscle membrane function. All 
data combined suggest that a certain level of membrane leakiness cannot be excluded in 
the highly complex DM1 phenotype.
Here, we investigated the possible involvement of membrane permeability in the context 
of AON-mediated treatment for DM1 using mouse models that replicate DM1 characteristics, 
i.e. in HSALR mice [27] and in DM500 [28,29] and DMSXL mice [30], both descendants from 
the DM300-328 line [31] (Table 1). Better understanding of cell membrane properties in 
these animal models will support preclinical development of effective therapeutic strategies 
in DM1 patients. We report on membrane integrity and related membrane characteristics in 
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these models, in comparison to findings in wild type (WT) mice and mdx mice, a DMD mouse 
model with leaky muscle membranes [32,33]. For comparison, these parameters were also 
studied in muscle biopsies from DM1 patients. Our study combining mouse and human 
samples demonstrates that cells in DM1 tissues most likely have a functional membrane. 
Future therapeutic studies in DM1 mouse models may therefore benefit from advanced 
targeting strategies for effective therapeutics for DM1.
 | M AT E R I A L S  A N D  M E T H O D S
Ethics Statement
Animal experiments were approved by the Animal Ethics Committee of Radboud University 
(Permit Number: RU-DEC 2012-102).
Human control #1 quadriceps muscle tissue was obtained from the VU University Medical 
Center (VUmc, Amsterdam, The Netherlands). The use of post-mortem material was approved 
by the VUmc research committee (project 2011-67), where relatives have given explicit prior 
written consent that tissue taken at autopsy can be used for research, after completion of 
the diagnostic process and informed consents were approved by institutional review boards. 
Table 1. Mouse models used in this study
Mouse 
model
Transgene/
Mutation Promoter/Expression Phenotype/Symptoms
Original 
references
DM500 Human DM1 
locus with 
~500 CTG 
triplets
Human DMPK promoter/
all DM1 related tissues 
(e.g., skeletal muscle, 
heart, CNS)
Homozygous mice: myopathy, 
reduced muscle strength, myotonia 
(generally very mild phenotype)
[28,29]
DMSXL Human DM1 
locus with 
~1600 CTG 
triplets
Human DMPK promoter/
all DM1 related tissues 
(e.g., skeletal muscle, 
heart, CNS)
Homozygous mice: myopathy, 
reduced muscle strength, myotonia, 
reduced body size (more severe 
phenotype than DM500 mice)
[30]
HSALR Human α-actin 
gene with 
~250 CTG 
triplets
Human α-actin 
promoter/ skeletal 
muscle only
Homozygous mice: strong 
myotonia, myopathy, no muscle 
weakness
[27]
Mdx Spontaneous 
point mutation 
in dystrophin 
gene
Ubiquitous (e.g., skeletal 
muscle, heart, CNS, 
retina)
Hemizygous mice: muscle 
degeneration and atrophy, skeletal 
muscle fibrosis and necrosis
[32,33]
WT No transgene 
(genetic 
background 
>90% C57BL/6)
n.a. n.a. n.a.
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Human control #2 and #3 quadriceps muscle tissues were obtained from a commercial tissue 
bank (Cambridge Bioscience, Cambridge, UK; www.bioscience.co.uk). The bank provides 
frozen human tissue samples that have been collected from pre-consented post-mortem 
donors in the UK.
Quadriceps muscle biopsies from the six DM1 patients were taken by B. van Engelen 
in a regular diagnostic procedure, performed routinely in the neuromuscular clinic. Oral 
informed consent was received from all patients, documented in the patients’ charts, to 
perform the procedure and to use the muscle material for research purposes. 
A quadriceps biopsy from a DMD patient was authorized by Dr. M. Tulinius (University 
of Göteborg, Sweden), with written informed consent for use in research from the patient’s 
parents, with approval by the Local Ethics Committee in Göteborg. 
All biopsies were anonymized before they were handed over for research.
Human material
All information regarding human muscle samples used in this paper is summarized 
in Table 2.
Mice
DM500, DMSXL, HSALR and WT mice (similar background as DM500/DMSXL strains, i.e. >90% 
C57BL/6) were bred under SPF conditions in the Central Animal Laboratory in Nijmegen. 
Female homozygous and male hemizygous mdx mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA). For the DM500, DMSXL and HSALR lines homozygous mice 
were used in experiments. From each mouse strain animals of different ages were used 
(2-6 months for EBD experiments, average 3.5 months; 2-3 months for CK measurements, 
average 2.2 months) to avoid bias with regard to possible developmental changes. Male and 
female mice were used to exclude gender-specific effects.
Exercise regimen in treadmill
A five-lanes treadmill (Panlab/Harvard Apparatus, Holliston, MA, USA) with air-puff control 
system and 0o slope inclination was used in the exercise regimen (adapted from [34]). Mice 
were settled with the treadmill belt stationary for 2 minutes, followed by a warm-up period 
of 8 minutes at a speed of 8 m/minute, immediately followed by the main exercise regimen 
of 30 minutes at 12 m/minute. Five mice participated in each exercise session (one animal 
of each strain). All mice performed well in the exercise regimen, except in one session, in 
which one DMSXL mouse and one mdx mouse stopped running after 20 minutes. In that 
case the treadmill was stopped and a rest period of 2 minutes was given to all mice. After 
that, the exercise was continued for 10 minutes without further difficulties.
Mouse blood collection and serum CK assay
Blood was collected before and after exercise via a tail cut (~100 µl/mouse). Samples were 
incubated for 1 hour at room temperature to allow clotting and were then centrifuged 
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at 12,000g for 10 minutes at 4°C. Serum was collected and snap frozen in liquid nitrogen 
before storage at -80°C. Serum samples were diluted 1:10 in 0.9% NaCl prior to analysis. CK 
activity was determined using the ARCHITECT system (Abbott Laboratories, Abbott Park, 
IL, USA) based on the IFCC method for the measurement of catalytic activity of CK [35] at 
the Department of Laboratory Medicine, Radboudumc.
EBD injection and tissue isolation
Evans Blue Dye (Sigma-Aldrich, St. Louis, MO, USA), 10 µg/µl in physiological saline (0.15 
M NaCl, 10 mM phosphate buffer, pH 7.4), sterilized by passage through a 0.2 µm pore size 
membrane filter was injected intravenously through the tail vein 30 minutes after exercise 
(50 µl/10 g body weight). Mice were sacrificed by cervical dislocation 24 hours later. Tissues 
were immediately harvested and frozen in isopentane pre-chilled in liquid nitrogen.
Table 2. Summary of information on patients and human controls and results from this study
Sample Gender
DM1 
phenotype
Estimated 
(CTG)n 
length in 
blood
CK value, 
in U/L  
(age of 
sampling)
Age at 
muscle 
biopsy, 
in years
Estimated 
(CTG)n 
length in 
muscle 
biopsy 
(see Fig. 
S6)
Dystrophin 
expression 
in muscle 
membrane, 
in a.u. 
(mean ± CI)
Calcium-
positive 
fibers in 
muscle 
biopsy
Control #1 Male n.a. n.a. n.k. n.k. 
(adult)
n.a. 146 ± 3 Absent
Control #2 Male n.a. n.a. n.k. 62 n.a. 60 ± 2 Absent
Control #3 Female n.a. n.a. n.k. 83 n.a. 94 ± 2 Rare
DM1 #1 Male Adult >200 670 (30), 
1182 
(32.6), 173 
(32.9)
36 ~100-300 121 ± 5 Absent
DM1 #2 Male Adult n.k. 173 (n.k.) 48 ~100-200 103 ± 4 Absent
DM1 #3 Male Adult 
(mild)
41-100 735 (n.k.), 
1198 (n.k.)
62 ~80-400 86 ± 6 Rare
DM1 #4 Male Adult >200 n.k. 48 ~100-400 146 ± 11 Rare
DM1 #5 Female Juvenile n.k. 123 (46) 41 ~100-500 n.d. Absent
DM1 #6 Male Adult n.k. n.k. 48 ~80-500 n.d. Absent
DMD Male n.a. n.a. n.k. 5 n.a. 7 ± 0.3 Abundant
n.a.: not applicable; n.k.: not known; n.d.: not determined
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Tissue cryosectioning
10 µm tissue sections were prepared from a representative middle part of each of the six 
tissues examined according to standard procedures using a Microm HM 500 Cryostat (Adamas 
Instrumenten B.V., Rhenen, The Netherlands), dried and stored at -80°C until further use.
EBD quantification
For EBD imaging, sections were dried at room temperature, dipped in acetone, xylene and 
mounted in DPX mounting solution (Fisher Scientific, Loughborough, UK). Images were 
acquired by red autofluorescence in a Leica DMI6000B automated high-content microscope 
(Leica Microsystems, Wetzlar, Germany) using the TRITC filter. The percentage EBD-positive 
area was calculated by dividing the EBD-positive area by the total area of the section using 
ImageJ software.
Immunohistochemistry
Mouse muscle cryosections were dried at room temperature and incubated for 1 hour in 
PBS with 0.05% Tween-20 and 5% horse serum, followed by three washing steps in PBS for 5 
minutes. Rabbit anti-dystrophin antibody ab15277 (Abcam, Cambridge, UK) was diluted in 
PBS with 0.05% Tween-20 and 5% fetal bovine serum, applied to the sections and incubated 
for 2 hours. After washing in PBS 3 times for 5 minutes, sections were incubated with Alexa 
488-conjugated goat anti-rabbit in PBS with 0.05% Tween-20 for 1 hour. Samples were 
rinsed in PBS and then mounted in Mowiol containing 2.5% sodium azide overnight at room 
temperature. Images were acquired by epifluorescence using the Leica microscope.
Immunostaining and quantification of dystrophin in human samples was done as 
described [36]. In short, muscle cryosections were dried at room temperature and fixed 
in acetone for 1 minute, rinsed and washed with PBS for 5 minutes and blocked for 1 
hour in PBS with 0.05% Tween-20 and 5% horse serum, followed by another rinsing and 
washing step in PBS. Rabbit anti-dystrophin ab15277 or IgG isotype antibody (used as 
control) were diluted in PBS with 0.05% Tween-20 and 5% fetal bovine serum and applied 
to the sections for 2 hours, followed by 1 hour incubation with ab15277 and mouse anti-
spectrin (Novocastra, Newcastle, UK) combined. After rinsing and washing in PBS twice for 
5 minutes, sections were incubated with Alexa 488-conjugated goat anti-rabbit and Alexa 
594-conjugated goat anti-mouse in PBS with 0.05% Tween-20 for 1 hour. Samples were rinsed 
and washed twice for 5 minutes in PBS and then mounted using Vectashield (Vector Labs, 
Burlingame, CA, USA). Images were acquired using the Zeiss LSM 710 confocal microscope 
(Zeiss, Oberkochen, Germany). The healthy control muscle section displaying the highest 
dystrophin intensity was used to adjust the confocal settings for the Alexa 488 and 594 
channel. These parameters were maintained for all other sections. To minimize variations in 
laser intensity due to changes in lamp temperature, the laser intensity was kept constant by 
performing a calibration using a mirror slide. Four to five images per patient or control were 
acquired, which were subsequently processed using Definiens Architect software (Definiens, 
Munich, Germany). The software used spectrin signal to locate the membrane of muscle 
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fibers and to define the region of interest. The operator manually excluded areas that were 
not correctly identified by the program. Dystrophin intensity was calculated in the region of 
interest, giving a representation of DMD expression per muscle fiber.
Calcium staining
Muscle sections were dried at room temperature and stained for 5 minutes in 1% Alizarin 
Red S (Sigma-Aldrich, St. Louis, MO, USA) in distilled water adjusted to pH 5.4 with 
ammonium hydroxide, as recommended [37]. Samples were dehydrated in acetone (20 
dips), incubated in acetone-xylene (1:1) solution (20 dips) and cleared in xylene prior to 
mounting in DPX mounting solution (Fisher Scientific, Loughborough, UK). Muscle slides 
were left to dry overnight at room temperature and then stored at 4°C. Images were 
acquired in the Leica microscope with a TX2 cube and a DFC480 color camera 
(Leica Microsystems, Wetzlar, Germany).
(CTG)n length determination by heat pulse extension PCR
Genomic DNA was isolated from muscle sections following standard procedures. To 
amplify expanded (CTG)n repeats a heat pulse extension PCR protocol was used [38], that 
allows the generation of DMPK (CTG)n amplicons of up to 1750 CTG repeats. 40 ng 
DNA was used in a PCR mixture containing 2.25 M betaine (Fluka, Sigma-Aldrich, 
Germany), 0.2 mM dNTPs (Invitrogen, Carlsbad, CA, USA), 1.33 units DyNAzyme EXT 
DNA Polymerase (Thermo Scientific, Waltham, MA, USA) and 250 nM of each forward 
(5´-GCCAGTTCACAACCGCTCCGAGCGTGGGTC-3´) and reverse (5´-ACGCTCCCCAGA 
GCAGGGCGTCATGC-3´) primers (Biolegio BV, Nijmegen, the Netherlands). Cycling conditions 
were kept as described [38], except that an annealing temperature of 66°C followed 
by ramping to 83°C (0.9 °C/sec) was used. PCR was performed in a DNA engine Peltier 
Thermal Cycler (Bio-Rad, Hercules, CA, USA). The size of the expected DMPK amplicon was 
324 bp long excluding the (CTG)n repeat.
PCR products were run on a 1% agarose gel and transferred to a Hybond-XL nylon 
membrane (Amersham, GE Healthcare). The blot was incubated with a 32P-end-labeled 
(CAG)9 probe and after washing exposed to a phosphor imager screen (Kodak, Rochester, 
NY, USA) for 3 hours. Signal was developed using a Personal FX Phosphor Imager (Bio-Rad).
Statistics
To compare values of serum CK and EBD-positive fibers between groups, we used a one-way 
ANOVA test. We applied a paired Student’s t-test to assess whether serum CK activity 
was significantly different before and after the exercise regimen. All values in graphs are 
presented as mean ± SEM (unless indicated otherwise). Differences between groups were 
considered significant when P<0.05: *, P<0.05; **, P<0.01; ***, P<0.001. Statistical analyses 
were performed with GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).
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For our study of cell membrane integrity we compared WT mice with DM500, DMSXL and 
HSALR mice, three transgenic models frequently used in preclinical DM1 studies [39] (Table 1). 
For an overt DM1 muscle phenotype, all three models were bred to homozygosity. Mdx mice, 
a well-established model for DMD, were included as positive control, as these demonstrate 
increased muscle fiber membrane permeability. To minimize possible effects of differences 
in physical activity between mice and to stimulate muscle contraction, mice were subjected 
to a 30 minute exercise protocol on a motorized treadmill. Before and after exercise several 
biomarkers for cell membrane integrity were measured.
Creatine kinase activity in mouse serum
Creatine kinase (CK) is released in the circulation upon muscle damage [40] or because of 
disease-induced loss of membrane integrity. Dystrophin-deficient mdx mice, for example, 
show an increased basal serum CK level compared to control, which rises significantly after 
exercise [34]. Under basal conditions, the three DM1 models showed similar serum CK values 
as WT controls (Fig. 1A). In contrast, the corresponding levels in mdx mice were indeed around 
20-fold higher. After exercise, serum CK levels increased only around 2-fold in WT, DM500 
and HSALR animals (Fig. 1B), whereas a 40-fold increase was observed in mdx mice. Markedly 
enhanced sensitivity of DMSXL mice to exercise was detected, compared to the other DM1 
models and WT mice (6-fold increase in CK level; Fig. 1). This effect was probably due to 
their more severe muscle weakness phenotype, leading to extra muscle wasting necessary 
to complete the exercise regime, rather than to intrinsic muscle membrane permeability of 
the model. Nevertheless, neither basal CK levels nor levels after exercise in DMSXL mice were 
statistically different from those in WT mice.
Evans Blue Dye uptake in mouse cells in vivo
To evaluate vasculature of living animals and integrity of cell membranes in vivo after 
exercise, we used cell membrane-impermeable Evans Blue Dye (EBD) as tracer [41,42]. EBD 
binds to albumin in the bloodstream, leaks into muscle fibers that are damaged and can be 
observed microscopically by its red autofluorescence. DM1 mice did not show permeability 
to EBD in any of the skeletal muscles investigated (quadriceps, gastrocnemius, tibialis 
anterior, diaphragm), similar to WT controls (Fig. 2A,B; Supporting Figs S1-3). As expected 
[42], relatively large, damaged EBD-positive areas were present in mdx muscle. Only once, 
very few isolated positive fibers were found in a quadriceps muscle of a DMSXL mouse (data 
not shown). We did not find positive fibers in heart in any of the mice examined (Supporting 
Fig. S4), although it has been reported that ~50% of mdx mice show EBD-positive fibers in 
this tissue [41]. Finally, no EBD uptake was observed in brain in any of the mice examined 
(Supporting Fig. S5).
Dystrophin expression
Deficiency of dystrophin, a protein involved in muscle membrane structure and flexibility, 
leads to progressive muscular dystrophy and degeneration in DMD patients and mdx 
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mice [32]. Also in DM1 patients, abnormal production of dystrophin isoforms has been 
demonstrated [26]. We verified dystrophin protein expression by immunohistochemistry in 
muscles of exercised DM1 animals and found that the staining pattern was indistinguishable 
from that in WT mice in all tissues analyzed (Fig. 2C and Supporting Figs S1-4). As expected, 
apart from few so-called revertant fibers [43], no dystrophin staining was detected in 
mdx mice.
Cell membrane integrity in DM1 patients
To evaluate our findings obtained in DM1 mouse models, we investigated muscle membrane 
integrity in human quadriceps muscle. We used biopsies from three healthy controls, six 
DM1 patients and one DMD patient. (CTG)n repeat lengths in the DM1 muscle biopsies 
Figure 1. Serum CK level in DM1, mdx and WT mice. (A) CK levels were measured in mouse serum 
before (blue) and after (red) exercise. CK level was significantly higher in mdx mice than in WT and DM1 
model mice, both before and after the exercise regimen (P<0.001). Exercise resulted in a significant 
increase in CK level in mdx mice (P<0.05), but not in other mice. (B) Exercise in the treadmill resulted 
in a forty-fold increase in CK level in mdx mice, whereas only a two-fold increase was observed in WT, 
DM500 and HSALR mice and a six-fold increase in DMSXL mice (n=3-5 per genotype).
A
B
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Figure 2. Membrane integrity analysis in mouse quadriceps muscle. (A) Representative images of 
quadriceps sections from DM1 mice and controls after injection with EBD following exercise. One 
WT mouse was not injected to appreciate autofluorescent background signal (No EBD). Areas with 
EBD-positive fibers were regularly seen in mdx samples (arrowheads), but never in WT nor DM1 
model samples. Scale bars indicate 250 µm. (B) Quantification of the EBD-positive area compared 
to total muscle section (n=4 per group). (C) Representative images of quadriceps sections stained 
for dystrophin. Staining intensity and pattern observed in WT animals were very similar to those 
observed in DM500, DMSXL and HSALR mice. Right panels show high magnifications of insets to 
appreciate dystrophin staining. As expected, essentially no signal was detected in mdx mice. Scale bars 
indicate 150 µm.
A
B
C
Chapter 5
158
5
ranged between ~80 and >500, as measured by heat pulse extension PCR [38] (Supporting 
Fig. S6; Table 2). For some of these patients slightly elevated CK levels had been measured 
in the past (Table 2).
As an alternative method to the EBD injections done in mice, we performed Alizarin 
Red staining on human muscle sections to detect elevated intracellular calcium levels or 
deposits, suggestive of membrane abnormalities [37]. Calcium-positive muscle fibers were 
indeed abundant in DMD muscle (Fig. 3A, Table 2). However, no or only few calcium-positive 
fibers were observed in controls and DM1 patients.
Next, we performed immunostaining of dystrophin in serial muscle sections from the same 
patients and controls. Spectrin immunostaining was used to visualize the membrane of 
muscle fibers. In all healthy control and DM1 biopsies overt cell membrane expression 
of dystrophin was observed, whereas essentially no dystrophin protein was detected in 
the DMD sample (Fig. 3B). We quantified the amount of dystrophin using a novel method 
for immunofluorescence quantification [36]. Dystrophin expression in DM1 samples turned 
out to be similar to that in control samples (Fig. 3C, Table 2). As expected, dystrophin level in 
the DMD sample was extremely low.
 | D I S C U S S I O N
Efficient systemic cellular uptake of therapeutics is an important determinant for the success 
of future clinical trials in DM1, because all known molecular targets, e.g., expanded (CUG)n/
(CAG)n transcripts or CELF1 and MBNL1 proteins that bind to these repeat-containing RNAs 
[44] are located intracellularly. The effective concentration of any DM1 drug will therefore 
depend on its chemical and pharmacokinetic characteristics and the ability to pass plasma 
membranes of endothelial cells and target cells in muscle, heart or brain of patients. 
From research on DMD, we have learned that the disease-related loss of dystrophin alters 
membranes of muscle and brain cells, leading to increased permeability for oligonucleotides 
and other large molecules [19].
In this study, in comparison to the situation in DMD, we examined cell membrane 
integrity in DM1 mouse models and in patient muscle biopsies. Our findings on human 
material suggest that cell membranes in DM1 patients are intact. Expression and localization 
of dystrophin was normal. We therefore assume that sufficient functionally active protein 
was present to support membrane function, in spite of an abnormal dystrophin splice mode 
that affects the protein’s c-terminus responsible for interaction with the sarcolemma [26]. 
Furthermore, in concordance with previous studies [37], calcium deposits, indicative of 
membrane damage, were rare or absent in DM1 muscle biopsies tested.
In a group of moderately affected, ambulatory DM1 patients one in four male patients and 
one in two female patients showed mildly elevated basal CK values in serum [24]. Fluctuating, 
slightly elevated CK levels were also measured in our small cohort of DM1 patients (Table 2). 
These elevated CK values could be related to a mild membrane defect but, more likely, they 
are related to myopathy and associated with tissue loss in these patients. More extensive 
clinical studies in a much larger cohort of individuals are necessary to relate CK values in 
serum to known variables of DM1 manifestation – e.g. (CTG•CAG)n-repeat length, somatic 
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Figure 3. Membrane integrity analysis in DM1 patient biopsies. (A) Calcium staining using Alizarin 
Red S. No or only few calcium-positive fibers (arrowheads), indicative of abnormal elevated calcium 
level, were found in DM1 and control biopsies. Calcium deposits were abundant in the DMD sample. 
DMD muscle sections showed fatty tissue infiltration (asterisks) and fibrosis (stars), which were also 
detected in some of the DM1 patient biopsies. Scale bars indicate 100 μm. Results from only one of 
the three controls and three of the six examined DM1 patients are shown. All data are summarized 
in Table 2. (B) Dystrophin immunostaining. In contrast to the DMD patient biopsy, expression and 
localization of dystrophin in DM1 and control quadriceps muscles were normal. Spectrin staining was 
included as a cell membrane reference. Scale bars indicate 100 μm. (C) Quantification of dystrophin 
expression. Data is represented as mean intensity per fiber (n>50). Error bars indicate 95% confidence 
interval (CI). Data are summarized in Table 2.
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repeat expansion rate, disease onset and severity, and exercise and life-style habits – before 
we can draw further conclusions.
The main focus of our study was to obtain better understanding of cell membrane 
integrity in transgenic DM1 mouse models currently in use for testing new therapies [44]. 
From a series of observations in models that faithfully replicate most important characteristics 
of disease in DM1 [39], we conclude that cell membrane function is not affected by presence 
of repeat RNA. Firstly, we found that serum CK levels in all three models are normal. Even 
after intense exercise, only a two- to six-fold increase was measured, similar to wild type 
control animals. Secondly, dystrophin immune-staining was comparable to that in WT mice. 
Thirdly, we did not observe permeability to EBD in any of the tissues analyzed. With respect 
to the HSALR model, our microscopy findings match those presented in an earlier report, 
where EBD presence was measured in whole muscle lysates by spectrophotometry, using 
a protocol without exercise regimen [9].
It should be noted that we cannot exclude the possibility that cell membrane integrity 
in DM1 mice might deteriorate during aging. This aspect was not part of our study and we 
chose the age group of 2-6 month-old mice, since mice of that age are usually included 
in therapeutic studies for DM1. For the DMSXL strain in particular, it has been shown that 
the strongest symptoms are indeed seen in rather young mice [30].
Most of the treatments for DM1 that are currently under development involve the use 
of relatively large compounds that neutralize expression of expanded DMPK transcripts 
or block binding to MBNL1 [44,45]. For these approaches to become effective, active 
compounds must reach the cell nucleus, i.e., the cellular compartment where most of 
the toxic (CUG)n RNA is located. Since we find no evidence for membrane alterations or 
increased membrane permeability in the transgenic DM1 mice, we assume that drugs 
that were administered systemically and showed efficacy in preclinical studies must have 
reached their destination via naturally existing cellular uptake and routing mechanisms 
either independently [9, Mulders et al. unpublished,12] or promoted by advanced targeting 
moieties [8, Mulders et al., unpublished]. Based on our findings, we consider it unlikely that 
the disease state had a major effect on drug fate in these studies, although we do not know 
whether carrier-mediated transport, receptor-mediated endocytosis or any other transport 
route was involved [46,47].
In sum, we conclude that cell membranes of DM500, DMSXL and HSALR mice are intact 
and have normal physical stress resistance and properties for chemical passage. Our 
observations in muscle biopsies from DM1 patients corroborate this picture. Further study is 
now necessary to know how compounds that have been shown to bind or degrade (CUG)n 
RNA are internalized by myofibers or other cell types. Future therapeutic studies in DM1 
mouse models may benefit from advanced targeting strategies for effective therapeutics 
for DM1, given the fact that cell membranes are probably intact in patients. As there is no 
need to concentrate these studies on DM1-affected tissues only, this opens up prospects for 
the simultaneous development of therapy for other neurodegenerative disorders.
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Figure S1. Membrane integrity analysis of gastrocnemius muscle. (A) Representative images of 
gastrocnemius sections from DM1 mice and controls after injection with EBD after exercise. Scale bars 
indicate 200 µm. One WT mouse was not injected to appreciate autofluorescent background signal 
(No EBD). Areas with EBD-positive fibers were regularly seen in mdx samples (arrowheads) but never 
in WT nor DM1 model samples. (B) Quantification of percentage of EBD-positive area compared to 
total muscle section (n=4 per group). (C) Representative images of gastrocnemius sections stained for 
dystrophin. Scale bars indicate 150 µm. Staining intensity and pattern observed in WT animals were 
very similar to those observed in DM500, DMSXL and HSALR mice. As expected, essentially no signal was 
detected in mdx mice.
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Figure S2. Membrane integrity analysis of tibialis anterior muscle. (A) Representative images of 
tibialis anterior sections from DM1 mice and controls after injection with EBD after exercise. Scale bars 
indicate 200 µm. One WT mouse was not injected to appreciate autofluorescent background signal 
(No EBD). Areas with EBD-positive fibers were regularly seen in mdx samples (arrowheads) but never 
in WT nor DM1 model samples. (B) Quantification of percentage of EBD-positive area compared to 
total muscle section (n=4 per group). (C) Representative images of tibialis anterior sections stained for 
dystrophin. Scale bars indicate 100 µm. Staining intensity and pattern observed in WT animals were 
very similar to those observed in DM500, DMSXL and HSALR mice. As expected, essentially no signal was 
detected in mdx mice.
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Figure S3. Membrane integrity analysis of diaphragm muscle. (A) Representative images of diaphragm 
sections from DM1 mice and controls after injection with EBD after exercise. Scale bars indicate 100 
µm. One WT mouse was not injected to appreciate autofluorescent background signal (No EBD). Areas 
with EBD-positive fibers were regularly seen in mdx samples (arrowhead) but never in WT nor DM1 
model samples. (B) Quantification of percentage of EBD-positive area compared to total muscle section 
(n=4 per group). (C) Representative images of diaphragm sections stained for dystrophin. Scale 
bars indicate 100 µm. Staining intensity and pattern observed in WT animals were very similar to 
those observed in DM500, DMSXL and HSALR mice. As expected, essentially no signal was detected 
in mdx mice.
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Figure S4. Membrane integrity analysis of heart muscle. (A) Representative images of heart sections 
from DM1 mice and controls after injection with EBD after exercise. Scale bars indicate 100 µm. One WT 
mouse was not injected to appreciate autofluorescent background signal (No EBD). (B) Representative 
images of heart sections stained for dystrophin. Scale bars indicate 100 µm. Staining intensity and 
pattern observed in WT animals were very similar to those observed in DM500, DMSXL and HSALR mice. 
As expected, essentially no signal was detected in mdx mice.
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Figure S5. Absence of Evans Blue Dye in brain. Representative images of mesencephalon (midbrain) 
from total brain sagittal sections of DM1 mice and controls after injection with EBD after exercise. Scale 
bars indicate 150 µm. One WT mouse was not injected to appreciate autofluorescent background signal 
(No EBD). No EBD signal was found in any other brain region either.
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Figure S6. (CTG)n repeat length determination in human muscle biopsies. Genomic DNA isolated 
from human muscle biopsies was used in a heat pulse extension PCR protocol to amplify the (CTG)n 
repeat of DMPK genes. Control sample represents genomic DNA from a healthy individual carrying 
a (CTG)5 and a (CTG)12 repeat. The smears in patient samples demonstrate somatic instability. The size 
marker at the left indicates the estimated number of CTG triplets. Note that lane 1 and 2 were exposed 
longer for clarity.
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Clinical efficacy of antisense oligonucleotides (AONs) for the treatment of neuromuscular 
disorders depends on efficient cellular uptake and proper intracellular routing to the target. 
Selection of AONs with highest in vitro efficiencies is usually based on chemical or physical 
methods for forced cellular delivery. Since these methods largely bypass existing natural 
mechanisms for membrane passage and intracellular trafficking, spontaneous uptake and 
distribution of AONs in cells are still poorly understood. Here, we report on unassisted uptake 
of naked AONs, so-called gymnosis, in muscle cells in culture. We found that gymnosis works 
similarly well for proliferating myoblasts as for terminally differentiated myotubes. Cell 
biological analyses combined with microscopy imaging showed that a phosphorothioate 
backbone promotes efficient gymnosis, that uptake is chlathrin-mediated and mainly 
results in endosomal-lysosomal accumulation. Nuclear localization occurred at low level, 
but the gymnotically delivered AONs effectively modulated expression of their nuclear 
RNA targets. Chloroquine treatment after gymnotic delivery helped to increase nuclear 
AON levels. In sum, we demonstrate that gymnosis is feasible in proliferating and non-
proliferating muscle cells and confirm the relevance of AON chemistry for uptake and 
intracellular trafficking with this method, which provides a useful means for bio-activity 
screening of AONs in vitro.
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Antisense oligonucleotide (AON) therapeutics involve a broad range of approaches to 
adjust levels of RNA targets via effects on posttranscriptional processes [1]. AONs are in 
(pre)clinical development for many diseases, including cancer, inflammatory conditions, 
cardiovascular disease and neurodegenerative and neuromuscular disorders. Clinical 
efficacy of AONs largely depends on biodistribution to and uptake by target cells and routing 
to the desired intracellular location (nucleus or cytoplasm). Although this is true for any 
disease for which AON therapy is an option, it is especially relevant for degenerative muscle 
disorders. In this class of diseases, muscle tissue throughout the entire body can be affected, 
requiring a therapeutic effect in up to 40% of total body mass. Examples of multisystemic 
neuromuscular disorders for which AON therapy is currently under development are spinal 
muscular atrophy [2], Pompe disease [3], iron-sulphur cluster deficiency myopathy [4], 
Duchenne muscular dystrophy (DMD; [5]) and myotonic dystrophy type 1 (DM1; [6,7]).
Here we focus on DMD and DM1, both muscular dystrophies characterized by typically 
early and highly variable onset, respectively, with progressive general muscle dysfunction [8]. 
DMD, the most common lethal chromosome X-linked disease in man, is caused by mutations 
in the dystrophin (DMD) gene creating a premature stop codon that abrogates synthesis 
of functional dystrophin protein [9]. As dystrophin is a structural protein responsible for 
connecting the cytoskeleton of muscle fibers to the extracellular basal lamina, its absence 
affects membrane stability of myofibers, eventually leading to cell death and replacement 
by connective tissue [10]. Myotonic dystrophy type 1 (DM1), the most common muscular 
dystrophy in adults [11], has a different etiology. Expansion of an unstable (CTG)n repeat in 
the 3’ UTR of the DMPK gene is responsible for a highly variable multisystemic phenotype 
[11,12]. When the number of (CTG)n triplets in the repeat exceeds a certain threshold, 
expanded DMPK (CUG)n transcripts are produced that accumulate in the cell nucleus and 
aberrantly bind a variety of ribonucleoprotein factors. Sequestration of these factors causes 
RNA processing abnormalities of other mRNAs and miRNAs resulting in a broad spectrum of 
toxic gain-of-function effects [13].
Therapeutic correction at the RNA level by AON-mediated exon skipping of mutant 
dystrophin pre-mRNA is a promising disease-modifying treatment option for DMD [5]. 
Similarly, for DM1, proof-of-concept studies have demonstrated that gene silencing via 
AON-mediated breakdown and prevention of nuclear accumulation of expanded DMPK 
(CUG)n mRNA may become a useful therapeutic modality in the future [6,7,14-18]. Notably, 
although the therapeutic strategies for DMD and DM1 are mechanistically distinct, they 
share an important aspect: exon skipping of mutant DMD pre-mRNA as well as breakdown 
of expanded DMPK (CUG)n RNA must take place in the nucleus of target cells.
To be able to improve AON delivery to the nucleus in diseases like DM1 and DMD, it is 
important to study cellular uptake and intracellular distribution aspects upon treatment, 
including the impact that AON chemical modifications have in these processes. Preclinical 
selection of AON candidates is primarily based on comparative analysis of their bioactivity 
in cell cultures, typically using transfection or electroporation. Although these methods are 
useful to study bioactivity, they are less reliable predictors of cellular uptake and trafficking 
in vivo, since cellular barriers are artificially bypassed.
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Uptake of AONs by cells in vitro without use of transfection reagent or other delivery 
strategy was coined gymnosis by Stein et al. in 2010 [19]. This method was based on prolonged 
incubation of cells with AONs dissolved in the culture medium, which progressively resulted 
in cellular internalization by endocytosis, via mechanisms that are currently under debate 
[20,21]. It is generally accepted that a small fraction of AONs is able to escape from endocytic 
vesicles and reach their RNA target in nucleus or cytosol, but this behavior is not well 
characterized either [22].
To date, unassisted uptake of AONs has been applied successfully to studies in proliferating 
cell types [23]. However, less is known about the applicability to non-proliferating cells, such 
as those that have undergone terminal differentiation. In addition, limited research has been 
dedicated to address how different chemical modifications of AONs influence free uptake 
and subsequent intracellular trafficking. Phosphorothioate moieties have been suggested to 
promote gymnosis, presumably through AON binding to heparin-binding proteins on the cell 
surface and with a role in the subsequent formation of intracellular vesicles [24]. Whether 
that holds for other types of AON chemistries and to what extent chemical modifications 
allow or influence endosomal escape, particularly in muscle cells, has remained unclear 
thus far.
In this study, we used a myogenic cell model derived from DM1 mice to test effects of 
AON chemistry and sequence on gymnosis and subsequent nuclear efficacy. Two classes 
of AONs were compared: (i) analogs of a CAG7 AON for degradation of expanded DMPK 
(CUG)n transcripts for DM1 [7,15] and (ii) variants of DMD23, an AON capable of 
inducing exon 23 skipping in mouse Dmd transcripts [25] (Table 1). We followed uptake 
and intracellular distribution of these AONs during gymnosis by means of fluorescence 
microscopy during myoblast proliferation and differentiation. In parallel, we measured AON 
activity towards nuclear DM1 and DMD targets. Facilitated uptake using polyethyleneimine 
(PEI) was usually included as a positive control to bypass cellular uptake and trafficking 
pathways. Despite the relative high subcellular AON accumulation, we found that already 
low levels of AONs in the nucleus may be effective. Thus, gymnosis may be a supportive 
method for comparative analysis of therapeutic AON candidates in (differentiated) muscle 
cells in vitro, that takes into account natural uptake and intracellular trafficking.
 | M AT E R I A L  A N D  M E T H O D S
Antisense oligonucleotides
AONs used in this study are listed in Table 1 and were synthesized by BioMarin Nederland 
B.V. The nucleotide sequence of CAG7 AONs is 5’-CAGCAGCAGCAG CAGCAGCAG-3’ and 
targets the (CUG)n repeat in expanded DMPK transcripts (PS58 [15]). The sequence of DMD23 
AONs is 5’-GGCCAAACCUCGGCUUACCU-3’ and targets an exon splicing enhancer in exon 
23 of mouse Dmd pre-mRNA (M23D(+02-18) [26]). Three types of chemical modification 
were used: 2’-O-methyl phosphorothioate (-OMePS), 2’-O-methyl phosphate (-OMe) and 
DNA phosphorothioate (-PS). Some AONs were conjugated at their 5’ or 3’ end with a Cy3 
or FAM fluorophore or with P4, a muscle targeting peptide of sequence LGAQSNF [27]. 
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Cy3-CAG3-ENA is a 5’-CAGCAGCAG-3’ AON with an ethylene-bridged nucleic acid (ENA) 
phosphate backbone, 5’ conjugated to Cy3.
Cell culture
DM500 myoblasts were derived from a DM1 mouse model as described [15]. DM500 myoblasts 
express human DMPK (CUG)500 transcripts, the disease-causing agent in myotonic dystrophy 
type 1 [28]. DM500 myoblasts with EGFP-stained nuclei were used for most experiments and 
obtained after stable transduction with a pLZRS retroviral vector expressing a EGFP-hMBNL1 
fusion protein (plasmid gift from Dr. D. Brook, Nottingham). Myoblasts were cultured on 
0.1% (w/v) gelatin-coated dishes in DMEM (GibcoBRL, Gaithersburg, MD) supplemented 
with 20% (v/v) FCS, 50 µg/ml gentamycin, 10 U/ml IFN-γ (BD Biosciences, San Jose, CA, USA) 
and 2% (v/v) chicken embryo extract (Sera Laboratories International, Bolney, UK) at 33oC 
and 5% CO2. 
When myogenic differentiation was applied, myoblasts were seeded on Matrigel® (BD 
Biosciences, Breda, The Netherlands) and grown until 100% confluency. Subsequently, 
differentiation medium (DMEM supplemented with 5% (v/v) horse serum and 50 µg/ml 
gentamycin) was added and the cells were incubated at 37oC for 7-10 days. In some cases, 
after 3 days of differentiation, 4 µg/ml cytosine β-D-arabinofuranoside (Ara-C) (Sigma, Saint 
Louis, MO, USA) was added for 2 days to remove undifferentiated myoblasts.
Gymnosis and transfection
For gymnosis, AONs were supplemented directly in the cell culture medium. A range of 
concentrations (0.2-5 µM) and incubation times (4 hours to 13 days) was tested, as specified 
for each experiment. During proliferation, cells were seeded at 30-40% confluency and 
incubated with AONs in the growth medium. Every time that the medium was refreshed 
(every 2-3 days) or cells were passaged (before reaching confluency), fresh growth medium 
containing the same AON concentration was used. In experiments where myogenic 
differentiation was applied, cells were grown until 100% confluency and incubated with 
differentiation medium containing AON. Medium was refreshed every 2-3 days, containing 
the same AON concentration.
Polyethyleneimine (PEI)-mediated transfection of AONs was done as described [15] at 
a final AON concentration of 500 nM. Myoblasts and myotubes were imaged and RNA was 
isolated 48 hours after transfection.
Use of endocytosis modulators
To block clathrin-dependent endocytosis, cells were supplied with new medium containing 
80 µM dynasore (Sigma-Aldrich, Saint Louis, MO, USA) at one hour prior to AON treatment. 
Incubation was then continued in the same medium, but containing the AON, during 
the entire gymnosis process (24 hours). In these experiments, DMEM supplemented with 50 
µg/mL gentamycin and 10 U/ml IFN-γ, without serum, was used. Longer incubation periods 
were not possible due to significant cell dead and toxicity.
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Table 1. AONs used in this study
AON Chemistry # Sequence (5’ > 3’) Target
CAG7-OMePS (PS58 [15]) 2’-OMe PS
CAG CAG CAG CAG CAG CAG CAG
Expanded DMPK 
transcripts
CAG7-OMe 2’-OMe PO
CAG7-PS [7] DNA PS
P4-CAG7-OMePS* 2’-OMe PS P4-CAG CAG CAG CAG CAG CAG CAG
Cy3-CAG7-OMePS 2’-OMe PS
Cy3-CAG CAG CAG CAG CAG CAG CAGCy3-CAG7-OMe 2’-OMe PO
Cy3-CAG7-PS DNA PS
FAM-CAG7-OMePS 2’-OMe PS FAM-CAG CAG CAG CAG CAG CAG CAG
CAG7-OMePS-Cy3 2’-OMe PS CAG CAG CAG CAG CAG CAG CAG-Cy3
P4-CAG7-OMePS-Cy3* 2’-OMe PS P4-CAG CAG CAG CAG CAG CAG CAG-Cy3
DMD23-OmePS
(M23D(+02-18) [26])
2’-OMe PS GGC CAA ACC UCG GCU UAC CU
Mouse Dmd
pre-mRNA  
(exon 23)
DMD23-OMe 2’-OMe PO
DMD23-PS DNA PS
P4-DMD23-OMePS* 2’-OMe PS P4-GGC CAA ACC UCG GCU UAC CU
Cy3-DMD23-OMePS 2’-OMe PS Cy3-GGC CAA ACC UCG GCU UAC CU
Cy3-DMD23-OMe 2’-OMe PO
Cy3-DMD23-PS DNA PS
P4-DMD23-OMePS-Cy3* 2’-OMe PS P4-GGC CAA ACC UCG GCU UAC CU-Cy3
# 2’-OMe = 2’-O-methyl; PS = phosphorothioate; PO = phosphate
* P4 = LGAQSNF [27]
To induce release of endosomal and lysosomal contents, cells were treated with 75 µM 
chloroquine (CHQ) for 4 hours at the end of the gymnosis incubation period. No signs of 
toxicity were observed at this CHQ concentration.
Confocal microscopy and immunochemistry
Myoblasts were grown in µ-Slide 8 well plates (ibidi®, Martinsried, Germany) or in GWSt-3522 
WillCo-dish® wells (WillCo Wells B.V., Amsterdam, The Netherlands). After treatment with 
179
6
Free uptake of oligos in muscle cells in vitro
Cy3-labeled AONs (Table 1), analysis was performed using a Zeiss LSM510-Meta confocal 
microscope. For live cell imaging, cells were put in a culture chamber that was maintained at 
a stable temperature of 37°C with a 5% CO2 supply. DM500 myotubes were incubated prior 
to analysis with 5 µM CSFE (carboxyfluorescein succinimidyl ester; Invitrogen) for 5 minutes 
and with 10 µg/ml Hoechst (Life Technologies) for 30 minutes to visualize cytoplasm and 
nucleus, respectively. Images to evaluate AON distribution were acquired in live cells or 
immediately after fixation, at different time points after start of gymnosis. These approaches 
for image acquisition were adopted because pilot experiments revealed that standard 
paraformaldehyde protocols did not fix AONs permanently when the cells were kept in 
phosphate-buffered saline (PBS) after fixation, giving experimental variation and a false 
impression of their intracellular distribution (Suppl. Fig. S1). For fixation, cells were washed 
twice with PBS and then incubated for 15 minutes at 37oC in 0.1 M phosphate buffer (pH 7.5) 
with 4% (w/v) paraformaldehyde.
For visualization purposes, certain images displayed in the figures were adjusted 
to the maximum exposure level within the range of negative background signal. This 
results in overexposed areas but allows visualization of AONs in other parts of the cell 
where the concentration is lower, such as the nucleus. For fluorescence quantification 
(Fig. 1B and Fig. 6), confocal settings were calibrated below Cy3-channel saturation using 
the well displaying highest fluorescence signal (see Suppl. Fig. S7). Identical parameters 
were kept to quantify all other wells in the same microscopy session, including all treatments 
(n=3). Several images of each treatment (25-30 cells) were processed using ImageJ (Wayne 
Rasband, National Institute of Health, USA). Masks of either nuclear or cytoplasmic regions 
(determined by the EGFP signal) were used to select cellular areas of interest from where Cy3 
intensities were measured and corrected for background (see Fig. 6).
For Lamp1 immunochemistry, cells were fixed and blocked with 4% (v/v) animal serum 
(corresponding to the origin of the secondary antibody) and 0.33% (v/v) Triton-X-100 in PBS 
for 60 minutes at room temperature. Rabbit Anti-Lamp1 primary antibody (Sigma, Saint Louis, 
MO, USA) was diluted in 10 mg/ml BSA and 0.33% (v/v) Triton-X-100 and applied overnight at 
4oC. Samples were blocked with goat serum and incubated with Goat Anti-Rabbit alexa-647 
secondary antibody (Abcam, Cambridge, UK) for one hour at room temperature.
RNA isolation and RT-PCR analysis
RNA was isolated from cultured cells using the Aurum™ Total RNA Mini Kit (Bio-Rad, 
Hercules, CA, USA), according to the manufacturer’s protocol. Primer sets for PCR and qPCR 
were designed using Primer-BLAST [29] in the NCBI database and validated in silico using 
OligoAnalyzer 3.1 [30] to prevent formation of hairpins and dimers during amplification 
(Suppl. Table S1). Resulting products were visualized on agarose gels and sequenced to 
verify identity.
For reverse transcription (RT), typically 0.5 mg of total RNA was subjected to cDNA 
synthesis using the SuperScript® first-strand synthesis system with random hexamer primers 
in a total volume of 20 ml.
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Skipping of exon 23 in Dmd transcripts was analyzed using conventional nested PCR with 
primers annealing in exon 22 (forward primer) and exon 24 (reverse primer; Suppl. Table 
S1). Per reaction, the mix contained 10.4 µl MilliQ, 4 µl 5x Q5 Reaction Buffer, 0.2 µl Q5® High 
Fidelity DNA Polymerase (2U/µl) (BioLabs® Inc, Ipswich, MA, USA), 0.4 µl dNTPs (Invitrogen, 
Eugene, Oregon, USA), 2 µl forward primer (5 µM), 2 µl reverse primer (5 µM) (Biolegio BV, 
Nijmegen, The Netherlands) and 1 µl cDNA template. Thermal cycling conditions consisted 
of 30 seconds at 98oC followed by 34 amplification cycles of 6 seconds at 98oC, 20 seconds at 
64oC (annealing) and 10 seconds at 72oC (elongation). The final elongation step was carried 
out for 2 minutes. Fragments were analyzed on 2% agarose gels. Images of ethidium-stained 
products were acquired under UV-light below pixel saturation. Quantification of signals was 
done using ImageJ (Wayne Rasband, National Institute of Health, USA), measuring pixel 
intensity and correcting for background.
For the detection of degradation of expanded DMPK transcripts real-time quantitative 
PCR (qPCR) was used, following a protocol previously described [7]. Samples were analyzed 
using the CFX96™ Real-time System (Bio-Rad, Hercules, CA, USA). A melting curve was 
obtained for each sample in order to confirm single product amplification. Relative mRNA 
levels were calculated using the ΔΔCt method [31]. Gapdh and Actb expression levels were 
used together for normalization. 
Quantitative PCR was also used to measure mRNA levels of differentiation markers Aqp1, 
Myh1, Mylfp and Cav3. In this case, samples were analysed by the ViiA™ 7 Real-Time PCR 
System (Life Technologies, Bleiswijk, The Netherlands), by means of commercial TaqMan® 
assays (Applied Biosystems, Foster City, CA, USA) (Suppl. Table S1), following manufacturer’s 
instructions. Data was normalized using Gapdh and Hprt as reference genes. Levels of 
the group showing the highest expression were set to 100% using the ΔΔCt method.
Statistical analysis
We performed unpaired student’s t-tests to test whether DMPK levels after CAG7-OMePS 
treatment (either alone or in presence of dynasore or chloroquine) differed significantly 
from levels that remained after treatment with a control AON. To determine whether 
the average signals of Dmd skipped products were significantly different from background, 
we performed a t-test analysis against a zero theoretical mean. The effect of Ara-C treatment 
in the expression of differentiation markers was analyzed by unpaired t-tests in each gene 
group. To compare the effect of AONs of different chemistries on DMPK transcript levels we 
used a 1-way ANOVA followed by a Bonferroni’s Multiple Comparison Test. To test whether 
Cy3-CAG7-OMePS accumulation in time was significantly different from Cy3-CAG3-ENA 
behavior we used a 2-way ANOVA. In all these cases, values were considered significantly 
different when: *: p<0.05, **: p<0.01 or ***: p<0.001.
 | R E S U LT S
Gymnosis in proliferating myoblasts
Experiments in this study were performed in the immortal DM500 cell model [15], derived 
from a transgenic mouse model for DM1 [28]. DM500 myoblasts show nuclear accumulation 
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of transcripts from a human DMPK transgene bearing an expanded (CTG)500 repeat. The cells 
show normal growth and myogenic differentiation capacity. Previous studies revealed that 
AON transfection characteristics did not overtly differ between DM500 and normal primary 
mouse or human myoblasts [7,15]. Here, we mainly used a population of DM500 myoblasts 
that stably expressed low levels of EGFP-MBNL1, a green fusion protein with predominant 
nuclear location [32], for easy microscopy visualization of localization of fluorescent AONs 
in the nucleus.
To study gymnosis and intracellular AON distribution, we followed the behavior of 
Cy3-conjugated CAG7-OMePS, a 21 nt repeat AON containing a fully modified 2’-O-methyl 
phosphorothioate backbone (Table 1) [15]. In proliferating myoblasts, CAG7-OMePS-positive 
vesicular structures in the cytoplasm were present in essentially all cells after four hours of 
incubation with 200 nM naked oligo in the medium (Fig. 1A). The vesicular accumulation 
appeared more prominent after 24 hours and quantification of staining revealed that it 
became even more intense over the subsequent two days (Fig. 1B). Interestingly, we also 
noticed local accumulation of AON signal in spots in the nucleus in many, but not all cells at 
>24 hours of gymnosis. In addition, a diffuse nuclear staining was observed in ~1% of cells 
at 72 hours and ~2% after 6 days (Fig. 1C). The fraction of Cy3-positive nuclei did not further 
increase after longer incubation (up to 13 days) or upon use of a higher AON concentration 
(5 µM; data not shown).
Gymnotic uptake and distribution characteristics were entirely different from those seen 
with polyethylenimine-(PEI)-mediated transfection, a commonly used procedure to deliver 
AONs in cultured cells [33]. PEI transfection of DM500 myoblasts resulted in a predominant 
nuclear staining of Cy3-CAG7-OMePS in around 50% of all cells (Suppl. Fig. S2).
The typical uptake and distribution behavior of naked AONs was not influenced by 
the type of fluorophore conjugated to the AON (Fig. 1C). Neither did the conjugation 
position of the fluorophore, to the 5’ or the 3’ end of the AON, have any obvious effect on 
AON localization (Suppl. Fig. S3).
To examine potential effects on gymnosis by the nucleotide composition of the AON 
we followed also the fate of Cy3-DMD23-OMePS, an AON that induces exon 23 skipping 
during splicing of mouse Dmd pre-mRNA [25]. When used under the same experimental 
conditions, a similar localization was observed with this AON (Fig. 2A), including 
the predominantly vesicular and low intranuclear accumulation pattern that was found 
for Cy3-CAG7-OMePS (Suppl. Fig. S4).
Interfering with intracellular trafficking using endocytosis modulators
A significant fraction of the vesicles that incorporated Cy3-DMD23-OMePS or 
Cy3-CAG7-OMePS stained for the late endosomal/lysosomal marker Lamp1 (Fig. 2A). This 
suggested that at least a proportion of the vesicles that contained gymnosis-delivered 
OMePS AONs followed the endocytic route up to lysosomes, confirming earlier observations 
[20]. To study this pathway more specifically for myoblasts, we examined whether 
endocytic modulators like chloroquine and dynasore would affect intracellular distribution 
of DM1 and DMD AONs. Chloroquine is a lysosomotropic agent that leads to endosomal 
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Figure 1. Live imaging of gymnosis in proliferating DM500 myoblasts. DM500 EGFP myoblasts were 
cultured for three days in the presence of Cy3-CAG7-OMePS (200 nM). (A) Confocal images showing 
intracellular localization of the AON (red). Nuclei are green due to expression of a nuclear EGFP-fusion 
marker protein. Cy3-CAG7-OMePS quickly accumulated in cytoplasmic vesicle-like structures. The AON 
accumulated in a fraction of the cells in spots in the nucleus (arrowheads). Scale bars indicate 20 µm. 
(B) Quantification of red fluorescence per cell (n=3; 30 cells per experiment) using images under 
saturation levels. (C) DM500 myoblasts were grown in the presence of a mixture of Cy3- and FAM-
conjugated CAG7-OMePS (200 nM each). An identical vesicular, cytoplasmic staining was observed for 
both AONs after two days. After four days a clear diffuse staining in cytosol and nucleus was detected 
in a minority (<5%) of the cell population (arrowheads). Scale bars indicate 20 µm. For visualization 
purposes, images displayed in (A) and (C) were adjusted to the maximum exposure level within 
the range of negative background signal.
A
B
C
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disruption in vitro [34] and can release AONs from endocytic vesicles [35]. Dynasore inhibits 
dynamin, a protein essential for clathrin-dependent endocytosis [36].
Dynasore was added one hour before starting the incubation with AONs and kept 
in culture during the rest of the gymnosis period in order to block clathrin-dependent 
endocytosis during the entire process. Dynasore treatment completely blocked AON uptake 
and distribution, supporting the hypothesis that 2’-OMe PS AONs are internalized by 
clathrin-mediated endocytosis (Fig. 2B; reviewed in [20]). In contrast, chloroquine treatment 
resulted in strong increase in nuclear accumulation in many cells. Chloroquine was present 
during the final four hours of gymnosis, to allow AONs to reach all endosomal compartments 
first. The combination of these observations suggests that upon gymnotic uptake of AONs, 
endosomal escape is required for subsequent transfer to the cell nucleus.
Gymnosis in differentiated myotubes
Gymnosis in non-proliferating cells is reported to be challenging [23]. We therefore studied 
independently unassisted AON uptake during differentiation of myoblasts to myotubes 
in vitro. We added Cy3-CAG7-OMePS and Cy3-DMD23-OMePS to differentiating myoblast 
cultures for up to seven days. As in myoblasts, AONs accumulated in myotubes in cytoplasmic 
vesicles and multiple myonuclei were AON-positive (Fig. 3). We questioned whether this 
resulted from intrinsic uptake mechanisms in these differentiated cells or whether they were 
donated by AON-loaded myoblasts during fusion. To evaluate this point, we performed 
gymnosis experiments with cell cultures that had first undergone differentiation for three 
days and were then treated with cytosine β-D-arabinofuranoside (Ara-C) for two days 
(Fig. 4A). Ara-C, a nucleoside analog that interferes with DNA replication, causes apoptosis 
of proliferating cells [37] and has been used to remove myoblasts during differentiation 
to achieve a pure myotube culture [38]. Non-fused myoblasts were largely removed from 
the adhered myotube layer after Ara-C treatment and this correlated with a significant 
change in gene expression of several markers reported to be up- or downregulated during 
myogenesis [39,40] (Suppl. Fig S5). Gymnosis initiated after Ara-C treatment resulted in 
intracellular AON distribution patterns in myotubes that were indistinguishable from those 
observed before or in myoblasts (Fig. 3; data not shown). These experiments thus indicate 
that differentiated myotubes, like proliferating myoblasts, are able to internalize 2’-OMe PS 
AONs by endocytosis.
AONs gymnotically delivered during proliferation and differentiation are 
active in the nucleus
To analyze whether gymnotically delivered AONs in myoblasts were released from endosomes 
to become active towards nuclear targets, we first examined the ability of CAG7-OMePS to 
silence DMPK (CUG)500 transcripts. Silencing of expanded DMPK mRNA in myoblasts could 
be measured and was further increased in presence of chloroquine, whereas breakdown 
was prohibited in presence of dynasore (Fig. 2C). In line with earlier observations [7,15], 
we did not see an effect of the Cy3 modification on nuclear activity, be it conjugated to 
the 5’ or 3’ end (Suppl. Fig. S3B). Not surprisingly, the bioactive effect of Cy3-CAG7-OMePS on 
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Figure 2. Intracellular trafficking of AONs during gymnosis. (A) Confocal images of DM500 EGFP 
cells after 24 hours of growth in the presence of Cy3-CAG7-OMePS or Cy3-DMD23-OMePS. Lamp-1, 
a lysosomal marker protein, was visualized by immunochemistry and co-localized with some 
of the AON-positive vesicles. Scale bars indicate 25 µm. (B) Uptake of Cy3-DMD23-OMePS and 
Cy3-CAG7-OMePS (500 nM) in presence of chloroquine or dynasore after 24 hours of gymnosis. Merged 
images are a composite of Cy3 and EGFP channels. Scale bars indicate 25 µm. (C) Quantification of 
expanded DMPK RNA expression after 24 hours of gymnosis incubation with Cy3-CAG7-OMePS in 
combination with chloroquine or dynasore. DMPK mRNA levels after Cy3-CAG7-OMePS and control 
AON treatments were compared by unpaired t-tests. CAG7-OMePS activity in presence of chloroquine 
compared to vehicle was analyzed by 1-way ANOVA followed by a Bonferroni’s Multiple Comparison 
Test (*: p<0.05, **: p<0.01).
A
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Figure 3. Gymnosis during myogenic differentiation. DM500 myoblasts were grown to 
confluency and transferred to differentiation medium in the presence of Cy3-CAG7-OMePS 
or Cy3-DMD23-OMePS (500 nM). These culture conditions were continued for seven days. After this 
period, a vesicular cytoplasmic localization was observed in fully differentiated myotubes (live imaging). 
Clear nuclear signal (arrowhead) could be observed in some myotubes.  Compare this faint diffusive 
staining with total absence of staining in nuclei in other myotubes. For visualization purposes, images 
displayed were adjusted to the maximum exposure level within the range of negative background 
signal. Scale bars indicate 20 µm.
DMPK mRNA levels in differentiating myotubes was also sensitive to chloroquine treatment 
and very comparable between cultures that received Ara-C treatment and those that did 
not (Fig. 4B).
We next examined the ability of gymnotically delivered DMD23-OMePS to skip exon 
23 during DMD pre-mRNA splicing. Since DMD expression, as opposed to that of DMPK, 
is rather low in myoblasts but strongly induced during myogenic differentiation (data not 
shown; [41]), we only investigated DMD23 effects in differentiated myotubes. We found 
that the skipping effect of this AON was the same in Ara-C-treated and untreated myotube 
cultures (Fig. 4C). Chloroquine treatment enhanced the activity of DMD23-OMePS to levels 
comparable to those achieved by PEI-mediated transfection. This suggests that intracellular 
trafficking of AONs in differentiated myotubes is a process that is amenable for modulation, 
and thus for improvement of its translational value. Finally, we examined exon 23 skipping 
levels in myotubes after dedicated gymnosis protocols during either proliferation or 
differentiation or during both periods (see Fig. 5A). DMD23-OMePS-mediated exon skipping 
was AON concentration-dependent and most effective when applied during the entire 
period of proliferation and differentiation (Fig. 5B).
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Figure 4. Gymnosis in differentiated DM500 myotubes. (A) Experimental protocol used for treatment 
of myotubes with CAG7-OMePS and DMD23-OMePS. Differentiation of DM500 myoblasts was initiated 
at 100% confluency at day 0. In protocol T, as a positive control, at day 8 of differentiation myotubes 
were transfected with AON (500 nM) using polyethylenimine (PEI). Alternatively, cells were allowed to 
fuse for three days and were then incubated with Ara-C for two days or left untreated (protocols G and 
Q). At day 5, gymnosis was started and myotubes were incubated with AON (500 nM) for 5 days (protocol 
G) or for only 3 days after which they were treated with chloroquine (CHQ) followed by the addition 
of fresh differentiation medium without AON (protocol Q). In all protocols, RNA was isolated at day 10. 
(B) Analysis of DMPK mRNA expression (n=3). All groups treated with CAG7-OMePS showed significantly 
lower levels compared to the matched controls that received DMD23-OMePS (unpaired t-tests; only 
shown for the transfection pair; **: p<0.01). We also tested whether the effect of CHQ was significant in 
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each experimental group by t-test analysis (*: p<0.05, **: p<0.01). (C) Analysis of Dmd exon 23 skipping 
(n=3). The gel image shows results of one of the triplicates, while the graph depicts quantification of 
skipping percentage (n=3). A t-test analysis against a zero theoretical mean was performed in each 
case to determine whether the average signal of Dmd skipped products was significantly different from 
background (***: p<0.001). DMD23 = DMD23-OMePS; CAG7 = CAG7-OMePS; RT(-) = no RT control; 
NTC = no template control.
Effects of AON chemistry on gymnosis delivery and nuclear activity
In the course of pilot studies, wherein gymnosis was tested for a range of chemically modified 
CAG AONs, we observed different trafficking results. For example Cy3-CAG3-ENA gave almost 
undetectable endosomal accumulation [7] (Suppl. Fig. S6).This finding was consistent with 
previous observations in other cells [24], where AON uptake behavior was strongly influenced 
by chemical modification. As this aspect is relevant for future therapeutic applications, we 
tested effects of a selected set of oligo chemistries on gymnosis in our DM1 myogenic cell 
model. Four modifications for both AON sequences, CAG7 and DMD23, were analyzed: 
2’-O-methyl phosphorothioate (OMePS), 2’-O-methyl phosphate (OMe), DNA 
phosphorothioate (PS) and OMePS including a 5’ conjugation with a muscle-homing peptide 
(P4), which has been shown to enhance activity of DMD23-OMePS and CAG7-OMePS in vivo 
([27]; Mulders et al., unpublished). Note that AON DMD23-PS was included to complete 
the set, but is in fact not useful for therapeutic purposes, since this AON may induce 
RNAse-H-dependent breakdown of Dmd pre-mRNAs instead of exon skipping.
By using immunofluorescent image acquisition, we were able to quantify Cy3-signals 
separately for nucleus and cytoplasm in myoblasts (Fig. 6A; note that this protocol could not 
be applied to myotube cultures). Activity of DM1 and DMD AONs was measured in parallel 
in seven-day-old myotubes (Fig. 6B). Forty eight hours of gymnosis led to a predominant 
cytoplasmic location for all AONs, irrespective of the chemical modification and sequence 
(Fig. 6C). However, a significantly lower uptake was observed for AONs with a phosphate 
instead of a phosphorothioate backbone, which corresponded to a lack of activity towards 
their nuclear target (Fig. 6D). Conjugation of peptide P4 to OMePS AONs had an inconclusive 
effect on gymnosis as it increased uptake of CAG7-OMePS, but had essentially no effect on 
uptake and cytosolic accumulation of DMD23-OMePS. Assisted delivery of the AONs by 
PEI transfection led mainly to nuclear localization (Fig. 6E), but with lower efficiency for 
AONs with only OMe or PS backbones. The tendency of nuclear accumulation is obviously 
promoted by the well-known facilitating effect of PEI on endosomal escape [42,43].
Nuclear activity clearly correlated with gymnotic uptake efficiency as assessed by 
cytoplasmic accumulation. The CAG7-OMePS AONs had most, CAG7-OMe least, and 
CAG7-PS intermediate silencing potential (Fig. 6D). Interestingly, PEI-assisted transfection 
yielded similar efficiency differences between the OMePS, OMe and PS AONs and the effects 
on breakdown and exon skipping (with the exception of RNase H recruiting AON DMD23-PS) 
were moderately improved by PEI transfection (Fig. 6F). Our findings therefore challenge 
the suggested idea that a strong AON accumulation in the nucleus is required for a robust 
effect on nuclear targets [44,45].
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Figure 5. AON concentration- and time-dependent effects of gymnosis on Dmd exon 23 skipping. 
(A) Protocol used for DMD23-OMePS gymnosis in DM500 myoblasts. Gymnosis was performed during 
the last two days of proliferation (P), during seven days of differentiation (D) or during both periods 
(P+D). PEI transfection was carried out as a control on day 5 of differentiation. In all cases, RNA was 
isolated at day 7 of differentiation. (B) Analysis of Dmd exon 23 skipping. A t-test analysis against a zero 
theoretical mean was performed in each case to determine whether the average signals of Dmd skipped 
products were significantly different from background (*: p<0.05, **: p<0.01). Gel image compares 
results from gymnosis at 5 µM and transfection with 500 nM DMD23-OMePS. DMD23 = DMD23-OMePS; 
PEI = polyethylenimine; L = DNA size ladder; NTC = no template control; RT(-) = no RT control.
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Figure 6. Chemistry effects on AON uptake and activity during gymnosis. (A) Masking procedure 
used to quantify Cy3-fluorescence in nucleus and cytoplasm of myoblasts. Scale bars indicate 20 µm. 
(B) Protocols used for cell culture and gymnosis and subsequent quantification of AON uptake and 
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A number of studies have been reported in the past few years on effective treatment 
strategies using naked AONs in patients and mouse models for DMD and DM1 [6,46,47]. Since 
the AONs used were rather large, hydrophilic molecules that could not easily diffuse through 
muscle cell membranes [48], alternative cell internalization mechanisms must have been 
responsible for the observed biological effect in muscle. One distinct feature with regard 
to cellular uptake of AONs in vivo specific for DMD is that due to the dystrophin-deficiency 
some muscle fibers are more permeable to large compounds due to membrane alterations 
[49], while other fibers retain good membrane integrity [50], thereby directing treatment to 
the most affected ones [51]. In contrast, in muscles from DM1 patients and mouse models 
all myofiber membranes appear impermeable to large molecules [52]. Supportive insight 
concerning normal AON delivery and intracellular trafficking mechanisms may be provided 
by cell culture studies, since it was shown that cells are able to internalize AONs freely from 
the culture medium, a process now known as gymnosis [19,23].
We confirm here that gymnosis is a general characteristic of the DM500 myogenic cell 
culture model. After several hours of incubation in the presence of AONs, vesicular localization 
patterns were observed in proliferating myoblasts and in differentiated myotubes. Our 
findings thus demonstrate that myotubes retain AON uptake potential after differentiation 
and strengthen the hypothesis that similar uptake mechanisms may be at play in muscle in 
vivo (knowing that differentiated myotubes in vitro exhibit several characteristics of mature 
muscle myofibers in vivo, like excitation contraction coupling and expression of muscle 
differentiation biomarkers [53,54]).
The first step in unassisted AON uptake must occur at the cell membrane and involves 
AON binding and initial engulfment by endocytosis [55]. We found that gymnosis was 
blocked by dynamin inhibition, which suggests that the endocytic mechanism by which 
AONs enter cells is clathrin-mediated [20]. Although it is not known how naked AONs are 
initially recognized and endocytosed in myogenic cells, a phosphorothioate (PS) modified 
backbone is apparently important, as AONs in our study carrying a phosphate backbone (and 
either 2’-OMe or ENA ribose modification) were inactive. This idea is supported by a study 
showing enhanced cellular binding of AONs with PS modification compared to an unmodified 
phosphate backbone [56]. The importance of PS backbone is further consistent with earlier 
nuclear activity. (C) Stacked bar charts illustrating mean fluorescence intensity in cytoplasm (white) 
and nucleus (black) of DM500 myoblasts after two days of gymnosis (500 nM) of Cy3-conjugated CAG7 
and DMD23 AONs (n=3; ~30 cells per experiment). (D) Effects on expanded DMPK mRNA expression 
and Dmd exon 23 skipping measured after seven days of differentiation. Control AONs are depicted 
in bold. (E) Stacked bar charts illustrating mean fluorescence intensity two days after PEI-assisted 
delivery in cytoplasm and nucleus of DM500 myoblasts (n=3; ~30 cells per experiment). (F) Effects on 
expanded DMPK mRNA expression and Dmd exon 23 skipping after PEI-assisted delivery in myotubes. 
Control AONs are depicted in bold. Raw images are shown in Suppl. Fig. S7. DMPK qPCR data was 
compared using a 1-way ANOVA followed by a Bonferroni’s Multiple Comparison Test. Signal of Dmd 
skipped products was analyzed by t-test against a zero theoretical mean. Comparisons were considered 
significant when: *: p<0.05, **: p<0.01, ***: p<0.001.
191
6
Free uptake of oligos in muscle cells in vitro
reports on successful gymnosis of a variety of AON chemistries, all carrying this modification 
[19,24,57,58]. The endocytic process might be triggered by the surrounding proteins that 
bind to PS AONs in a non-specific manner [59], rather than by the oligonucleotide itself.
In the presence of polycationic transfection reagents, like PEI, the internalization process 
is mediated by the recognition of positively charged PEI-AON complexes by proteoglycan 
membrane receptors [60]. Initial steps in unassisted AON endocytosis may be triggered by 
polyanion-interacting proteins that specifically bind phosphorothioate moieties in AONs 
[59]. Some of the candidates involved may have been identified in a recent screen for proteins 
that bind phosphorothioate linkages with high affinity [61]. Normal uptake efficiency of 
phosphorothioate AONs may be enhanced in vivo by conjugating peptide ligands, as was 
observed for P4-CAG7-OMePS [17,27,62].
A second important step required to achieve AON activity inside the cell is escape from 
the endosomal compartment and subsequent trafficking to the target location, i.e. in our 
study the cell nucleus, where expanded DMPK RNAs and Dmd pre-mRNAs reside. It has been 
postulated that AONs may follow two distinct endocytic routes [57]: a non-productive route 
to lysosomal accumulation and degradation, and a productive route resulting in nuclear 
trafficking and effective RNA regulation. Some of the CAG7-OMePS or DMD23-OMePS 
AON-positive vesicles indeed co-localized with the lysosomal marker Lamp1, suggesting 
that the non-productive pathway was followed by a fraction of the internalized AONs. 
The non-co-localizing CAG7-OMePS/DMD23-OMePS AON fraction may be associated 
with the postulated productive route and may be present in early endosomes from which 
they escaped.
The exact mechanism by which AONs escape from endosomes is not known, but it 
may occur in the course of intracellular trafficking by membrane bilayer instability during 
vesicle fusion and budding [22]. We found that endocytic release, promoted by chloroquine 
treatment, indeed enhanced the activity of CAG7-OMePS and DMD23-OMePS towards their 
corresponding targets. Chloroquine treatment correlated with a switch from a vesicular 
staining pattern to a predominant nuclear signal, suggesting that soon after endosomal 
escape free AONs will quickly diffuse through nuclear pores into the nucleus [63,64]. A diffuse 
nuclear staining including spots has been reported previously after microinjection of AONs 
carrying a phosphorothioate backbone in the cytosol [63-65].
Despite the weak nuclear and strong cytoplasmic (vesicular) AON staining after 
gymnosis, a significant activity by both AON sequences was detected towards RNA targets 
that are clearly located in the nucleus [66,67]. In control experiments, we found that AON 
activity was higher when PEI-mediated transfection was applied, but the magnitude did 
not correlate with the higher nuclear AON concentration (estimated at 5-25 times higher, 
judging from fluorescence quantification; as a result of endosomal release induced by 
a proton-sponge effect of PEI [42,43]). So, how then can the apparent discrepancy between 
nuclear AON concentration (fluorescence intensity) and nuclear activity (RNA degradation 
or exon skipping) after gymnosis be explained?
We propose a few possible explanations, which are not mutually exclusive: (i) PEI 
molecules may remain associated and form stable complexes with AONs in the nucleus 
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[68], thus decreasing free AON concentration and impeding proper binding to the mRNA 
target. (ii) AON concentration in the nucleus during gymnosis may not surpass the limit of 
detection of our microscope in the majority of cells, but the minimal AON concentration 
required for a biological effect in this compartment may be much lower than generally 
believed and is already achieved under these conditions. Nevertheless, it is important to 
point out that several other factors may influence bioactive efficacy, like levels of target 
RNA, AON efficiency, speed of the process and whether one AON can modulate multiple 
transcripts. For instance, CAG7-OMePS AON activities after gymnosis and transfection were 
more similar than those of DMD23-OMePS, suggesting that the DM1 AON requires a lower 
concentration in the nucleus. (iii) Related to the previous point, cell imaging has shown that 
gymnosis is an intrinsic cellular process active in all cells, whereas PEI-mediated transfection 
involves only part of the cell population (depending on transfection efficiency: around 50% 
in our experiments). Therefore, the proposed minimal AON concentration in the nucleus for 
biological effect may be present in a larger portion of the cell population during gymnosis 
compared to transfection.
In sum, we demonstrate that gymnosis is feasible in proliferating and non-proliferating 
muscle cells and confirm the relevance of AON chemistry for uptake and intracellular 
trafficking with this method. Our data suggest that even low levels of AONs in the nucleus 
may be already sufficient for bioactivity and thus that gymnosis may be a useful method for 
comparative analysis of therapeutic AON candidates in muscle cells in vitro.
 | A C K N O W L E D G E M E N T S
We thank Jack Fransen, Cindy Dieteren and Antoine Khalil for their support with microscopic 
techniques and use of ImageJ, and members of the Department of Cell Biology and BioMarin 
Nederland for discussions.
 | AU T H O R  D I S C LO S U R E  S TAT E M E N T
Funding was provided by BioMarin Nederland BV, Leiden, The Netherlands, a company 
that develops RNA therapeutics. AG-B, BA, PCdV, NAD, SAMM and JCTvD are employees 
of BioMarin Nederland BV, which includes contribution to patent applications and 
participation in stock-option plans of the company. BA, PCdV, JCTvD, SAMM and DGW 
are inventors  in patents for oligonucleotidemediated exon skipping and/or treatment of 
myotonic dystrophy type 1 and other neuromuscular disorders. BN, JK, IDGvK, HJEC and BW 
have no financial conflict of interest.
193
6
Free uptake of oligos in muscle cells in vitro
 | R E F E R E N C E S
1. Bennett CF and Swayze EE (2010) RNA 
targeting therapeutics: molecular 
mechanisms of antisense oligonucleotides 
as a therapeutic platform. Annu Rev 
Pharmacol Toxicol, 50: 259-293.
2. Porensky PN and Burghes AH (2013) 
Antisense oligonucleotides for 
the treatment of spinal muscular atrophy. 
Hum Gene Ther, 24: 489-498.
3. Clayton NP, Nelson CA, Weeden T, Taylor KM, 
Moreland RJ, Scheule RK, Phillips L, Leger 
AJ, Cheng SH and Wentworth BM (2014) 
Antisense Oligonucleotide-mediated 
Suppression of Muscle Glycogen Synthase 
1 Synthesis as an Approach for Substrate 
Reduction Therapy of Pompe Disease. Mol 
Ther Nucleic Acids, 3: e206.
4. Kollberg G and Holme E (2009) Antisense 
oligonucleotide therapeutics for iron-
sulphur cluster deficiency myopathy. 
Neuromuscul Disord, 19: 833-836.
5. van Deutekom JC et al. (2007) Local dystrophin 
restoration with antisense oligonucleotide 
PRO051. N Engl J Med, 357: 2677-2686.
6. Wheeler TM, Leger AJ, Pandey SK, MacLeod 
AR, Nakamori M, Cheng SH, Wentworth 
BM, Bennett CF and Thornton CA (2012) 
Targeting nuclear RNA for in vivo correction 
of myotonic dystrophy. Nature, 488: 111-115.
7. Gonzalez-Barriga A, Mulders SAM, van de 
Giessen J, Hooijer JD, Bijl S, van Kessel ID, 
van Beers J, van Deutekom JC, Fransen JA, 
Wieringa B and Wansink DG (2013) Design 
and analysis of effects of triplet repeat 
oligonucleotides in cell models for myotonic 
dystrophy. Mol Ther Nucleic Acids, 2: e81.
8. Wicklund MP (2013) The muscular dystrophies. 
Continuum (Minneap Minn), 19: 1535-1570.
9. Aartsma-Rus A, Van Deutekom JC, Fokkema 
IF, Van Ommen GJ and Den Dunnen JT 
(2006) Entries in the Leiden Duchenne 
muscular dystrophy mutation database: an 
overview of mutation types and paradoxical 
cases that confirm the reading-frame rule. 
Muscle Nerve, 34: 135-144.
10. Kharraz Y, Guerra J, Pessina P, Serrano AL and 
Munoz-Canoves P (2014) Understanding 
the process of fibrosis in Duchenne muscular 
dystrophy. Biomed Res Int, 2014: 965631.
11. Harper PS. (2001) Myotonic dystrophy. 3rd 
ed. WB Saunders, London, UK.
12. Groenen P and Wieringa B (1998) Expanding 
complexity in myotonic dystrophy. 
BioEssays, 20: 901-912.
13. Udd B and Krahe R (2012) The myotonic 
dystrophies: molecular, clinical, and therapeutic 
challenges. Lancet Neurol, 11: 891-905.
14. Wheeler TM, Sobczak K, Lueck JD, Osborne 
RJ, Lin X, Dirksen RT and Thornton CA 
(2009) Reversal of RNA dominance by 
displacement of protein sequestered on 
triplet repeat RNA. Science, 325: 336-339.
15. Mulders SA, van den Broek WJAA, Wheeler TM, 
Croes HJE, van Kuik-Romeijn P, de Kimpe SJ, 
Furling D, Platenburg GJ, Gourdon G, Thornton 
CA, Wieringa B and Wansink DG (2009) Triplet-
repeat oligonucleotide-mediated reversal of 
RNA toxicity in myotonic dystrophy. Proc Natl 
Acad Sci USA, 106: 13915-13920.
16. Lee JE, Bennett CF and Cooper TA (2012) 
RNase H-mediated degradation of toxic 
RNA in myotonic dystrophy type 1. Proc Natl 
Acad Sci USA, 109: 4221-4226.
17. Leger AJ, Mosquea LM, Clayton NP, Wu IH, 
Weeden T, Nelson CA, Phillips L, Roberts E, 
Piepenhagen PA, Cheng SH and Wentworth 
BM (2013) Systemic Delivery of a Peptide-
Linked Morpholino Oligonucleotide 
Neutralizes Mutant RNA Toxicity in a Mouse 
Model of Myotonic Dystrophy. Nucleic Acid 
Ther, 23: 109-117.
18. Pandey SK et al. (2015) Identification and 
Characterization of Modified Antisense 
Oligonucleotides Targeting DMPK in Mice 
and Nonhuman Primates for the Treatment 
of Myotonic Dystrophy Type 1. J Pharmacol 
Exp Ther.
19. Stein CA et al. (2010) Efficient gene silencing 
by delivery of locked nucleic acid antisense 
oligonucleotides, unassisted by transfection 
reagents. Nucleic Acids Res, 38: e3.
20. Juliano RL, Ming X, Carver K and Laing B 
(2014) Cellular uptake and intracellular 
trafficking of oligonucleotides: implications 
194
6
Chapter 6
for oligonucleotide pharmacology. Nucleic 
Acid Ther, 24: 101-113.
21. Juliano RL and Carver K (2015) Cellular uptake 
and intracellular trafficking of oligonucleotides. 
Adv Drug Deliv Rev, 87: 35-45.
22. Juliano RL, Ming X and Nakagawa O (2012) 
Cellular uptake and intracellular trafficking 
of antisense and siRNA oligonucleotides. 
Bioconjug Chem, 23: 147-157.
23. Soifer HS, Koch T, Lai J, Hansen B, Hoeg A, 
Oerum H and Stein CA (2012) Silencing of 
gene expression by gymnotic delivery of 
antisense oligonucleotides. Methods Mol 
Biol, 815: 333-346.
24. Souleimanian N, Deleavey GF, Soifer H, 
Wang S, Tiemann K, Damha MJ and Stein CA 
(2012) Antisense 2’-Deoxy, 2’-Fluroarabino 
Nucleic Acids (2’F-ANAs) Oligonucleotides: 
In Vitro Gymnotic Silencers of Gene 
Expression Whose Potency Is Enhanced by 
Fatty Acids. Mol Ther Nucleic Acids, 1: e43.
25. Verhaart IE, Tanganyika-de Winter CL, 
Karnaoukh TG, Kolfschoten IG, de Kimpe SJ, 
van Deutekom JC and Aartsma-Rus A (2013) 
Dose-dependent pharmacokinetic profiles 
of 2’-O-methyl phosphorothioate antisense 
oligonucleotides in mdx mice. Nucleic Acid 
Ther, 23: 228-237.
26. Lu QL, Rabinowitz A, Chen YC, Yokota T, 
Yin H, Alter J, Jadoon A, Bou-Gharios G 
and Partridge T (2005) Systemic delivery 
of antisense oligoribonucleotide restores 
dystrophin expression in body-wide 
skeletal muscles. Proc Natl Acad Sci 
U S A, 102: 198-203.
27. Jirka SM et al. (2014) Peptide conjugation 
of 2’-O-methyl phosphorothioate antisense 
oligonucleotides enhances cardiac uptake 
and exon skipping in mdx mice. Nucleic Acid 
Ther, 24: 25-36.
28. Seznec H, Lia-Baldini AS, Duros C, Fouquet C, 
Lacroix C, Hofmann-Radvanyi H, Junien C and 
Gourdon G (2000) Transgenic mice carrying 
large human genomic sequences with 
expanded CTG repeat mimic closely the DM 
CTG repeat intergenerational and somatic 
instability. Hum Mol Genet, 9: 1185-1194.
29. Ye J, Coulouris G, Zaretskaya I, Cutcutache 
I, Rozen S and Madden TL (2012) Primer-
BLAST: A tool to design target-specific 
primers for polymerase chain reaction. BMC 
Bioinformatics, 13: 134.
30. Owczarzy R et al. (2008) IDT SciTools: 
a suite for analysis and design of nucleic acid 
oligomers. Nucleic Acids Res, 36: W163-W169.
31. Livak KJ and Schmittgen TD (2001) Analysis 
of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta 
Delta C(T)) Method. Methods, 25: 402-408.
32. Fardaei M, Rogers MT, Thorpe HM, Larkin 
K, Hamshere MG, Harper PS and Brook JD 
(2002) Three proteins, MBNL, MBLL and 
MBXL, co-localize in vivo with nuclear foci 
of expanded-repeat transcripts in DM1 and 
DM2 cells. Hum Mol Genet, 11: 805-814.
33. Boussif O, Lezoualc’h F, Zanta MA, Mergny 
MD, Scherman D, Demeneix B and Behr 
JP (1995) A versatile vector for gene and 
oligonucleotide transfer into cells in culture 
and in vivo: polyethylenimine. Proc Natl 
Acad Sci U S A, 92: 7297-7301.
34. Michihara A, Toda K, Kubo T, Fujiwara Y, 
Akasaki K and Tsuji H (2005) Disruptive effect 
of chloroquine on lysosomes in cultured rat 
hepatocytes. Biol Pharm Bull, 28: 947-951.
35. Mae M, El Andaloussi S, Lundin P, Oskolkov 
N, Johansson HJ, Guterstam P and Langel 
U (2009) A stearylated CPP for delivery of 
splice correcting oligonucleotides using 
a non-covalent co-incubation strategy. J 
Control Release, 134: 221-227.
36. Kirchhausen T, Macia E and Pelish HE 
(2008) Use of dynasore, the small molecule 
inhibitor of dynamin, in the regulation of 
endocytosis. Methods Enzymol, 438: 77-93.
37. Grant S (1998) Ara-C: cellular and molecular 
pharmacology. Adv Cancer Res, 72: 197-233.
38. Mastroyiannopoulos NP, Nicolaou P, 
Anayasa M, Uney JB and Phylactou LA 
(2012) Down-regulation of myogenin can 
reverse terminal muscle cell differentiation. 
PLoS One, 7: e29896.
39. Tomczak KK, Marinescu VD, Ramoni MF, 
Sanoudou D, Montanaro F, Han M, Kunkel 
LM, Kohane IS and Beggs AH (2004) 
Expression profiling and identification 
of novel genes involved in myogenic 
differentiation. FASEB J, 18: 403-405.
195
6
Free uptake of oligos in muscle cells in vitro
40. Sterrenburg E, Turk R, t Hoen PA, van 
Deutekom JC, Boer JM, van Ommen GJ 
and den Dunnen JT (2004) Large-scale 
gene expression analysis of human skeletal 
myoblast differentiation. Neuromuscul 
Disord, 14: 507-518.
41. Lev AA, Feener CC, Kunkel LM and Brown 
RH, Jr. (1987) Expression of the Duchenne’s 
muscular dystrophy gene in cultured 
muscle cells. J Biol Chem, 262: 15817-15820.
42. Lin C and Engbersen JF (2008) Effect of 
chemical functionalities in poly(amido 
amine)s for non-viral gene transfection. J 
Control Release, 132: 267-272.
43. Akinc A, Thomas M, Klibanov AM and Langer 
R (2005) Exploring polyethylenimine-
mediated DNA transfection and the proton 
sponge hypothesis. J Gene Med, 7: 657-663.
44. Bennett CF, Chiang MY, Chan H, Shoemaker 
JE and Mirabelli CK (1992) Cationic lipids 
enhance cellular uptake and activity of 
phosphorothioate antisense oligonucleotides. 
Mol Pharmacol, 41: 1023-1033.
45. Ming X, Sato K and Juliano RL (2011) 
Unconventional internalization mechanisms 
underlying functional delivery of antisense 
oligonucleotides via cationic lipoplexes and 
polyplexes. J Control Release, 153: 83-92.
46. Goemans NM et al. (2011) Systemic administration 
of PRO051 in Duchenne’s muscular dystrophy. N 
Engl J Med, 364: 1513-1522.
47. Tanganyika-de Winter CL, Heemskerk H, 
Karnaoukh TG, van Putten M, de Kimpe SJ, 
van Deutekom J and Aartsma-Rus A (2012) 
Long-term Exon Skipping Studies With 
2’-O-Methyl Phosphorothioate Antisense 
Oligonucleotides in Dystrophic Mouse 
Models. Mol Ther Nucleic Acids, 1: e44.
48. Dias N and Stein CA (2002) Antisense 
oligonucleotides: basic concepts and 
mechanisms. Mol Cancer Ther, 1: 347-355.
49. Allen DG and Whitehead NP (2011) Duchenne 
muscular dystrophy - What causes the increased 
membrane permeability in skeletal muscle? Int 
J Biochem Cell Biol, 43: 290-294.
50. Straub V, Rafael JA, Chamberlain JS and 
Campbell KP (1997) Animal models for 
muscular dystrophy show different patterns of 
sarcolemmal disruption. J Cell Biol, 139: 375-385.
51. Heemskerk H, de Winter C, van Kuik P, 
Heuvelmans N, Sabatelli P, Rimessi P, 
Braghetta P, van Ommen GJ, de Kimpe S, 
Ferlini A, Aartsma-Rus A and van Deutekom 
JC (2010) Preclinical PK and PD studies 
on 2’-O-methyl-phosphorothioate RNA 
antisense oligonucleotides in the mdx 
mouse model. Mol Ther, 18: 1210-1217.
52. Gonzalez-Barriga A, Kranzen J, Croes HJ, Bijl S, 
van den Broek WJ, van Kessel ID, van Engelen BG, 
van Deutekom JC, Wieringa B, Mulders SA and 
Wansink DG (2015) Cell membrane integrity 
in myotonic dystrophy type 1: implications for 
therapy. PLoS One, 10: e0121556.
53. Mohun T (1992) Muscle differentiation. Curr 
Opin Cell Biol, 4: 923-928.
54. Mulders SA, van Horssen R, Gerrits L, Bennink 
MB, Pluk H, de Boer-van Huizen RT, Croes HJ, 
Wijers M, van de Loo FA, Fransen J, Wieringa 
B and Wansink DG (2011) Abnormal 
actomyosin assembly in proliferating and 
differentiating myoblasts upon expression 
of a cytosolic DMPK isoform. Biochim 
Biophys Acta, 1813: 867-877.
55. Ming X (2011) Cellular delivery of siRNA and 
antisense oligonucleotides via receptor-
mediated endocytosis. Expert Opin Drug 
Deliv, 8: 435-449.
56. Zhao Q, Matson S, Herrera CJ, Fisher E, 
Yu H and Krieg AM (1993) Comparison of 
cellular binding and uptake of antisense 
phosphodiester, phosphorothioate, 
and mixed phosphorothioate and 
methylphosphonate oligonucleotides. 
Antisense Res Dev, 3: 53-66.
57. Koller E, Vincent TM, Chappell A, De 
S, Manoharan M and Bennett CF 
(2011) Mechanisms of single-stranded 
phosphorothioate modified antisense 
oligonucleotide accumulation in 
hepatocytes. Nucleic Acids Res, 39: 4795-4807.
58. Wojtkowiak-Szlachcic A, Taylor K, Stepniak-
Konieczna E, Sznajder LJ, Mykowska A, Sroka 
J, Thornton CA and Sobczak K (2015) Short 
antisense-locked nucleic acids (all-LNAs) correct 
alternative splicing abnormalities in myotonic 
dystrophy. Nucleic Acids Res, 43: 3318-3331.
59. Brown DA, Kang SH, Gryaznov SM, 
DeDionisio L, Heidenreich O, Sullivan 
196
6
Chapter 6
S, Xu X and Nerenberg MI (1994) Effect 
of phosphorothioate modification of 
oligodeoxynucleotides on specific protein 
binding. J Biol Chem, 269: 26801-26805.
60. Mislick KA and Baldeschwieler JD (1996) 
Evidence for the role of proteoglycans in 
cation-mediated gene transfer. Proc Natl 
Acad Sci U S A, 93: 12349-12354.
61. Liang XH, Sun H, Shen W and Crooke ST 
(2015) Identification and characterization of 
intracellular proteins that bind oligonucleotides 
with phosphorothioate linkages. Nucleic Acids 
Research, 43: 2927-2945.
62. Moulton HM and Moulton JD (2010) 
Morpholinos and their peptide conjugates: 
therapeutic promise and challenge for 
Duchenne muscular dystrophy. Biochim 
Biophys Acta, 1798: 2296-2303.
63. Leonetti JP, Mechti N, Degols G, Gagnor C 
and Lebleu B (1991) Intracellular distribution 
of microinjected antisense oligonucleotides. 
Proc Natl Acad Sci U S A, 88: 2702-2706.
64. Fisher TL, Terhorst T, Cao X and Wagner 
RW (1993) Intracellular disposition and 
metabolism of fluorescently-labeled 
unmodified and modified oligonucleotides 
microinjected into mammalian cells. Nucleic 
Acids Res, 21: 3857-3865.
65. Lorenz P, Baker BF, Bennett CF and Spector 
DL (1998) Phosphorothioate antisense 
oligonucleotides induce the formation of 
nuclear bodies. Mol Biol Cell, 9: 1007-1023.
66. Davis BM, McCurrach ME, Taneja KL, Singer 
RH and Housman DE (1997) Expansion 
of a CUG trinucleotide repeat in the 3’ 
untranslated region of myotonic dystrophy 
protein kinase transcripts results in nuclear 
retention of transcripts. Proc Natl Acad Sci 
U S A, 94: 7388-7393.
67. Aartsma-Rus A (2010) Antisense-mediated 
modulation of splicing: therapeutic 
implications for Duchenne muscular 
dystrophy. RNA Biol, 7: 453-461.
68. Godbey WT, Wu KK and Mikos AG 
(1999) Tracking the intracellular path 
of poly(ethylenimine)/DNA complexes 
for gene delivery. Proc Natl Acad Sci 
U S A, 96: 5177-5181.
197
6
Free uptake of oligos in muscle cells in vitro
 | S U P P L E M E N TA R Y  M AT E R I A L S
Table S1. Primers and TaqMan® assays used in this study.
Name Sequence (5’ -> 3’) or assay ID*
mDmd e22-e24 Fw ATCCAGCAGTCAGAAAGCAAA
mDmd e22-e24 Rv CAGCCATCCATTTCTGTAAGG
hDMPK e1-e2 Fw ACTGGCCCAGGACAAGTACG
hDMPK e1-e2 Rv CCTCCTTAAGCCTCACCACG
hDMPK e15 (5’) Fw AGAACTGTCTTCGACTCCGGG
hDMPK e15 (5’) Rv TCGGAGCGGTTGTGAACTG
hDMPK e15 (3’) Fw TGCCTGCTTACTCGGGAAATT
hDMPK e15 (3’) Rv GAGCAGCGCAAGTGAGGAG
mActb Fw GCTCTGGCTCCTAGCACCAT
mActb Rv GCCACCGATCCACACAGAGT
mGapdh Fw GTCGGTGTGAACGGATTTG
mGapdh Rv GAACATGTAGACCATGTAGTTG
mHprt1 Fw CCTAAGATGAGCGCAAGTTGAA
mHprt1 Rv CCACAGGACTAGAACACCTGCTAA
Myh1 (TaqMan) Mm01332489_m1*
Mylfp (TaqMan) Mm00443940_m1*
Cav3 (TaqMan) Mm01182632_m1*
Aqp1 (TaqMan) Mm01326466_m1*
*Assay ID according to Applied Biosystems (Thermo Fisher Scientific) denomination.
Primers for Gapdh were described earlier (Fu et al. (2007) J. Biomed. Mater. Res. A, 83, 770-778).
198
6
Chapter 6
Figure S1. Intracellular AON distribution changes in time after regular formaldehyde fixation. DM500 
myotubes grown in the presence of 500 nM Cy3-DMD23-OMePS for seven days were imaged live 
(compare Fig. 3) and at different time points following formaldehyde fixation, as indicated. Following 
fixation, AON signal progressively diffused into nuclei (e.g., arrowhead) when cells were kept in PBS. 
Scale bars indicate 20 µm. 
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Figure S2. Representative AON localization patterns after PEI-mediated transfection.DM500 
myoblasts were transfected using PEI with a mixture of Cy3- and FAM-conjugated CAG7-OMePS 
(each 200 nM) and imaged after two days. The image shows two cells with different uptake patterns. 
The upper one displays strong nuclear signal (traditionally considered positive for transfection), whereas 
the lower one presents only faint vesicular staining and essentially lacks nuclear signal (traditionally 
considered negative for transfection). Scale bars indicate 10 µm.
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Figure S3. No effect of the fluorophore position on gymnosis. (A) Localization of CAG7-OMePS, 
Cy3 conjugated at either its 5’ or 3’ end, after 48 hours of gymnosis or PEI transfection (500 nM) in 
DM500 EGFP-Mbnl1 myoblasts. Scale bars indicate 25 µm. (B) Quantification of expression of expanded 
DMPK transcripts after 48 hours of gymnosis with CAG7-OMePS Cy3-conjugated at either its 5’ or 3’ 
end (500 nM). Data was analyzed by 1-way ANOVA followed by a Bonferroni’s Multiple Comparison 
Test (***: p<0.001).
A
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Figure S4. Examples of cellular distribution patterns after gymnosis of Cy3-DMD23-OMePS. DM500 
myoblasts were imaged after 24 hours gymnosis incubation with Cy3-DMD23-OMePS (500 nM). 
A spotted distribution in the nucleus was observed in some cells (top row) and, less frequently, AON 
signal appeared diffuse throughout the nucleus (bottom row). Scale bars indicate 20 µm.
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Figure S5. Validation of Ara-C treatment.  (A) Scheme illustrating Ara-C treatment on day 3 to 5 of 
myogenic differentiation. (B) Representative images of cell cultures acquired at the end of the Ara-C 
incubation period and four days later. Scale bars indicate 50 µm. (C) Comparison of myogenic marker 
expression at day 10 of myogenesis (with/without Ara-C treatment). RNA from proliferating myoblasts 
was taken along as a control (n=6). Myh1, Mylfp and Cav3 expression was induced during myogenesis 
and was significantly enriched after Ara-C treatment. Aqp1 was mainly expressed in myoblasts, silenced 
during myogenesis and increasingly lost after Ara-C treatment. For each gene, mRNA levels of untreated 
and Ara-C-treated myotubes were compared by unpaired t-tests (***: p<0.001).
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Figure S6. Gymnosis of Cy3-CAG7-OMePS versus Cy3-CAG3-ENA. DM500 EGFP-Mbnl1 myoblasts 
were cultured for three days in the presence of Cy3-conjugated AONs (200 nM). The behaviour 
of Cy3-CAG7-OMePS (compare Fig. 1) was compared with that of Cy3-CAG3-ENA, a much shorter 
repeat AON carrying an ethylene-bridged nucleic acid phosphate backbone. (A) Confocal images 
showing intracellular localization of AONs (red). Cy3-CAG7-OMePS quickly accumulated in 
cytoplasmic vesicles. In contrast, Cy3-CAG3-ENA was poorly taken up. Scale bars indicate 20 µm. 
(B) Quantification of red fluorescence (n=3; 30 cells per experiment). Data was analyzed by 2-way 
ANOVA (**: p<0.01, ***: p<0.001).
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Figure S7. Representative images used for quantification of Cy3 signal in nucleus and cytoplasm (see 
Fig. 6). Images were acquired below saturation limits in the same microscopic session after treatment 
with the indicated AONs (A) during 48 hours of gymnosis or (B) PEI-mediated transfection. Merged 
images are a composite of Cy3 and EGFP channels. Scale bars indicate 50 µm.
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 | B A C K G R O U N D
Myotonic Dystrophy type 1 (DM1) is an archetypal member of the group of trinucleotide 
repeat disorders (TREDs), caused by an expansion of a repetitive DNA sequence of three 
nucleotides (Chapter 1 – Myotonic dystrophy). DM1 was the first disease ever described 
for which the underlying cause of the pathology involves an RNA gain-of-function (RNA 
toxicity) of transcripts coming from a mutated gene (DMPK) [1]. Evidence for RNA being 
at the center of disease etiology came, among others, from the finding that the mutation 
itself, an expanded (CTG)n repeat, is expressed as part of the 3’ untranslated region (3’-UTR) 
in DMPK mRNA transcripts. When swapped by transgenesis to another transcription 
unit, the repeat can exert its dominant toxic effects as part of other RNA products [2]. 
Production of expanded DMPK mRNA (or transgenic RNAs) with an expanded (CUG)n 
repeat leads to nuclear accumulation of the transcript and interferes in trans with normal 
splicing, polyadenylation and other aspects of RNA processing in all cells of the organism in 
which the repeat-containing RNA is expressed [3]. Based on this knowledge, there is clear 
consensus in the DM1 field that the most promising therapeutic interventions should focus 
on neutralizing the RNA toxicity seen in DM1 patients [4]. Many different strategies are being 
developed, each trying to reduce the load of expanded DMPK mRNA. From the biological 
toolbox available for modulation of gene expression, several approaches have been tested, 
including the use of RNAi [5,6], ribozymes [7-9] and antisense oligonucleotides (AONs) 
[10-14]. The research described in this Ph.D. thesis is devoted to study AONs of triplet-repeat 
sequence, complementary to the (CUG)n stretch, as a therapeutic platform for DM1.
 | T R I P L E T - R E P E AT  A O N s  F O R  T H E  R E D U C T I O N  
O F  E X PA N D E D  D M P K  T R A N S C R I P T S
In antisense technology, chemical modifications in the ribose and/or phosphate backbone 
of the nucleotide sequence are necessary to confer resistance against nucleases, improve 
pharmacokinetics and enhance binding activity to the target [15] (Chapter 1 – Antisense 
oligonucleotides). We performed extensive pre-clinical studies in vitro on AONs of different 
length, sequence and chemical composition in myoblast-myotube cell models derived from 
patients and from a DM1 mouse model with a human DMPK (CTG)500 transgene (Chapter 2). 
First, we confirmed the positive aspects of the phosphorothioate (PS) modification to confer 
stability, since AONs without this type of chemistry showed lower activity. For instance, an AON 
with 2’-O-methyl (2’-OMe) modified riboses, a chemistry aimed to enhance binding affinity 
to the target, was much less effective without the PS backbone. In our hands, combining 
PS linkages with 2’-OMe riboses (2’-OMe PS) resulted in the most effective strategy, as 
compared to AONs with other chemical modifications like morpholino phosphorodiamidate 
(PMO) or 2’-O,4’-C-ethylene-bridged nucleic acid (ENA) and to RNAi-mediated knockdown 
by triplet-repeat siRNAs. We also found that a minimal AON length of five CAG triplets is 
required to achieve efficient silencing when using 2’-OMe PS chemistry. Furthermore, 
we performed several experiments with an oligo of (CIG)7 sequence (with inosines 
instead of adenines). We were interested in this AON because it can hybridize to 
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(CUG)n, (CAG)n, (CCG)n repeats or any combination of these triplets, making it an 
 attractive candidate for its potential ability to treat multiple TREDs, e.g. DM1, Huntington’s 
disease and several spinocerebellar ataxias. However, and perhaps not completely 
unexpectedly, this AON also affected the expression of the endogenous Dmpk transcript, 
containing a CCG(CUG)2(CAG)2CUG sequence. 
As a preclinical step to evaluate AON safety profile, we performed analysis of complement 
activation in vitro for some of them. We have to consider though, that the predictive value 
of this test is limited and possible immune responses have to be verified always in vivo. 
Since methylation of cytosines has been reported to improve the in vivo safety profile of 
AONs with PS chemistry [16], we used this modification in some of our experiments as well, 
and found that AONs with the 5-methyl C modification retained equal activity (Chapter 4 
and data not shown). All AONs tested in the complement activation assay did not show 
significant immune stimulation properties except for (CIG)7.
We gained ample evidence during the course of our in vitro experiments that 
the 2’-OMe PS (CAG)7 AON, binds to the (CUG)n repeat of DMPK transcripts and induce 
a potent and selective silencing of products from the mutant allele (with or without 
5-methylcytosines in the oligo). Furthermore, activity of this type of AON in vivo has been 
observed in multiple studies with different DM1 mouse models, both after intramuscular 
injection [11] and systemic administration (Mulders et al., unpublished data). The downstream 
therapeutic potential has been confirmed by observing that a modest reduction of expanded 
DMPK transcripts is already sufficient to partially reverse a characteristic gene expression 
pattern observed in DM1 cells towards normal levels (Chapter 4). Although we do not know 
the mechanism behind the observed silencing, the activity of these AONs correlates with 
the length of the target repeat, being more active against long repeats of >100 triplets 
(Chapter 2) and virtually inactive against normal repeats in DMPK mRNA (usually less than 
15-25 triplets) or (CUG)n repeats in transcripts from other genes (typically less than ~12) 
(Chapter 4). Since repeat length in DM1 also correlates with expected toxicity, we consider 
this an elegant approach, because careful design of AON chemistry and length can be 
applied to avoid affecting the expression of normal DMPK mRNA and proteins.
In contrast, we showed that (CAG)n AONs with RNase H activity affect expression of 
products from both normal and expanded alleles (Chapter 2), reducing also DMPK protein 
levels. This strategy can thus lead to complete DMPK knock-down, where symptoms 
associated with DMPK haploinsufficiency could be aggravated. Moreover, RNase H-recruiting 
AONs also affected expression of other transcripts with shorter (CUG)n repeats, something 
that could lead to detrimental adverse effects, which are difficult to predict. Interestingly 
though, clinical trials to evaluate safety, tolerability and efficacy of IONIS-DMPKRx, a gapmer 
AON with 2’-O-methoxyethyl and constrained-ethyl wings, are currently ongoing. This 
compound binds to DMPK transcripts outside the repeat (in theory with equal selectivity 
to both allele products) and makes use of the RNase H mechanism to degrade them. Since 
this strategy may further reduce the total amount of DMPK protein in cells of DM1 patients, 
some concerns have been raised regarding the putative detrimental effects of DMPK loss. 
DMPK insufficiency has been attributed as a possible cause of cardiac conduction defects 
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in a mouse model for DM1 [17], however, these effects could not be replicated in a recent 
study that analyzed the conduction system of Dmpk-/- mice or used AON-mediated 
DMPK knockdown in a DM1 mouse model [18]. Furthermore, cardiac complications could 
equally well arise from splicing abnormalities caused by MBNL1 sequestration in expanded 
(CUG)n repeats [19], so be mechanistically non-related to DMPK haploinsufficiency. 
Nevertheless, relevant effects of DMPK protein loss in other pathobiological manifestations 
in DM1 should not be dismissed as this protein has been associated with important roles, 
like Ca2+ modulation in the initial events of excitation-contraction coupling [20], actomyosin 
assembly [21], nuclear envelop integrity [22], prevention of ROS-induced cell death [23] and 
myoblast differentiation [24]. In this respect, results from the ongoing clinical trials with 
IONIS-DMPKRx can be expected to shed new light on these questions.
 | I N V E S T I G AT I N G  A O N - M E D I AT E D  D M P K  R N A  S I L E N C I N G 
M E C H A N I S M S
The silencing mechanism of 2’-OMe PS (CAG)n AONs towards expanded DMPK transcripts 
has remained elusive despite extensive efforts during the studies for this Ph.D. thesis. We 
consider it unlikely that direct effects on transcription of the mutant DMPK transcripts are 
mechanistically involved. Treatment with a (CAG)7 AON resulted in a significant reduction 
of expanded DMPK transcripts already within minutes after transfection (data not shown). 
Since the average half-life of DMPK mRNA is relatively long [25], inhibition of the already 
very low de novo production of DMPK (pre-)mRNA [26] cannot explain immediate effects of 
this AON. Silencing effects by the AON on the steady state levels of DMPK transcripts must 
therefore have another, but as yet unknown, basis. We explored the most common silencing 
mechanisms encountered in antisense technology: ribozyme activity, RNase H-mediated 
knock-down and RNA interference, but found that none of them is directly implicated in 
the mechanism (Chapter 2). We currently think that AON-induced degradation of the triplet 
repeat RNA must be mediated by endogenous nucleases present in the cell (similarly to 
RNase H) or by a yet to be identified mRNA decay pathway. This may happen in the nucleus or 
the cytosol because, although expanded DMPK mRNA is retained in the former compartment 
[27], hybridization with (CAG)n AONs may help to export the transcripts by disruption of 
ribonuclear foci, as has been postulated by others [10].
There is ample evidence that AONs can bind proteins in the cell or upon hybridization to 
the RNA target [28,29]. This binding is typically dependent on their chemical modifications 
and the nature of the target itself [29,30]. Proteins recruited by (CAG)n AONs upon binding 
to the (CUG)n repeat could thus give very important clues about the silencing mechanism. 
In our pull-down experiments using a biotinylated DMPK mRNA fragment (Chapter 3), we 
demonstrated that (CAG)7 AON was able to recruit proteins related to RNA processes, which 
could have implications for the biological fate of expanded DMPK transcripts. Importantly, 
many of these proteins interacted specifically with the AON-RNA duplex formed upon 
hybridization of the oligo with the (CUG)n repeat.  Ribonucleases and proteins from the DDX 
family of RNA helicases were significantly enriched in the group of candidate proteins. 
Potentially, these enzymes could play a role in the silencing mechanism observed after 
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(CAG)7 treatment. We tested in vitro the implications of one of the nucleases identified, 
FEN1, but failed to detect any RNA degradation products when used in combination with 
the oligo.
However, many other candidates enriched in the AON-RNA duplex remain to be tested 
for their possible implication in the mechanism. For instance, several factors listed in Chapter 
3 are involved in (pre-)mRNA processing, like splicing regulation, and could potentially play 
a role. Alternatively, we should also consider the possibility that the key protein involved in 
the mechanism escaped our pull-down assay, either because the right cellular conditions 
necessary for binding were not recapitulated or perhaps because the interaction of this 
protein with the AON-RNA duplex is very transient in nature. For instance, some candidates 
that we would like to propose to explore in future experiments, but were missed in our 
interactor search, are several ribonucleases involved in maturation of RNA precursors, like 
ribosomal RNA (RNase III), tRNA (RNase P) or miRNA (Drosha). These enzymes recognize and 
cleave certain RNA heteroduplex structures [31,32]. In fact, targeted mRNA knock-down 
with RNase P is a strategy that has been used in the past [33], usually requiring a so-called 
external guide sequence [34], which in our case could be represented by the AON. Perhaps, 
the (CUG)n hairpin formed by expanded DMPK transcripts in combination with (CAG)7 
hybridization generates a type of structure that can be recognized and processed by this 
class of enzymes. A mechanism like this (recognizing the structure rather than the sequence) 
would also explain the selectivity towards products of the expanded allele, since 
short (CUG)n repeats have lower tendency to form higher magnitude secondary 
structures [35,36].
The unexpected finding that (CAG)n AONs can induce exon skipping of transcripts that 
contain a (CUG)n tract in an internal exon (as in MAP3K4) (Chapter 2) points to the possibility 
that this type of repeats can work as splicing regulators. In fact, using an in silico analysis, 
a (CUG)n sequence is predicted to bind splicing factors SRSF2 and SRSF6 (data not shown), 
usually present in exonic splicing enhancers during pre-mRNA processing. Interestingly, 
SRSF6 is also predicted to bind (CAG)n repeats, where a direct role in the regulation of 
splicing has been demonstrated [37]. We can speculate then, that AON-induced skipping 
of MAP3K4 exon 17 was mediated by displacement of these factors from the trinucleotide 
repeat. The resulting exon17- variant of MAP3K4 retains the normal reading frame. However, 
a similar approach can be used to trigger nonsense-mediated decay (NMD) when the skipped 
exon generates an out-of-frame transcript [38]. But in the case of DMPK, we could not find 
any evidence of splicing in the area of the repeat (Chapter 2). Moreover, since the repeat is 
located in the last exon, even if a cryptic splice site was used, NMD would not be activated 
because it requires a newly generated stop codon upstream of the last exon junction [39].
 As a relevant example, we have a comparable situation with the HTT gene, where there is 
a (CAG)n repeat in exon 1 that, similarly to DM1, becomes pathogenic (causing Huntington’s 
disease) when expanded above certain threshold. In this case, (CUG)n AONs have been 
used to silence the transcript [40], but also in this study the authors could not unravel 
the mechanism by which silencing occurred. The mechanisms of DMPK and HTT silencing by 
triplet repeat AONs may thus share common characteristics and it is tempting to speculate 
that factors like SRSF2 or SRSF6 could have an important function (other than splicing 
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regulation) when binding to nucleotide motifs in the first or the last exon of a transcript. If 
true, displacement of these factors may lead to a yet-to-identify mRNA decay mechanism. 
This could be an interesting possibility to study in the future. There is clearly much work to 
be done to elucidate the mechanism of DMPK or HTT silencing by (CXG)n AONs.
 | D E L I V E R Y  A N D  C E L LU L A R  U P TA K E  O F  A O N s
Another aspect that could improve AON-mediated treatment of DM1 is the cellular uptake 
of these molecules in the relevant tissues of the patient. This is one of the parameters that 
may influence treatment success in antisense technology for many diseases [41]. Improving 
uptake may be challenging due to the fact that AONs are hydrophilic molecules of relatively 
high molecular weight (generally >7 kDa) [42]. They are most frequently administered 
systemically in vivo, by subcutaneous or intravenous routes [43]. Nevertheless, AONs with PS 
backbone have improved pharmacokinetics characteristics compared to their PO analogs or 
uncharged AONs, which are rapidly excreted from the body [44,45]. This advantage is due to 
PS binding to serum proteins, something that delays the process of glomerular filtration in 
the kidneys, resulting in improved tissue biodistribution and availability [46].
For animal models of DM1, it has been reported that AON treatment of muscle tissue can 
be relatively efficient in vivo, which is associated with a favourable pharmacodynamic profile 
when systemically administered ([14], Mulders et al. unpublished data). These observations 
triggered our own study of DM1 membrane permeability (Chapter 5), since we speculated 
that AON activity in vivo could be due to an abnormal leakiness of muscle fibers, as has been 
demonstrated in other muscular disorders, like Duchenne muscular dystrophy [47], where 
lack of dystrophin protein causes loss of muscle membrane integrity [48].
In congenital DM1 patients (the most severe form of DM1) DMD’s exon 78 is aberrantly 
skipped in ~50% of the transcripts as part of the downstream splicing effects of (CUG)n RNA 
toxicity [49]. Expression of abnormal DMD could thus affect membrane integrity, however, 
this remained a speculative possibility as the effect on muscle function of aberrantly spliced 
DMD exon 78 had not been elucidated until recently. Our analyses described in Chapter 
5 showed that DMD expression levels were normal in DM1 patients and mouse models, 
compared to levels in unaffected individuals and controls. DMD localization in the plasma 
membrane appeared also completely normal, arguing for a fully functional barrier function 
of the cell membrane, indistinguishable from controls. Our findings were confirmed in 
a recent study [50], where other aspects of muscle function were also explored. In a mouse 
model expressing DMD without exon 78 (lacking the WT DMD gene), the authors observed 
reduced muscle force, fiber type switch, ringed fibers, sarcoplasmic masses and Z-band 
disorganization. Although some of these features are also present in DM1 patients, it is in 
our opinion highly debatable whether this is due to DMD skipping, because DM1 patients 
still have ~50% of normal DMD expression, and there are other factors of mRNA toxicity 
that may contribute to these alterations as well. In any case, in neither of the studies signs 
of muscle leakiness were observed. We confirmed this by studying more robust parameters 
of membrane permeability, which were negative in all cases (Chapter 5). Taking all this 
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together, we concluded that DM1 membrane characteristics are undistinguishable from 
healthy individuals, both in DM1 mouse models and in patients.
Then, if muscle membranes in DM1 patients are impermeable to large molecules, how 
could AONs overcome this barrier in the studies that showed efficacy in vivo? We think that 
we can answer this question based on the mechanisms that myotubes use to internalize 
AONs in vitro (Chapter 6). When AONs are freely present in the culture medium, cells can 
actively incorporate them by endocytosis (i.e. by gymnosis, without assisted delivery), 
accumulating these molecules in vesicles that eventually reach the lysosomal compartment. 
According to our microscopic observations, AON nuclear levels via this pathway are expected 
to be low, yet we could clearly demonstrate AON activity on nuclear targets, indicating that 
the required concentration for biological activity may be lower than generally thought. 
We thus hypothesize that a similar mechanism of AON uptake must take place in vivo. As 
mentioned above, once in the circulation, AONs with PS chemistry bind proteins that delay 
renal filtration thus increasing their half-life in serum [46]. Since transport of plasma proteins 
to the subjacent tissues is mediated by transcytosis across endothelial cells [51], AONs bound 
to them could be passively transferred to the muscle interstitium by this process. Next, we 
propose that AONs will be internalized in muscle myofibers by endocytosis [52], following 
the same mechanism we observed in cultured myotubes (Chapter 6). A small percentage of 
AONs in the endosomes has been proposed to escape by unknown reasons, which could 
be related to membrane bilayer instability during vesicle fusion and budding [53]. Since 
we demonstrated that a low AON concentration in the nucleus is sufficient for effective 
silencing, the described process could explain the activity of systemically administered 
AONs in the previously cited in vivo studies.
From our experiments performed with free AON uptake by cells in culture, we can clearly 
point to endosomal entrapment as an important drawback to further improve efficacy, 
because exposure of AONs to the RNA target, located in either nucleus or cytosol, will be 
limited by this phenomenon. Thus, strategies aimed to facilitate endosomal escape could 
increase dramatically the therapeutic potential of AONs. We showed that chloroquine, a drug 
with well-known lysosomotropic properties [54], can be used to release AONs trapped in 
lysosomes. This release results in a substantially improved nuclear localization and AON 
activity. Future studies about the use of lysosomotropic compounds like chloroquine in 
combination with AONs in vivo are of especial interest. Alternatively, other possible strategy 
would be the combination (or conjugation) of AONs with molecules or protein domains 
known to facilitate endosomal escape, like those used naturally by certain microorganisms 
and toxins [55-58].
 | F I N A L  C O N C LU S I O N S
In summary, the research described in my thesis deals with multiple aspects of antisense 
technology which are important to develop AONs as therapeutic agents, with special 
dedication to key issues like cellular uptake, interaction with proteins or downstream effects 
in the transcriptome. We focused on the use of AONs as a therapeutic platform for DM1 and, 
in particular, explored how triplet repeat AONs can be used to silence DMPK transcripts with 
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expanded repeats. We opened the path to unravel the underlying mechanism of this process 
by searching for interacting proteins with a possible role in known or novel pathways, 
something that could be important to understand and improve this silencing strategy in 
the future, not only for DM1, but potentially also for other TREDs. In addition, by observing 
the whole-transcriptome consequences of reducing toxic DMPK transcripts, we expanded 
our knowledge about DM1 molecular mechanisms and the expression profile involved.
During our research, we have investigated multiple AON chemical modifications, 
sequences and targets. As such, many of the findings disclosed here shall be relevant 
for antisense technology as a therapeutic platform in general. This could be particularly 
important in regard to mechanisms of cellular uptake and intracellular trafficking, since they 
appear to be driven mostly by nucleotide chemistry rather than by sequence. Hopefully, 
my thesis shall be of future value for other studies using AONs, particularly those designed 
to target expanded trinucleotide repeats in human disease, and be a humble contribution 
to the efforts of the scientific community in finding a cure for patients suffering from 
these disorders.
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Myotonic Dystrophy type 1 (abbreviated DM1, for its Latin name dystrophia myotonica) is 
a genetic multisystem disorder caused by an expansion of a repetitive trinucleotide sequence 
(CTG•CAG)n in the 3’ untranslated region of the DMPK gene on chromosome 19. DM1 was 
the first disease ever described for which the underlying cause of the pathology involves an 
RNA gain-of-function of transcripts coming from a mutated gene. This repeat in the DMPK 
gene is actually carried by all individuals, but normally contains less than 37 triplets. When 
the repeat is expanded above this threshold, from one generation to the next, the person 
carrying it will develop DM1, with an age of onset and severity that loosely correlates with 
(CTG)n length: the longer the repeat, the sooner symptoms occur and the more severe 
they are.
Some of the adverse effects of the mutation are known to be independent of the DMPK 
gene context, as they also occur when the expanded repeat is artificially inserted in other 
genes. After transcription, expanded (CUG)n repeats form stable RNA hairpin structures that 
are retained in the cell nucleus, where they contribute to large inclusions, so called foci, by 
abnormal binding of ribonuclear proteins, some of which get sequestered and depleted (e.g. 
MBNL). Stress responses triggered by the expanded RNA lead to activation of some factors 
(e.g. CELF1) and inactivation of others (e.g. eiF2A), resulting in loss of cellular homeostasis 
(ribostasis and proteostasis). The most extensively studied factors, MBNL and CELF1, 
are antagonistic regulators of splicing and their imbalance leads to a pre-mRNA splicing 
pattern characteristic for embryonic development that is not normally present in adults. 
This aberrant splicing pattern leads to several downstream alterations in isoform expression 
that are responsible for a number of DM1 symptoms. For example, myotonia (delayed 
relaxation of the muscle after contraction, the most prominent symptom of DM1) is caused 
by the presence of the embryonic isoform of a protein (CLCN1) responsible for regulating 
the electric excitability of muscle membranes. In addition, other mechanisms likely play 
a role in DM1 pathogenesis. An extensive explanation of the fundamental aspects of DM1 
(including epidemiology, symptoms, genetics and additional pathomechanisms) is given in 
Chapter 1 –  Introduction to myotonic dystrophy.
There is general consent among experts that removing the load of expanded DMPK 
transcripts and/or avoiding its interaction with ribonuclear proteins would be beneficial 
for patients. Several studies tried to achieve this goal using different strategies, including 
treatment with ribozymes, siRNAs, small molecules and antisense oligonucleotides (AONs). 
During my research, I focused on the use of AONs as a potential therapy for DM1, particularly 
those directed against the expanded (CUG)n repeat itself, the root cause of the disease. 
AONs are single-stranded, short nucleotide sequences complementary to RNA or DNA 
targets in the cell. They are usually chemically modified to improve their stability, binding 
affinity and pharmacokinetics (necessary aspects for their use as therapeutic agents). In 
most cases, the phosphate groups linking nucleosides are substituted by phosphorothioates 
(PS) and other modifications are included in the ribose. For a detailed explanation of these 
chemical modifications and the development of AONs as a therapeutic platform see 
Chapter 1 –  Introduction to antisense oligonucleotides.
T H E S I S  S U M M A R Y  I N  E N G L I S H
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Previous work in our lab identified PS58, an AON of (CAG)7 sequence and 2’O-Methyl 
(2’-OMe) PS chemistry, which efficiently silenced expression of expanded DMPK transcripts by 
an unknown mechanism in cells derived from DM1 patients and mouse models. We continued 
this work by performing pre-clinical in vitro studies with (CAG)n AONs of different length, 
sequence and chemical composition. This part is covered in Chapter 2. The combination 
of a PS backbone with 2’-OMe riboses resulted in the most effective strategy, as compared 
to AONs with other chemical modifications, like morpholino phosphorodiamidate (PMO) 
or 2’-O,4’-C-ethylene-bridged nucleic acid (ENA). We also found that a minimal AON length 
of five CAG triplets is required to achieve efficient silencing with 2’-OMe PS AONs. Perhaps 
the most important finding was that this type of AON preferentially binds expanded repeats, 
allowing normal expression of non-expanded DMPK mRNA and other transcripts with shorter 
repeats. In contrast, RNase H-mediated knockdown led to the silencing of transcripts with 
repeats of normal size as well, lowering the amount of DMPK proteins in the cell.
In Chapter 2 we also describe several experiments aimed at elucidating the mechanism 
of action of (CAG)n AONs. Several possibilities were explored: transcription blockage, 
AON ribozyme activity, RNase H-mediated silencing and RNA interference (Chapter 2 and 
appendix), but found that none of them are directly implicated. We then speculated that 
expanded DMPK mRNA knockdown could be mediated by a novel pathway. Chapter 3 
describes how we explored this possibility using a pull-down assay with a synthetic DMPK 
mRNA fragment containing 90 CUG triplets. The RNA was biotinylated and incubated with 
myoblast proteins and (CAG)7 AON, and then used as bait to pull-down and identify proteins 
that interact specifically with the AON-RNA duplex by means of streptavidin-coated beads. 
We found several proteins that may be involved in the mechanism responsible for expanded 
DMPK degradation, like RNA helicases or ribonucleases, but have yet not confirmed their 
direct involvement.
In order to assess the effect of (CAG)7 AON treatment on the transcriptome in general, 
and the effect of reducing expanded DMPK transcripts, we performed gene expression 
profiling of muscle cells from DM1 patients and unaffected controls. These experiments 
are described in Chapter 4. Cells were treated with (CAG)7 AON before and after terminal 
differentiation to myotubes and analyzed by RNA-Seq and SAGE. The data confirmed that 
no overt side effects in the transcriptome are to be expected from (CAG)7 AON transfection, 
compared to a control AON with scrambled sequence. In turn, (CAG)7 treatment partially 
reversed the DM1 expression pattern to that observed in unaffected controls. Of note, this 
reversal was observed without the expected correction of several characteristic DM1 splicing 
abnormalities, something that could contribute to a different understanding of the events 
leading to DM1 pathology.
We then turned to one of the most important aspects of any AON-mediated therapy: 
efficient delivery. Our first question was whether the cell membranes of muscle myofibers 
in DM1 patients are permeable to large molecules. Dystrophin splicing has been reported 
to be affected in DM1, and defects in this protein are associated with loss of membrane 
integrity in other muscular disorders. Chapter 5 describes the evaluation of cell membrane 
integrity and dystrophin expression and localization in a number of muscle samples from 
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DM1 mouse models and patients, which did not reveal any abnormalities. Moreover, no 
increased permeability to large molecules was detected in mice in vivo.
Since a therapy with AONs would benefit from improved delivery strategies, we looked 
at the way myoblasts and myotubes take up AONs in vitro (Chapter 6). We tested AONs 
with different chemical modifications and found, as reported in previous studies, that 
free uptake is mediated by endocytosis and requires a PS backbone. In the past, efficient 
uptake of AONs was only considered possible in proliferating cells but, interestingly, we 
discovered that this also occurs in (non-proliferating) myotubes. We observed AON activity 
against targets in the nucleus, suggesting that at least part of the molecules escape from 
endosomes/lysosomes. Importantly, we showed that AON escape from these vesicles can 
be pharmacologically enhanced, leading to a remarkable increase in nuclear localization 
and activity.
Finally, an overview of our findings is presented and discussed in Chapter 7. In summary, 
the research performed for this Ph.D. thesis focused on the use of AONs as a therapeutic 
platform for DM1 and, in particular, explored how triplet-repeat AONs can be used to silence 
toxic DMPK transcripts with expanded repeats. This study also opened up the path to unravel 
the mechanism behind expanded DMPK silencing by identifying proteins that interact with 
the RNA-AON duplex and may be involved in DM1 pathology, something that could be of 
future value to better understand and improve this therapeutic strategy. Our findings will 
also help to improve AON-mediated therapies in other disorders, like those caused by similar 
trinucleotide expansions, or by improving AON delivery in muscular disorders in general.
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Myotone dystrofie type 1 (afgekort DM1, vanwege de Latijnse naam dystrophia myotonica) 
is een genetische multisysteemaandoening die veroorzaakt wordt door een verlenging 
van een zich herhalende trinucleotidevolgorde (CTG)n in het 3’ onvertaalde gebied van 
het DMPK-gen op chromosoom 19. DM1 was de eerste ziekte waarvan bekend werd dat de 
onderliggende oorzaak van de pathologie een RNA ‘gain-of-function’ betrof van transcripten 
afkomstig van een gemuteerd gen. De herhaling in het DMPK-gen is aanwezig in alle mensen, 
maar is normaal gesproken korter dan 37 tripletten. Wanneer de herhaling deze drempel 
overschrijdt, van de ene generatie naar de volgende, zal een persoon DM1 ontwikkelen, met 
een aanvangsleeftijd en ernst die min of meer correleert met de (CTG)n-lengte: hoe langer 
de herhaling, hoe eerder de symptomen optreden en hoe ernstiger ze zijn.
Sommige van de negatieve effecten van de mutatie zijn onafhankelijk van 
de DMPK-gencontext, aangezien deze ook optreden wanneer de geëxpandeerde herhaling 
kunstmatig in andere genen geïntroduceerd wordt. Na transcriptie vormen de geëxpandeerde 
(CUG)n-herhalingen stabiele RNA-haarspeldstructuren die ophopen in de celkern. Daar 
vormen ze inclusies, zogenaamde foci, door abnormale binding aan ribonucleaire eiwitten 
(bv. MBNL), waardoor de effectieve concentratie van deze factoren elders in de cel wordt 
verlaagd. Stressreacties veroorzaakt door het geëxpandeerde RNA leiden tot de activatie 
van een aantal factoren (bv. CELF1) en de inactivering van andere (bv. eiF2A), wat resulteert 
in het verlies van cellulaire homeostase (zowel ribostase als proteostase).
De meest intensief onderzochte factoren, MBNL en CELF1, zijn antagonistische regulatoren 
van het splicingproces en hun onbalans leidt tot een pre-mRNA-splicingpatroon kenmerkend 
voor de embryonale ontwikkeling, dat normaal gesproken niet aanwezig is in volwassenen. 
Dit afwijkende splicingpatroon leidt tot veranderingen in isovormexpressie van eiwitten 
die verantwoordelijk zijn voor een aantal DM1-symptomen. Zo wordt myotonie (vertraagde 
relaxatie van de spier na contractie, tevens het hoofdsymptoom van DM1) veroorzaakt door 
de aanwezigheid van de embryonale isovorm van een eiwit (CLCN1) dat verantwoordelijk 
is voor het reguleren van de elektrische prikkelbaarheid van de spiermembranen. Naast 
veranderingen in splicing spelen andere mechanismen waarschijnlijk ook een rol in de 
pathogenese van DM1. Een uitgebreide uitleg over de fundamentele aspecten van DM1 
(inclusief de epidemiologie, symptomen, genetica en aanvullende pathomechanismen) is 
terug te vinden in Hoofdstuk 1 - Myotone dystrofie.
Deskundigen zijn het erover eens dat het verwijderen van de geëxpandeerde 
DMPK-transcripten en/of het voorkomen van de interactie met ribonucleare eiwitten 
gunstig voor de patiënt zou zijn. Verschillende studies hebben geprobeerd om dit te 
bewerkstelligen met verschillende strategieën, waaronder behandeling met ribozymen, 
siRNA, ‘small molecules’ en antisense oligonucleotiden (AONs). Tijdens mijn onderzoek 
lag mijn focus op het gebruik van AONs als een potentiële therapie voor DM1, met 
name gericht op de oorzaak van de ziekte: de geëxpandeerde (CUG)n-herhaling. AONs 
zijn korte enkelstrengs nucleotidesequenties die complementair zijn aan de beoogde 
RNA- of DNA-strengen in de cel. Ze zijn meestal chemisch gemodificeerd om hun 
stabiliteit, bindingsaffiniteit en farmacokinetiek te verbeteren (noodzakelijke aspecten 
N E D E R L A N D S E  S A M E N VAT T I N G
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voor het gebruik van AONs als therapeutische middelen). In de meeste gevallen worden 
de fosfaatgroepen die de nucleosiden aan elkaar koppelen vervangen door fosforothioaten 
en worden er tevens andere modificaties aan ribosegroepen aangebracht. Voor 
een gedetailleerde uitleg van deze chemische modificaties en de ontwikkeling van AONs als 
een therapeutisch platform zie Hoofdstuk 1 - Antisense-oligonucleotiden.
Eerder werk in ons lab heeft aangetoond dat PS58, een AON met een (CAG)7 volgorde 
en 2’O-methyl (2’-OMe)-fosforothioaatsamenstelling, op efficiënte wijze de expressie van 
geëxpandeerde DMPK transcripten voorkomt in cellen afkomstig van DM1-patiënten 
en muismodellen, door een onbekend mechanisme. We hebben dit werk voortgezet 
door het uitvoeren van preklinische in vitro studies met (CAG)n-AONs van verschillende 
lengte, volgorde en chemische samenstelling. Dit onderwerp wordt behandeld in 
Hoofdstuk 2. De combinatie van een fosforothioaatruggegraat met 2’-OMe-riboses 
resulteerde in de meest effectieve strategie, vergeleken met AONs met andere chemische 
modificaties, zoals morfolinofosfordiamidaat of 2’-O,4’-C-ethyleen-gebrugd nucleïnezuur 
(ENA). We vonden ook dat een minimale AON-lengte van vijf CAG tripletten vereist is 
voor efficiënte transcriptonderdrukking met 2’-OMe-fosforothioaat AONs. Misschien wel 
de belangrijkste bevinding was dat deze vorm van AON bij voorkeur bindt aan 
geëxpandeerde herhalingen, waardoor de expressie van niet-geëxpandeerd 
DMPK mRNA en andere transcripten met kortere herhalingen niet of nauwelijks 
gehinderd wordt. Een RNase H-gemedieerde aanpak leidde daarentegen wel tot 
de onderdrukking van transcripten met (CUG)n-herhalingen van normale grootte en 
verminderde zo de hoeveelheid DMPK eiwit in de cel.
In Hoofdstuk 2 beschrijven we tevens verschillende experimenten met als doel het 
ophelderen van het werkingsmechanisme van (CAG)n AONs. Verschillende mogelijkheden 
werden verkend: transcriptieblokkade, AON-ribozyme-activiteit, RNase H-gemedieerde 
onderdrukking en RNA-interferentie (Hoofdstuk 2 en bijlage), maar geen van alle bleek 
rechtstreeks betrokken te zijn. Vervolgens hebben we gespeculeerd dat de afbraak 
van geëxpandeerd DMPK mRNA zou kunnen worden gemedieerd door een tot dan 
toe onbekende route. Hoofdstuk 3 beschrijft hoe we deze mogelijkheid onderzocht 
hebben met behulp van een zogenaamd pull-down experiment met een synthetisch 
DMPK-mRNA-fragment dat 90 CUG tripletten bevat. Het RNA werd gebiotinyleerd en 
geïncubeerd met myoblasteiwitten en (CAG)7-AON en vervolgens gebruikt als aas voor het 
identificeren van eiwitten die specifiek binden aan de AON-RNA-duplex met behulp van 
streptavidine gecoate bolletjes. We hebben een aantal eiwitten gevonden die betrokken 
zouden kunnen zijn bij het mechanisme dat verantwoordelijk is voor de degradatie van 
geëxpandeerd DMPK, zoals RNA-helicasen of ribonucleasen, maar hebben hun directe 
betrokkenheid nog niet bevestigd.
Om het effect van (CAG)7-AON-behandeling op het transcriptoom in het algemeen 
en op de vermindering van geëxpandeerde DMPK transcripten te evalueren, hebben we 
genexpressieprofilering uitgevoerd op spiercellen van DM1-patiënten en gezonde controles. 
Deze experimenten zijn beschreven in Hoofdstuk 4. De cellen werden voor en na terminale 
differentiatie tot spiervezels in kweek behandeld met (CAG)7-AON en geanalyseerd met 
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RNA-Seq en SAGE. De gegevens bevestigden dat er geen substantiële bijwerkingen 
van (CAG)7-AON-transfectie op het transcriptoom te verwachten zijn, vergeleken met 
een controle-AON met een willekeurige sequentie. Bovendien draaide (CAG)7-behandeling 
het DM1-expressiepatroon gedeeltelijk terug naar dat van gezonde controles. Het is 
belangrijk te vermelden dat deze normalisatie waargenomen werd zonder de verwachte 
correctie van een aantal karakteristieke DM1-splicingafwijkingen, wat zou kunnen bijdragen 
aan het verkrijgen van een ander inzicht in de gebeurtenissen die leiden tot DM1-pathologie.
Vervolgens hebben we ons gericht op een van de belangrijkste aspecten van elke 
AON-gemedieerde therapie: efficiënte aflevering van de AON in cellen. Onze eerste vraag 
was of de celmembranen van de spiervezels in spieren van DM1-patiënten permeabel 
zijn voor grote moleculen, als gevolg van het ziekteproces. Er is eerder gerapporteerd dat 
dystrofinesplicing is aangedaan in DM1. Defecten in dit eiwit zijn geassocieerd met het verlies 
van membraanintegriteit in andere spierziekten. Hoofdstuk 5 beschrijft de evaluatie van 
celmembraanintegriteit en dystrofine-expressie en -lokalisatie in een aantal spiermonsters 
van DM1 muismodellen en patiënten. Hierbij werden geen afwijkingen geconstateerd. 
Bovendien werd er geen toegenomen permeabiliteit voor grote moleculen gedetecteerd 
in muizen in vivo.
Aangezien een behandeling met AONs zou profiteren van betere afleverstrategieën 
in cellen, hebben we gekeken naar de manier waarop spierstamcellen (myoblasten) 
en spiervezels AONs opnemen in celkweek (Hoofdstuk 6). We hebben AONs met 
verschillende chemische modificaties getest en vonden dat, zoals reeds is gemeld in 
eerdere studies, vrije opname wordt gemedieerd door endocytose en dat hiervoor een 
fosforothioaatruggengraat vereist is. In het verleden werd efficiënte opname van AONs 
alleen in prolifererende cellen mogelijk geacht, maar interessant genoeg ontdekten we 
dat dit ook gebeurt in (niet-prolifererende) meerkernige spiercellen in celkweek. We zagen 
AON-activiteit tegen RNA-doelen in de celkern, hetgeen suggereert dat tenminste een 
deel van de moleculen ontsnapt uit de endosomen/lysosomen. Belangrijk is dat we 
aangetoond hebben dat het ontsnappen van AONs uit deze blaasjes farmacologisch 
kon worden verbeterd, wat leidde tot een opmerkelijke toename in nucleaire lokalisatie 
en activiteit.
Tot slot wordt er een overzicht van onze bevindingen gepresenteerd en bediscussieerd 
in Hoofdstuk 7. Kortom, het onderzoek uitgevoerd voor dit proefschrift was gericht op het 
gebruik van AONs als therapeutisch platform voor DM1. Er is met name onderzocht hoe 
AONs met een zich herhalende trinucleotidevolgorde kunnen worden gebruikt om toxische 
DMPK transcripten met geëxpandeerde herhalingen te neutraliseren. Deze studie opende 
ook de weg naar het ontrafelen van het mechanisme hierachter, door het identificeren 
van eiwitten die een interactie vertonen met het RNA-AON-duplex en dus mogelijk bij 
de DM1-pathologie betrokken zijn. Deze resultaten kunnen in de toekomst nuttig zijn bij het 
beter begrijpen en verbeteren van deze therapeutische strategie. Onze bevindingen zullen 
ook helpen bij het verbeteren van AON-gemedieerde therapieën voor andere aandoeningen 
die worden veroorzaakt door trinucleotide expansies of door het verbeteren van 
AON-aflevering aan cellen in spieraandoeningen in het algemeen.
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 | R E S U M E N  E N  C A S T E L L A N O
Distrofia miotónica tipo 1 (DM1), es una enfermedad genética dominante y multisistémica 
causada por la expansión de una secuencia repetitiva de tres nucleótidos (CTG)n 
en el gen DMPK, localizado en el cromosoma 19. Esta mutación del ADN no está presente 
en la proteína, pues se encuentra en una zona del gen no codificante (3’-UTR por sus siglas 
en inglés). DM1 fue la primera enfermedad descrita con una mutación que, tras ser transcrita 
como una repetición (CUG)n al ARN, produce que éste adquiera por sí mismo una nueva 
función dañina para la célula. La repetición en el gen DMPK se da en todos los individuos, 
pero normalmente contiene menos de 37 trinucleótidos. Solo cuando se expande por 
encima de este umbral (lo cual ocurre, usualmente, de una generación a la siguiente) 
la persona portadora desarrollará DM1, con una edad de aparición y severidad asociadas 
a la longitud de la repetición: a mayor número de (CTG)n, generalmente los síntomas 
aparecen a edad más temprana y son más severos.
Algunos de los efectos adversos de la mutación son independientes del locus 
de DMPK, ya que también se manifiestan cuando la expansión de trinucleótidos es 
insertada artificialmente en otros genes. La repetición (CUG)n en el ARN forma una 
estructura secundaria estable que se une a ribonucleoproteínas (ej. MBNL) que se 
mantienen secuestradas y contribuyen a la formación de agregados que quedan retenidos 
en el núcleo de la célula. Esto produce una respuesta de estrés celular por la que algunos 
factores se activan (ej. CELF1) y otros se inactivan (ej. eiF2A), llevando a una situación 
de pérdida de homeostasis. La alteración molecular más estudiada en el contexto de DM1 
es el splicing o empalme del ARN celular. MBNL y CELF1 son factores que regulan de manera 
antagónica este importante proceso. Su desequilibrio hace que se produzca un patrón 
de splicing en la célula que es característico de la etapa embrionaria, pero al mantenerse 
tras el nacimiento provoca varios de los síntomas asociados a DM1. Por ejemplo, la miotonía 
(el síntoma más característico en DM1, que consiste en el retraso de la relajación muscular 
tras la contracción) es causada por la presencia de la isoforma embrionaria de una proteína 
(CLCN1) responsable de regular la excitabilidad eléctrica de las membranas musculares. 
Además de splicing, es probable que otros mecanismos contribuyan al desarrollo 
de la enfermedad. Para una explicación más extensa (en inglés) de los aspectos 
fundamentales de DM1 (incluyendo epidemiología, síntomas, genética y otros mecanismos 
de la patogénesis) ver el Capítulo 1 (Chapter 1 –  Introduction to myotonic dystrophy).
Entre los expertos en DM1 existe el consenso que reducir la cantidad de moléculas 
de ARN con la expansión y/o evitar su interacción con ribonucleoproteinas serían estrategias 
terapéuticas prometedoras. Varios laboratorios han intentado conseguir esto con 
diferentes métodos, incluyendo tratamiento con ribozimas, siRNAs, pequeñas moléculas 
y oligonucleótidos anti-sentido. Durante mis investigaciones, me he dedicado al uso 
de estos últimos como un posible tratamiento para DM1, especialmente aquellos dirigidos 
específicamente contra la repetición (CUG)n en el ARN, causa directa de la enfermedad. 
Los oligonucleótidos anti-sentido (a los que me referiré simplemente como “oligos” 
de ahora en adelante) son pequeñas secuencias de nucleótidos complementarias a partes 
del ARN o del ADN que se quieren modular. Normalmente se modifican químicamente para 
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mejorar su estabilidad, fuerza de hibridación y farmacocinética (aspectos imprescindibles 
para su uso como agentes terapéuticos). En la mayoría de los casos, los grupos fosfato que 
unen los nucleósidos son sustituidos por fosforotioatos (PS por sus siglas en inglés) y otras 
modificaciones se incluyen en la ribosa. Para una explicación detallada (en inglés) de estas 
modificaciones químicas y el desarrollo de oligos como plataforma terapéutica en general 
ver el Capítulo 1 (Chapter 1 –  Introduction to antisense oligonucleotides).
En un estudio realizado previamente en nuestro laboratorio se identificó PS58, un 
oligo de secuencia (CAG)7 y con la modificación química 2’O-Metil (2’-OMe) PS, capaz 
de silenciar la expresión de DMPK mediante un mecanismo desconocido. Mi tesis comenzó 
con la continuación con este trabajo, realizando estudios pre-clínicos en modelos celulares, 
tratándolos con oligos de diferentes longitudes, secuencias y modificaciones químicas, 
todos dirigidos contra la repetición (CUG)n. Esta parte está cubierta en el Capítulo 2, donde 
se demuestra que la combinación de PS con 2’-OMe ribosas es la estrategia más efectiva al 
compararla con el uso de otras modificaciones químicas como morfolino fosforodiamidato 
(PMO por sus siglas en inglés) o 2’-O,4’-C-ethylene-bridged nucleic acid (ENA). También 
descubrimos que para ser efectivo, la longitud mínima de un oligo (CAG)n debe ser de 5 
tripletes. Pero probablemente el hallazgo más importante es que este tipo de oligos se unen 
preferentemente a repeticiones expandidas, permitiendo la expresión normal del alelo no 
expandido de DMPK y de otros genes que también contienen repeticiones (CTG)n más cortas. 
Esto ofrece una gran ventaja frente a otro tipo de oligos que actúan con un mecanismo 
diferente (mediado por la enzima RNasa H), los cuales también afectan la expresión de genes 
con repeticiones de longitud dentro del rango normal, incluyendo el alelo no expandido de 
DMPK. Esto lleva a una menor producción de la cantidad de proteínas de DMPK en la célula, 
que potencialmente podría tener efectos adversos, pues la proteína DMPK se ha relacionado 
con importantes funciones fisiológicas.
En el Capítulo 2 también se describen algunos experimentos en los que intentamos 
resolver el mecanismo de acción de nuestros oligos. Varias posibilidades fueron investigadas: 
bloqueo de la transcripción, actividad como ribozima, silenciamiento mediado por RNasa 
H y ARN interferente (Capítulo 2 y apéndice del mismo). Tras comprobar que ninguno 
de estos mecanismos está implicado, especulamos que el silenciamiento del ARNm 
expandido de DMPK podría estar mediado por una nueva vía desconocida por el momento. 
En el Capítulo 3 se describe cómo exploramos esta posibilidad con experimentos en tubo 
de ensayo. Para ello usamos un fragmento del ARNm de DMPK con 90 tripletes CUG, que 
fue biotinilado e incubado con el oligo PS58 y proteínas de mioblastos. El ARN fue usado 
entonces como “cebo” para extraer (por medio de bolitas magnéticas funcionalizadas con 
estreptavidina) proteínas que interactúan específicamente con el dúplex formado entre 
oligo y ARN. Usando este método, identificamos varias proteínas que podrían mediar en 
el mecanismo de degradación de DMPK, como helicasas del ARN o ribonucleasas, pero no 
hemos podido confirmar todavía la implicación de ninguna de ellas.
Después, con el objetivo de analizar el efecto de oligos (CAG)7 en el transcriptoma 
en general y las consecuencias de reducir ARNm de DMPK expandido, realizamos un 
estudio de expresión génica en células musculares de pacientes con DM1 y controles no 
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afectados. Estos experimentos se describen en el Capítulo 4. Las células fueron tratadas 
con oligo (CAG)7 antes y después de la diferenciación a miotubos y se analizaron con dos 
modernas técnicas de análisis genético (RNA-Seq y SAGE). Los resultados confirmaron que 
en el transcriptoma no se observan efectos secundarios de consideración debidos 
al tratamiento. De hecho, éste oligo es capaz de corregir parcialmente la expresión génica 
característica de DM1, acercándola a los niveles observados en las células de personas 
no afectadas. Inesperadamente, esta corrección se produjo sin cambiar las anormalidades 
de splicing características de la enfermedad, algo que tal vez podría apuntar a diferencias 
causativas en el modo que entendemos la patología de DM1.
A continuación nos centramos en uno de los aspectos más importantes de cualquier 
terapia con oligos: su transporte a los tejidos afectados del organismo. Empezamos 
investigando la membrana de las células musculares en DM1, para averiguar si son 
permeables a grandes moléculas como los oligos. La razón por la que sospechamos 
de dicha permeabilidad es debido al splicing incorrecto de una proteína (distrofina) 
en DM1, que es responsable de mantener la integridad de la membrana muscular. 
En el Capítulo 5 se describe una evaluación exhaustiva de la expresión y localización 
de distrofina y la integridad de la membrana celular en DM1, por medio de muestras 
de modelos de ratón y pacientes. Este análisis reveló que no existen anormalidades en la 
membrana muscular. Además, experimentos en los modelos de ratón más importantes en 
DM1 confirmaron que no hay permeabilidad a grandes moléculas in vivo.
Una vez que confirmamos la integridad de las membranas musculares en DM1, y dado 
que una terapia con oligos se vería beneficiada por una mejora en el transporte al interior 
de la célula, nos pusimos a investigar cómo estas moléculas son incorporadas in vitro por 
mioblastos y miotubos (Capítulo 6). Analizamos oligos con diversas modificaciones químicas 
y observamos que, tal como se ha descrito en estudios anteriores, la internalización es mediada 
por endocitosis y requiere la modificación PS. Sin embargo, hasta ahora se consideraba que 
una internalización eficiente de oligos (sin métodos artificiales para atravesar la membrana 
celular) sólo era posible en células en proliferación, pero descubrimos de manera inesperada 
que esto también ocurre en miotubos, que son células que no se dividen. Pudimos detectar 
actividad de los oligos en el núcleo de estas células, sugiriendo que al menos parte de las 
moléculas escapan de endosomas/lisosomas. Además, demostramos que es posible facilitar 
la salida de los oligos de estas vesículas usando ciertos fármacos, algo que se traduce en un 
incremento notable de la localización nuclear y actividad.
Para concluir la tesis, una visión de nuestros hallazgos en conjunto se presenta y analiza 
en el Capítulo 7. En resumen, las investigaciones desarrolladas durante mi doctorado se 
han centrado en el uso de oligos como una posible plataforma terapéutica para DM1, 
particularmente estudiando aquellos de secuencia (CAG)n, que pueden usarse para silenciar 
y reducir la toxicidad del ARNm expandido de DMPK. También hemos abierto el camino 
para identificar el mecanismo responsable de este silenciamiento al descubrir una amplia 
colección de proteínas que interactúan con el dúplex formado entre oligo y ARN. El estudio 
de estas proteínas, que podrían estar involucradas en la patología de DM1, puede ser de gran 
valor en el futuro para entender mejor y desarrollar más la estrategia terapéutica. Finalmente, 
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el conjunto de nuestros hallazgos pueden ayudar también a progresar en terapias con oligos 
para aplicaciones distintas, como otras enfermedades causadas por repeticiones similares 
de nucleótidos, o para mejorar el transporte de estas moléculas en afecciones musculares 
en general.
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R I M L S  P O R T F O L I O
Name PhD candidate: Anchel González Barriga
Department: Cell Biology
Graduate School: 
Radboud Institute for Molecular Life Sciences
PhD period: 01-01-2010 – 10-08-2016
Promotor: Prof. dr. B. Wieringa
Co-promotor: Dr. D.G. Wansink 
Year(s) ECTS
TRAINING ACTIVITIES
Courses & Workshops^
 – RIMLS Graduate course (2 weeks course)
 – RIMLS PhD retreat#,#,#,*
 – Course on Laboratory Animal Science (Art. 9)
 – Course on qPCR and Statistical Analysis of Gene Expression
 – Dutch course
 – MIC Workshop: Macro scripting for FIJI/ImageJ
2010
2010-2013
2010
2010
2011-2012
2012
3
5.25
3.5
0.5
2
0.1
Seminars & lectures
 – RIMLS Technical forum
 – RIMLS in the spotlight
 – Lecture series
 – Seminars
2010-2013
2011-2013
2012-2013
2013
2.55
1.1
0.3
0.2
Symposia & congresses^
 – Oligonucleotide Therapeutics Society meeting 2011#
 – International Myotonic Dystrophy Consortium meeting 8*
 – 7th Intl. Meeting of Microsatellite Instability & Human Disease#
 – Oligonucleotide Therapeutics Society meeting 2013#
 – International Myotonic Dystrophy Consortium meeting 9*
 – New Frontiers symposium: Synthetic Life
2011
2011
2012
2013
2013
2013
1
1.5
1.75
1
1.5
1
Other^
 – Organization RIMLS Technical Forum: RNAi
 – Journal Clubs* (attended weekly and 12 presentations given)
2012
2010-2013
1
1
TEACHING ACTIVITIES
Supervision of internships
 – Supervision of student Ingeborg van Kessel
 – Supervision of student Julia Kranzen
 – Supervision of student Bram Nillessen
2011
2012-2013
2013
2
3
2
TOTAL 35.25
^Indicate oral (*) or poster (#) presentation
